var title_f22_10_22688="Distal clavicle fracture type I";
var content_f22_10_22688=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F68939&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F68939&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Distal clavicle fracture type I",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 418px; height: 410px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This picture depicts a type I fracture of the distal clavicle (group II). The intact ligaments hold the fragments in place.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Rockwood CA Jr, Green DP, Bucholz RW, Heckman JD (Eds). Rockwood and Green's Fractures in Adults, 4th ed, Lippincott-Raven, Philadelphia 1996. Copyright &copy; 1996 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_10_22688=[""].join("\n");
var outline_f22_10_22688=null;
var title_f22_10_22689="Differential diagnosis of basic electrocardiographic abnormalities";
var content_f22_10_22689=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Differential diagnosis of basic electrocardiographic abnormalities",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/10/22689/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/10/22689/contributors\">",
"     Ary L Goldberger, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/10/22689/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/10/22689/contributors\">",
"     David M Mirvis, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/10/22689/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/10/22689/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/10/22689/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 5, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The electrocardiographic diagnosis of a variety of cardiac diseases, such as ischemia or infarction, pericarditis, and conduction disturbances, is based upon certain characteristic findings. However, none of these findings alone is usually pathognomonic for a particular disease.",
"   </p>",
"   <p>",
"    This topic presents a series of tables that list the major causes of a number of common findings and abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?22/10/22689/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. Their differential diagnosis is discussed in detail in the appropriate topic reviews.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Q waves &mdash; (",
"      <a class=\"graphic graphic_table graphicRef58569 \" href=\"UTD.htm?35/15/36091\">",
"       table 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      ST segment elevations &mdash; (",
"      <a class=\"graphic graphic_table graphicRef81757 \" href=\"UTD.htm?38/35/39483\">",
"       table 2",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Low QRS voltage &mdash; (",
"      <a class=\"graphic graphic_table graphicRef80629 \" href=\"UTD.htm?32/46/33515\">",
"       table 3",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Prominent T wave inversions &mdash; (",
"      <a class=\"graphic graphic_table graphicRef63807 \" href=\"UTD.htm?38/0/38923\">",
"       table 4",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Tall, positive (peaked) T waves &mdash; (",
"      <a class=\"graphic graphic_table graphicRef73040 \" href=\"UTD.htm?23/16/23819\">",
"       table 5",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Wide QRS complex &mdash; (",
"      <a class=\"graphic graphic_table graphicRef70491 \" href=\"UTD.htm?1/59/1980\">",
"       table 6",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Right axis deviation &mdash; (",
"      <a class=\"graphic graphic_table graphicRef71386 \" href=\"UTD.htm?13/61/14299\">",
"       table 7",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Long QT interval &mdash; (",
"      <a class=\"graphic graphic_table graphicRef57431 \" href=\"UTD.htm?2/48/2830\">",
"       table 8",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Tall R wave in",
"      <span class=\"nowrap\">",
"       VI/V2",
"      </span>",
"      &mdash; (",
"      <a class=\"graphic graphic_table graphicRef53051 \" href=\"UTD.htm?16/23/16763\">",
"       table 9",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Bradyarrhythmias &mdash; (",
"      <a class=\"graphic graphic_waveform graphicRef64425 \" href=\"UTD.htm?15/49/16151\">",
"       waveform 1",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Goldberger AL, Goldberger ZD, Shvilkin A. Goldberger&rsquo;s Clinical Electrocardiography: A Simplified Approach, 8th ed, Elsevier/Saunders, Philadelphia 2012.",
"    </li>",
"    <li>",
"     Goldberger AL. Myocardial infarction: Electrocardiographic differential diagnosis, 4th ed, Mosby Year Book, St Louis 1991.",
"    </li>",
"    <li>",
"     Mirvis DM, Goldberger AL. Electrocardiography. In: Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine, 9th edition, Bonow RO, Mann DL, Zipes DP, Libby P (Eds), W.B. Saunders Company, Philadelphia 2011.",
"    </li>",
"    <li>",
"     Surawicz, B, Knilans, TK. Chou's Electrocardiography in Clinical Practice, 6th ed, W.B. Saunders Company, Philadelphia 20008.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2108 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-83.177.194.223-2AD339225F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_10_22689=[""].join("\n");
var outline_f22_10_22689=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/2108\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/2108|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?35/15/36091\" title=\"table 1\">",
"      Causes of Q waves on the electrocardiogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/35/39483\" title=\"table 2\">",
"      Causes of ST segment elevation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?32/46/33515\" title=\"table 3\">",
"      Causes of low QRS voltage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/0/38923\" title=\"table 4\">",
"      Causes of T wave inversion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/16/23819\" title=\"table 5\">",
"      Differential diagnosis of tall (peaked) T waves",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/59/1980\" title=\"table 6\">",
"      Major causes of wide QRS complex",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/61/14299\" title=\"table 7\">",
"      Major causes of right axis deviation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/48/2830\" title=\"table 8\">",
"      Causes of long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/23/16763\" title=\"table 9\">",
"      Causes of tall R wave V1 V2",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/2108|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?15/49/16151\" title=\"waveform 1\">",
"      Sinus bradycardia tutorial",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_10_22690="Instruments";
var content_f22_10_22690=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F71814&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F71814&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 529px\">",
"   <div class=\"ttl\">",
"    Instruments for corneal culturing and specimen staining",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 509px; height: 216px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCADYAf0DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwCS1tr6+1Wz0zSbMXV5ch2VHlEYAUZJya3P+EK8X+b5P9jWnm4zs/tGPdj1xipfhz/yU7Qv+uN1/wCgCuS/trWf+Fvf8LK/szVP7E/tf+y/tXHkfYMeRnbnfnd+8+7jPfNevjMZVpVXCL0PCwGBo1qKnNa6mjLb31lq13purWa2l5bBGZVlEikOMjkfSpQvYCtv4g5PxO10D/nja/8AoBrIADZ3cj+VehhqkqlKMpbs8vGUo0q0oR2Q3aOeD6UKuRnvUihc9qcygDPPFbHORiPA47Uu0Mf16VOgz37YpVHXIGaLgReXknrkdMUFMH72BnucYqUDHqT79aUjPBHFIZD5Z3EdvfvRsGff0FT7fm+lOC5AHXNICHYAenNOCY6ipcDI5/GjYfUUCIccjNOxz6fU0/aTn39KMdCB9aAGgAe5pWHQAdaeBkkdqAuMdTQMiAHXr9aXaM57VJ9cD3ppAJHvSAiCjGD270pHB96kGSDnjHApeRz3oAhK8dAaMDI9+3vUhGSQePSlK9wRTAh2c8Z55NNCk49fSpJVLphJDGSeWA5x6c/zpWwFJ556ADpSuBGR0GM/SoZ3WGOSWX5UQEk46VaHIyw/+vSOpw2MZNMCtwwU7SoYA88fnS7eSMGpgpcZIHH40gXPOeT2oEQlcdifSm7R9f6VM444PNNCkLnOD/OmMgKDIJFM2gYqw3HPtTTnHHfpTQmQhTgjHI6014/XjHpU/wBTzSHgdKZJW2dc0hXvgZqcqc8YzTSMAY70AVmXcB7UzaOc557GrO3HJ703jr26dKZLKxxx6UMvcDr781Nj5jx+tI/Jz096olspToPLkw3Y8V3O3ULzXE0zRtOF7ctA9y26dYgqKyr1PfLiuKnA8tsDPFeq+ARj4oc/9Aif/wBHQ15maNqMWvP9D2MlipTmn5fqZEOj+KLhysGi2cjAZKpqcROPXiqVnNcPcX1tfWn2W7srg28sYkEgztVsgjrw4ryr4KwCHW/hzLa2dnPqMF9MlzBY2k8N6kbs4MtzMQY3jQYO0YO0gc817DdDPjDxb/2E/wD2hDXjRm29T3504xV0NKc0oSpcUqg4ptkIj28YqxY4E6Eg9OlR7e+alt03ToucZOM+lSnqN7EmpkPKu1cADvVML61oajAsZUq+7PB55qoBRLccNtCLaOaNue9SnA7ik4rO5dhm2lC+9PHtTs5//VVJhYaB7VWnkVXIJOR6VbH0NZ9zxKc4Bz3qroXK2RRth89cio/C+rxXmo6paKx320u9Qx+9GQBkewYH8xWb4h1IacsEbojR3IdG/ebSOB0PrzXmcuozWOrQ3tjM0V3ExK7SMKMYKkHhgeeCK68MnfmPPx0lb2fXc7Hxzp2sW2sTy20U1zBcsSsqjcFU9VcdsdPTFXRocj+G7K30ILHeW7NK6SDAumdQH3ds8YHbHFcTeeLPEzwNINQ1AhMtiMkD9BTbK+8a3WmwWus6zB4e06f96NS1WYW1xIgOf3a7g7/gAPU10zrqnqzjpYV1lZHW+F9JubHWFn1qwlikiJFpDIS0dpkn7hOeeeOT+fNd2VB4PUViaH4M0rTp4b5pL3VL4Jxd3100oYkffCZ2jjp1x+tdEY8/wj864alTnd0j1aVL2atc46CS+sdVs9S0q8Fre2wkVWaISAhxgjBrf/4TTxpnB163H/bgn+NYaHJyRT+SD6DvXvVMLSqPmlG7PmqWNrUo8kJWQyWS/vtWvNS1a8F1eXIRWZYRGAEGBwKnUDGPzpqg5BbnH609RzyTj1rWEIwjyxWhjUqSqScpu7YoB7cDrTuvGec0iYyOnPQ0vUDPXvTEO5J6ck4NLj6U1cZ6Y9/SlzgcE0hXH4HrinZxz0zTOflPNL70hjxnkY/+vSjqTwO9NPQE9qQEnHv+VKwXHnPt9aVenXpTen1pw7UDEwc0pXoc8dKVeuDgigHHXGKBABk+v4UuMDNIfcflS/xcZNIdxDyOc4NGPl7ml65GO9J27UDEwehPFJx3HWjOfrQ2MD+dAAfxPHNKBnA5z70A8ZPJpAR27UCA9wc8Uxcg855/SpOc5HX3pO3vQA3GMDPamnngdKcT2/yKTOOO3WgBCAOO1NIOCB0pQeeCfpSP35pgNwoHHWkK496cTxzTQSSCOgpgNZRz1qPA6E09sHIJprHCjH5A0wGDjoeaRjmlPTvQfxxTJGMOg7UwBt7FtuwAYx19/wClObn69DSYPbv60CI5dwUbBk5HBOOO9B5IP4UrZB5GKD9ccelUSyLABxjNNKnzA2cAD/OaeB05+tIW6fzpktle5H7txjtXdSR6ja66mp6NqIsrhYHtm3QLKGRmVuh6HKCuHuOh+leiyr85+tebmauor1/Q9fJm05teX6gde8YD/mYof/BfH/jWdYWtxFPfXN9dfa7u9uDcSyeWIxu2qmAo9kFX8e1AXmvG5Utj3udvcbt9aXbTwvtTglFhXIsUEZqXZzTigqWirlcIM0yRts9vGACJH2kntwTVuOPPaq99BIRG0DrHKjblJwcH8aloakSm35+8c+y05bbJ6v8AoP6VmtbatITv1Fx7Kqj+lN/su6f/AFuoXJ+krD+VLlXYfM+5uW9oHmQNu2kgH5sV45YeO/FV549j0mTT7WPSBftbyTCzcYiBPJdmIHA616MdDiY/vZZZP95yf5mpRo9rs2sGYehquVAp23Jpr3TIiQ17aDn/AJ6KaydW1/SIFUG+j3HtHGWOPwFaB0uzTgQiqGpWFrvVjbp93HIzVWI5vM5u+8TWE88UaWf9oQ/xiZNpXnqu4YrJ1a10eaaS90/TDa4UExtHkE89xn2Hb6VY8azWum6dBdRwSvN5ohVIEBHzfxOewHrWDH4osLKxZb+K7hkZsFvLDKOeuQc/pXZh0nE8/FSkp23Rs6X4a/tyzka3ms1Zgd8RRiyg/j+taXxE8CS+NLrT7q7maJbS1+yhICCfvZLHcP5VmWdwIWiura4Cnho542zkHofcV6P4b1mPVImWTZFeouXXI2uP7ymtqlCE0c9LF1KcrogD6zJ3sYVAAAWEnAAx3al8rVjydQVfZYUx+oq7qmpWOl6NcarqTNa21uoeUEbioJA6DPciuIuPjD4Ohfast9KP7yQjH864px5HaR6lOoqsbxRMrgjJHNSA5BxUKkDpUmc19RY+OTJAdpGBn+VPGc461EOM46d6cSCec0mVckUep5xmnZJ5/Kozjgk05SM+3epsO48HnPalIGOTxTAeDz06U7I44pWC4oYjGeakzj2qMHB4zg04MccDvz2pWHceMfhS59se1Rg5/Gl57jJ9KB3JPrS9OtNByPXmgOMkZ+ZeopWHceOeR/KkB6dKQHPNBxgd6VhXHYx+FKRxxyaaDk04nPtQO4Dv6dKTBz6UcdqCwFACbee5FKR69etJkZz2o4xQMQc4OCOOR6U4HnBPFIWz/jRn5gOtAgbvTeo46+9B9/5008c96LA2L39qae/egn14ozz1+lMLjQCHJ3kqR93HT3pAeCCDQzcg7fxph5J28ihILjmbJ5700nHfpTWY5IPFJnoT+dOwXHE8ZA5phIPsKXouBxn0pjHsadhNh2pCMHr2oz19qQtuPHpTsTcTuOcZpG5Yj0o69fypGPA60BcDgjBPfvTc569fQdqRiemeaQgkj1ppEtjR7/XpTTgtyAfwpzE54FMYkMMjJ9u1UkQ2R3PCnvxzXpUyAOR05rzWTLIVA5FekXl1bQsxnuraPn+KVR/WvNzP7Hz/AEPVyh6z+X6htoCYrLufFHh+2J+0a1ZLjrh938qzLj4i+D4Ad+tqxHZInP8ASvIZ7abOpVadtrz27+Mng+3z5cl5OR6IFH6msW6+O2iqSLPS5Zj/ALcpH6AVN0WoTfQ9eC+tB+6celeJ2/xj17Wp3h8O+GjcSLjIjiaTbnpk5GPxrC8RfFPx1p149nf2p0u427vLeAKdp6EZByPeldFKEj23XLk2ixziOWYMQhGPkX1J9KxtC8QXOqvFNFpVtbafJyZZp0Lj2Ea5bPtXkfgfxL4s8Ua9Dpn9oTTG4nTzFbAURgMWycHA75xXe6cL7wzcahDqd1bX1xv/AHU+WcFQuQVU49QDmtIwurmM5uD5TtbG7trO3kFzqUFnEXLDznxz/EFLYOM0WnifQJPOWHV4LiWKJppQjbyqL1bivnb4n6rqV/qdlHqFzFILeEqgtojEnJyfl7n3r1/9nzwjZW3hm4vNd0Nl1G7aSPzLlDmSBgPlwex+lKMW5NFSajBSbLl58WfB1uuVvrif/rnFjP8A31isZ/jRo891Da6TpN/e3M7iOKPcFLsTgAYzXmvxk8Iy+HvGGoS2WjSWOhTOptXRSYugyAecc9jTfgh4Z1XXfH1jd6dbrJb6XMk9y7OFCA524z1OR2qEnzcrNXyKm5rseyahr/ilneLStL8O3F0vyvbrq8byRt/dYZHI9K848b+M/iFpZX+1tIXSYidqyCHcjE+jZINcf4q+HvifStUv3vdIkZPOZ/OhdXU5yRgg1H4V8M6h4ptJrW3v5muY5P8AjxkkIBAH3vmOOOadubRLUa5YLmbTX9eZ0fw98YRXOr6hN4y16SG3htTJDH5YxM452DA6noB3rS1/VtF8SeBZ9U0iG7svs8whnW4RWEbFC2VK/eGAeCBWJd/Cyez3G91jS7ZFXcxluQCvtjrUunweHdK0G80i78Y2UllczxzSw29pJKzFQej9uuK2hz01Z7HPWVKtLmje+nQzfhvqc51iXT1O+yeJ5ESQcoy45HpnuK9q8GCQXd0wiMrC1JRQdpzkd/8APSvKPCq+HV8WGTw/NdSolrJu86PZj5lAxnr+lev+DZHkubp9u1fJAB9fmrroJypb9zzsW4xxOi7aHM+MZfEMnwy8WT69ZR29v9kgSIbyWLm4iGcdhjNfPsrHdz1r6j+MrY+E2v56sbZf/I8Z/pXy3IU3Hdv/AArgxUOWaVz18DU56bduvT5H0/GRnpUicdPwqEDGOM4qaPgivqj4lMf+gNK3U80nOOCelLz8p460ixwIGcc8c05ThiO3bFRgHaCTgU5eCRxSY0OVsMRjNO5U9MU3I4xx2pxwB05NIBcZJBPHtShuM/l70g69vejAJ6UhjwcnjHHNAIxzSDAJ5wSKcu0dSKQ0L0Py07OPpSDAA4wPegdKQw2fNuDMM9eaUDA4oOCOmaU/d6UAGc+2KOg4ye1CmnZx2pDAHnpTsHcMYpp/ECmNN5LeY+PLjTPHdieP60PQcVzOxUk1BFBKW17MobbujgJHHHBOM/hmn2t9a3bPHE7rPGMvDLGY5F9ypAOPfpVw6bZXckC6nq+k2ckwWSGG9u497qehUE+oxWTqeY0mthKn2oKyQvuBIYcjafTI6VjGqm7JnRKg0tUaWDzj86XaDjLcj0psTs8UbyAJIyAsB0BxyKdkYAPWtTmEKnPam4yeoNOYkg0nqMcUxDSOvrj1pCCe35UdWOB7dKTPTJNMYpXBH+NRjgkg8DgU4kkdOc1GW+br74piuDY6jjH60YA+8ec0rHnpznNNyMYJ59KAuKemScjPHvTD0ywHFLnoPf1pm48U0JsCSTwOD15o79DSnk5PNNJ5HFArhjA4/Kmk4xjNBbHH60h29vrTsK41j7cmmk4560revbtUZ9SPwp2IchcnGSaRiR34prMNxYk8dqQsBnLe4qrENk1oN9wi8YJr5m/tC9uVBlupXJ65NfS9g4N5Djk7x0r5et87FryM2v7lvP8AQ+gyCz9pfy/U2vDmlvrviPStJa8+z/2hdR23nvkhN7Yzjv1r3rxX+zvpWkeFNX1S01m6lubCymuQjxgiVkUtz6ZAxx614h4F0xtV8S2yfbWsha4uTPH99SrDbt98459q+j9T1bUdX8PTxarrU0+mTAwTRpIkbyIeMHHODz9a4KOGlUjzI9TEYtUqihc8G+ENrolz8SvD8PiSOCTSpXcSLO+2Pd5bFNx9NwWvcf2hdP8AA9n8O5G06LRYdZjmh+yC2ZPNILgOPl6jbu614j4j8B3aa3NH4X07UNU09YUl2Rp5rx7iwwQOSMoecVZPw81y8s7FdO8P6yt5tZbltRgW1gT02u5Gep/Ks/Z8t4y3LdRTlGUdjsv2a/G1n4YuNftL63vHt70wsktvDvVWXcCrfUMPyqr+0brD+J/EmlahYaZeRWMFubQTzKF3yF84x2A9/Wrfgfwd4v00SWFjZ2t1Bb3PlTSxyjyt+1XOScMRhwM4rR+IXh/xTBoup6lqtlZW2mW4VmWKcMGyQAVHXqe+K6lh6Tpq8tTjeJqKs2o6XJPhb4A1vw3pGuT3qwW+r6kqWlqRJvWOM/fbI6E8AV2Hi3QINKs7PUb22ubqQeXbslqpcnA449Mjk1f+H2oPe+FbR55ZGjXG3B7YHH0rrr/7PdWwhmZyrr1RyrL757VHK4qyJdXnfNI8Ys/h7NqHiaHxQvMVtch/sM64Ij25z7kHtXottrMr3yrcgtGQAu1sVy/h7TrzTfiNGzapPc2UsUtr5M75YkA/Njoe3OK9D0LR7abTbOWa3jMsa8krktThNQTuTVg5tWexwfxFnkvvA3ie2lHmRR2bzBGOcFCGB/Sk+DegaV4U0Szlh83+09St4prqdm+UkrkKB2Aya7D4g6Ysnw+8SwWMKpPNp0yrsTG5ipwv1PT8a0tF0izOjaZ9otSs8dpEpK8YIUCjnjKV2h8kow5U+v8AkeVfHvXH03w/Zy6ZDC0pmkCzEfNCcAbh/wB9Gvl/zpjcqRNIsjNw+4g5PHUc19PftJ2Nlb+HtLjXdDGbgqxByQpZcn36Zrh7fwVpY1SJtFWW22SL5Mt0GO49mDAEc9eaTpOtL3dkbUq8cPD3lds8r1S01vRDB/alpNb74/3a3KAiVN27v1Ge9dJeR2Nn4bstUeyEJuZCigDEcoAOWUHnAIxXSfEOz1XVYZbbXdQ+0yabGfIbaSxPPyhtvI/GuA8OeHdW8V6lBo+lq1xdiNnCSybVjReT16ckD6mj2c6D01vsV7SGKXvaW3Oy8CaVcXl7d30NqEtWg8grGfn3bg27HXGPSvW/BcLQm9JOFKqAp7cmvny58Q6pFqzbZn0l7LeiQIpyJFONr+5PBNfQXw/1htf8MW2qShBLNlWKjByvBB/HNddKcJ3Ueh5lejWpWlU2f4f0ih8dpvK+F1yv/Pe9t4/1Lf8AstfMcmSxxX0j+0PLj4c6fGvWTVYs+4EUp/wr5ufk15+M/iHs5b/BufUKnBBzT0f+9jrVRXJ5H5VKH9a+rsfDKZNJKVRioLEY4FP8znFV92eR1pQ2D1+tLlK5yyGzzxRuyc5/Cq+4n3FOLAHk1NiuYnLHFLu74/WqwfselLv3AetHKHOWdwJ9Saf5nIH8NVgeBinhuPelYrmJy+OPQUqHnPb0qHPI5H0pwwwG09amw7kwP0/GlDc5BqJR8uCaXPp3pMpMm3Y79aXPGCecd6iUn+LP0pwPUZxniiwJkoIxn0pxPGe1RKQepqQPg4x2496Vh3H9sjrWH4x1YaD4b1PVWjWb7MI1SNjgO7EgA/z/AArcXO44AOTXkPxVurnUtT1TRraZfs4lhcxk8F0j/wDsjWGIqezg2jpwlNVaqi9up5Rr2qXmt6tLqF/IpuJCM7BgKB0AHYCvSPhf4hkvII9Ju8NNZSCWCZmyxVmwVOfTdx7GvPZNEu4siS3cHpkPwK0dAtJ9H1S2vY5gky8qoGR+NePTqShPn77n0leNKdPk2tt/X4H0vbsXt42PcZqTjHYdqx/C0xufD1hNuLsyNuJPfcc1qkjHfrXuxakk0fKSTi3F9AL8nn60wt04pXbOB059KaSMEA8e9UiLgrHA6Un1NJxjGKRj1GadguKRgHrnFRk/Lj9ae2cY/D60zHXjn1oFcCMgY7U1l/i/iqQetIe1MLifwnI/+tTeh4FOXGOfemn19eKEDY0ksuKTGepxUg6npTdvI70CI275qNsnGO/NPx60hwB6D1NNEsjb1NNbofpTipPGccZpuCTz2qiCFscHOT7HtUbE7uwp75yMDnjtTCM9COelUjKTY+wb/ToDzw4zXzVbqPLXmvpWyP8ApiYPIPFfM8JYIp7V5GcO3J8/0PoeG9XV/wC3f/bjp/AcIn8ZaVZPM0CX1wlo0qjJTewAOPrivp3TPhZp0VvJHqOpX11NyFaJfL2jHbJIJr5v8D+HNU1LTtT8Q2EFyq6Htu4rgIDFJLGyt5R7k4+bI6Ac9RXp9t8cPFF1bZW00uEtzv8AKLHH4n1rkw8p8lkzvxsabqczV2tGdzb6BYeGfi3ptlbxE2V/oMhzdOZN08c2SSf90gccV31uqIFIVE6D7oIH4V8yWPjzVW+I2ma7rurQPJCkkaveo5t40bgqVjGVB9QDg4JBFezz/ErRYIBK2u+F4cnJaOae5IX2RY+vscVM9G03qKMXJJxWhUk8faJ4U8a+I9K1qO6VbmaK+hljQMMNEqMCO3+rrA+KvxV8P6t4K1LRNJtLyaa+QJ5sihFjAYHPqTxXmnjzWJPE3iU65aJqF5YIv2Z9TntRCkrhmYBVXIRQrAAEkkDJrMg0u+8QSxW2kWs11OTjbEhbHuT0A9zRGPNG4TfJUXY98+CMcmoeAYTGAXjkK4zjsK9BTSroOrOERcYJLZNc78O9Ji8JacdPuZCAzCTP9xiBkfnmuxS8sxIN0zS9wDn+tEm07IzhaS5mfNPxw1rX/DPxBZrG/e1SOLzbRocKRu+9n8R3r2XwpeaqfDWkzz3haea2SSQqQQWIyeRxXzOfEKW3jLW7vxdbz3F3cmaN0eQIY2YnBwyngcYAx9a9T/Zaea/tvEFnPJMbKHypoE3HCkkhiuexrCE7yszur0rU010/E9Nv5Lu6DK7yS54CE8GpbC+v7aNY4nYRjjB5ArpobCKF90cZL9mY5xTZbGKRyWgwx67Ttz+Vb8yOGzOS1PRLXxdILXxDALu1aKRGU8EZKkEHsR61xI8PxaJezAXV7LYaXpsscn74xszo2yI5BHJDD8RXrYQ21xiKPHy9zmuI120tL++1OzvnQQ3WBKvmbDlXVgM+5Arooat27GVS9ld9TzPV9EbxFrd4kc8ySWgG9pWLZJPAyfpn8aisNPfwZqa64L23a+iBUI6kCRDwVOPwrpvFGg+KdNF3q3hS1F2FuUluLRly00SoRtAHXrnjB5GKk02+8LeM9EF3JJHbsnyT21wdssL91xjn6iuhzg5OPU5J0aqSmnp/X5niGtaHqOua3falDLbS3N/cyXEkagxhS7Fjjk8DNe2/DPT/AOx/BlnYs++WNnaQjoXZiTj25qreab4asdOl/skXLXSAGNgp2nJAx83OOewrQ0e9gsfDN5qN65isbd3Z5MEgKoVfqcnpilChCmnNaBPF1a8lTm7pbd/wOY/aHW4l8KaMYYJpLWK6eSeVFJWL5Qq7j2yWOM18/sDmvbvjB4wuJdIt9L8O3Lz6bqVqJbuW3G4Fd/CHA4Py8jivFTFI3JUj/e4rysb/ABG0fQZbf2KUvM+klGM08YJOeAaaq54x7VIqAY719cfBoUfj70Dg+2afjqaXGTj9ai5aQi9cHpTyAoJHtSgduaCPXmkUJx0x7UoHUjtS8nHbtWp4esft+sW8Dj5M73/3VGf/AK1ROSinJl04OclFdTNB56ipFTkjPWvVLLw9p10ks1xbQ5kbbgLj8a53xNo1jY3FtDbW0yCQlmaKCSU7QcdRwD1rz3mdNbpnrrJq0tmjjR/+qnoMDn16102m6RYXesQ2s8d2kcm4qz2kqZx0BJ4Gf6V1Y8KaSp4iU49Qx/rUvNKXZ/cUslrrdr7zzBcZ5YDPNOABxyK9TXw7pYGDbwHb32HNZ2v6VY28VtHFbQ5kc5/dnIwPaoeZ0+zLWTVf5kefADoKcATnOefQV2kVmkcJ/cW7zBcxssThSc96dbWV3klnhCM20hYifXGPyFS8zj0iy45LLrNHGDnsTn2p5UqEBUjPAz3rsLO3uyyedFagsSWYxPx6njoK8v1fxYdR8SXxyvkQQFLdY8gHB+ZhnucCrp4/nv7uxFTKnTsue7ZY1y9nAaCzcRqPvydCfx7CvEvF6T6fr016rvLayHcJV557hvyrvryS91VyWyIx0UHApLXS7ecskpLOykAj7ue2fasq6c4uUn8jahy05RpwW+lzzTUNajufKEciRq2C3PQ1Ekz3JENrvurosAqRryf/AK1ekaB4Q0vUtQuJZobLETBRG5K7vU8dq2Lnw7Bp8hbTbZEs3PJhXr9T6VyUYurojtxNqHvS9DsvAHh8yfC20ktZIptZsFeW5iifPmrvJKY7MBjHrRJMoKhtyhyANwxjPrXn0kN5ps5vNIlljKckxsQy/l2p954jubnSLoXkm6UhVRsc5z+nrXbQ56K3uvyOLFKliLK3LK3yZ37ZDHJ4BqLAyAOBWX4e1J9Q0dJ5CC6N5TkeuOPzq95gPc8dq9SHvK6PBqXhLlkS5GOcZoZvT/8AVUG/JHHPUUjP1JGMVVjPnJATtAf7wHOKUNgHPc1vHR7dtLWSLeZ2jDhyeCcZxivOPGvjXTfCghimR7q/lXeII2xtXsWPbPpWXtoKLk3ZI6Pq9VzUIq7Z1Y5PFGcHqPpXE+B/iDZeJ9T/ALOe1ezvHUtFl9yyYGSPY4ruQM9R7U4VI1FzQd0KrSnRlyVFZjAMscf/AKqivLi2sIt+oXENsnXdKwXP0Fcz488XHQIktdO2NqEi5ZiMiJe3414/fXlxf3DT3s0k8rdWck15mNzSGHlyQV5fgfS5PwzVx0FWqy5YPbu/8l/Vj2W68ceHYOBfPK5PPlxEioYvHvh1sZubhD33RGvGxGfLMmNsa9WPAqs95ao5BmDY/ujNeZ/bGJk9Evu/4J9BLhfLKStOTv6r/I98tfE+g3TBYNSgyeiyZQ/rWmm2ZA8TLInZkIYfpXzat9ZkfM0g/wCAZrQ0vWpdPnEmmak8L+m4qD+B4NdNLOKqf72F15HnYnhjCTX+z1rPz2+/T9T6BIyTnrTCAFywrjPC/jpL6VbXWkSK4bCpMgwjn39DXZnDDg17mHxFPER5qb/4B8dj8BWwNT2dZa9Oz80yF1IwR16GmMhBbnI7cYxUxBXBzyeoqNl+fJ6mulHnSG2qBLuM4OfWvmyFf3C/SvpaEqtynPOa8F0/wzrc9ojppdysTfKJJF2KSe3PevJzhOSp2Xf9D3uHJRhKtzO3w/8Atx9M/AOztpPhHBaMD5M0twkwx95iQCfyxXGXvwU16O7dNOvNLazJ+R5ZGVgPdQp5+lei/AOEf8Ko0d1A+eW4J74Pmkf0r0EQDjcWP6VxqfKrI7JQbk2zyzwd8I9I0mK5fxE8OsXVzEYGTyysUSnGdvcnj73FWLb4I+B0uPMNjqMqZ/1T3bBPpxg4/GvUVjReeP50/KgdfzqJTuVFOOzM7StJtdK0+Kx0u2gsrGIYWGJflH+J9zVtI0iUqmAO4AxUxIPRd344FKM+iqPYVHMx8iM6901btQVAVx3K8Gs/+xWVxvliT3GTXQld33iTUckBlG0HHpRcdrbGHpLrqVhby3UVlNMgIb/VybSDjjIyOmag0y7im+IWoi3nikCaXCjCMg7D5jccV4t4s8Y6NoY1vRtX0PWtL1+MyRQXVndFIJzk7ZGjYgAHqcKc10f7Mtvq14Nb1nVTdywzpFDDcXGcSbc52k9QPbih8relzVwlGN3az7f1/me4dR1J+tRT4UA/Nu6BVGSfwqzimywLMuCSrDoy8EVNxctzk7HW4dXnvYbaOUPA4iZX+Ut8xBHX5c44JxXN61ocF5qsyXH2RcLhBfF7Vzjs3G2QD+8p7d69Qa2klCq0rMg6j+9SS3sNufJ89d6j/VIdzD/gIyf0reFfkd4mU6CqK0jlvCNq1tHFDFLHKFI3GASGNFx/fbgnOOBWd41+GOgeKbiW6Z73StTlHzXmmyeX5h7GRPusffr71va74ps9Kj8zU5YbKMjKyaldJaqforHef++a8y8TfHnQtKhkOkXa6veYISKyt2SJG9WmlAyP91KwqV4yd2zopYaovhVjx74ofCrxD4BePUZb5b7TXcLDfRy+XKGPZoy24H3XcPUjpXC3XiLXZtL/ALNudXv30/kG3Mx2Nznkd+fWo9d1q/1zU5tR1e7mvL6YktNM5cgdlGeijOABwKzSc9TWHO9UmekqS0ckm15Do55YlKxTSxq33lViAfrTOp5BP40sQjMjecZAu04KAHDduPSm1m22a2SPp5QOpFSgZIpFUgemDVWRLy4nQCQW1sDlgvMj+2egFfbNn5ql3LqjGfyp6jJxTYowihRwo9TmpUz696ktDCPWlVen588AU/pyRiuP+K2oXFl4Ju1s1y9wywyEHBSM8kj8gPoaipLkg5djSlD2k4wXVpHWxpvj8yNleM/xoQw/StHR9Qn0q4ae0SB5GQxkS5AxwcjFfJ2ieItW0SUSaZfTQY/hDZU/UdK9a8H/ABVtb7Za+II0tbk4AuEH7tj7j+GvPp46liFyT0v/AFuetWyyvhH7Wn7yXbf7j2p/G/iaOMRWlroaqM4ZxIxrn7zXPF1zem5mvdLOVC+XEkkaj06H3zT4XSUK8bK6MMqynII9qJGSJGeVtqDua1eCoreP5mCzLEO1pfgv8ixoHiLxLp100t49rexsmwRtcSBRzycc810sHjq7G55NIhyQQFFycD9K462kkmZmaDZDj5Cx+Yn3HarPPoPwqPqVB7L8zT+0sRF6y/BHYR+O7nP7zR7fHbbcH/Cs7WPGurXEsZ0/TbSFVU7vMlLEt2IrCAPXr60BSTR9Qo9vxYf2piO/4I6iw8damtqyXdhamQBQpU8HH3s/WoV8QWkC+XFpKrGIigxcNycZAPtux+Vc/sJ6A4ocE8c5+lL+zqL6P72H9sYiPVfcjotP8W3K20Wmx2VvbW0ivEWEhdl3g8gn0JrwbVreew1SSKLcZoHKD8Dj8q9Mmma3bzAOV+asC7jjdH1K/IW4u182JD0RRxz7kc1x4qEcJJRgvi6eZ6OAqyx9OUqkl7r1fZW/4cg0W8fU4ltWgFsEH76SNdxPsK2r3S5mgtbOBVsbaaUKbiQZIz/E3tXGw6pJY3kN1HIlpbI4xLIcBz9O9dbrXxHi1XTrOKa403IIJw21lXJ4OPaoqOcFyON772NaEadZ+1jKzjtdaP07GjN8KVkW2WHxJBE0LEl9ozIT+PQVpp4dfw75Fqb1b+OZM7lHyr2rjptd0MWNvOmuadvOdyFjvVs/ToBj86deeNdJk0wWyanc/dBYW9s7EhjgYPGAT0PvUQlJStCDNZUU4OVWafl/SLniu403R5WeOfy52GGjA3rjpmsG80kRpJqjSwXmlTR+VFLbfMockZLL1U4HeuQv/Edtbm7/ALNt9QuPs+WnS4AwuXA5HUckCm311qmj6vp3kiys5bq8a1ktoG3kFCv3h0IO4VvVhNrmizDDyjF8tSPpr5dvTU9U8L+GprLwbq2s71Ns0sOzachiX2/pn9aRWOfasrQ/E97J4al0cMI7ITBmiA4Lgkn8M4P4VoQPvFehlvtHSbqdW/uPCzt0lXSpbJL79SwrHNNuVfyGKnBxmlVRnr7VO6lo+K7tmeVujrvD0xn8PWLtyxgXd9Rwa+efFfgXWfGHxouNC0iMNcSxrKZZDhIoQAN7HsOn4nHevoHwKgl0O1jfojSRn6bjWhptnFpXxD0fU441D39vNpE0ncnImhP/AJDkH4ivBxT0lDzPsMCtYVPK332PMf8Ahm6fRYYtQ0XxdC+uWrCSJJINsTSDkLuzwDjFWbfUpWgEtxCbe425kgP/ACzfHzL+ByK9Y8Q+K9A0/U5bCe6EsyuS0cKFxFnBwSO+c15b4igtYtcuJLO5E1rdfv0cds9QQeh/xrTK6sed077nLn1KTpqslt+X/Dnjfj6RjrWZerwxsD+Bz+pNYbeVZWv2m8GWwCkWevpmu28aaK82qwMQTGhLHj+HqR9K8z1+aV5lSY/P95vqTXjYug4V5OXc+zwOYqeChGk+hTv76a8kLSsdv8KDhVHsKplecjr7U4mk6mszJ67iK3Y8Up96QjNJnA5NMm9tyzbXc1sSYnOP7p5FeyeAfGsOrRQ2F2fJ1CNQqknibHH514nkHkHpT4pXhmWWJmSRCGVlOCDXRhcTLDT5o/PzOPH4KGOpezm9tU+z/rdH1MxVl61G4AB5ziua8F662ueHobx/9ejeTP8A74HX8RXQpL0POfSvrKclUgpx2Z+e14ulUlSqK0loI+eTng9cVsTM11pUZnkO/wA8HbnIHyN2rFnYiBsHtnNeq6zp/g7Rb6K0urGcTSq0qRQi6mJVcAsQmcD5gOfWuDMpJKN/P9D08mV5Sa8v1ML4ASl/hrbxg8QXkyfmFb/2avRznnmuP8O3vhLw3YPZaHY6pa2ryeaU+wX0mWwFzl0J6KPyqj40+Iun2+iyWnhi7M/ie5kENvbGFleDBUvJIkijaoU8EjknjPOPJ5lJ2R7bhKKu0d7+NLyD05rhvB+pa/Lp0Q1rU/tV1kh3+zxp+GFUCuR+Knj3xJoWri10TUhbqkKFx9nif5mY92U9lP51fs2YqrE9rBY//XpwB7187eFviZ4vvNUS3vtZ8xGQ4/0SBeccdEFeq6drl9Np8kkt2TKAjbiicDnPGMelHsZCeIgjthjtSjiuOXWNQ2g/aTj/AK5r/hVhNVvWjG6Zs+oRf8KXsmH1qPZnVSkNGDMIzGvOZQCF/PpVVdTgnOIbhbphxi2BmI/BM4rlWAmuTcTAXD+lyPNVf91Xyq/gBWb4jtE1iHZqU2otARsMMF/PbxEe6Ruqn8qXspdLFLE0vtX+5f5nU634p0rQkZtav7LTcDIF7dRxM30QEufptrz7W/j54PsNy2d3fam/YWNpsXP+/KR+i1zbfDbwOZjnQBnuxvLg5P8A38qnc/D/AMExM2dByueD9suP/i6l4as+qN443Cr7Lf3f5mZrv7ROp3OV0fQrO3Xkb7+4e5b67F2J+hrzzW/ip401hWjuPEN3BAePJscWsf5RgZ/EmvW7LwX8OPtAhufDbysenlXdySPr+86V08nwm+Hzab9rtvBtxLGV3Ai6uhn8TIAPxNZSwk0/eOqnmNF/BF/cv8z5IlkMkhkfLyE5LudzE+5NMLHvX0HdeE/AHmvGvhZrd1ONkl5cBvr/AKzp9KZc+DfAqWa7fD2JmkPzfa7ggKB/v1awc9roUs0pLVp/h/mfPrMWOTQTxXrc3h3wrPeSR22jrGqHGBcTHPOO71haxoWjQ3DJb2QQD/pq54z7tR9Tmr6r+vkQs3ouys9fT/M4HnPWivWG8I6BceB7fUrXTQt1DcPFcOJ5DvXhlOC2B8pA4p8vhTw4kFuE0wu5jBd/Pl+Yn/gVQ8NNdjRZnSeln+H+Z6SABnmngeopFXHJ471IARnpX1rPhkhDz9KXpx1pQCTmnjO8ikXa4w9qoarZR31o8MyB0PqK0lHGOx603y2LYAznpilcHE8L8XeApbZnn04EoSTtrz2aJ4ZWjlUq6nBBr6c13VrDT8xyuktyBzErYC+7Ht9OvtXNNpdprFsl1fWSW28kCNUw0mOjZPIFeTicDTqT/dOz7dP+Ae9g8zrUofv1ePR9X/n+XdkHgiJtFtrfTLG9uL/VJEEj2+f3EHGeW7Yzj3NdxvkS4C3al7ojcingAeoH9a4vTbDVfDtws1jE97pw+9ETmVR149RXDaKtxq+r6zrus6nc2l7bHdAFVizyEnCADoAB/KvDoYnH5XVlHGe9SWz3d2+lunl0/E9qvg8Bm1JTwT5ar3W3/gX+a38z3mEXMj7nbCntjmlmkZW2W6edOeCM4VR7muN0jxJfCG0t/ENvPaGWLzPNAwZF/wBrHTjHSuqglNzEosiqwkZBX0r6bD4qni4c9CV0fLYjCVMHPkxEbP8AD7+v9XNSIuIlWUqXA5KjAz7U7eo6kVVihKKA8jMTVbVH8qymYdlPNdKRySl1R2Q8LMdMg1O/isYra42eXNNqEyAh/u5CjA7VoP8AD5lKLLbaWpbAQHUp/mz0x612MWk/8U9pM4QTmKwS3ubfPy3EWwZB9xyR+I71xOpWVnq8Vn4MuZbqGN4Y7nR9U3ErcIDlo8DG10HCg9OD1AB+Ut7Spe2j1b7fifoscRKlRUVNqSskujVvTS2xja54Euort7dNAaRvNgWIQX8nlzRnf5rsx5Xb8n/164XXYYbG9vNJ1KWEXmnXLqbdWJRo8ZUBjyeMV7x4M15tcvZtOub6VLu0CSqrMqySJkht6AYUqwKnk/XFfNvxNeE/G7xbaXLx7ZZo/KLttG/yUwpPbOcZq8PS9nN66/lcyzHGyxNKMWlZWv52t/l+L8raPi3wwLrwNcoxh/tRxE0bPIAkQDZIX0GM1wV5NfpYW1vHa6dbtDaR2zSgBmJjk3hxxwex9cmuzMUs4s7XVXjiljjXzUD5z7r68elZ1/p9law7IZ0O5iT5h55+tdFXEyo2UUeZhsP7ZPml1MaS+1DULaWG4sNMnWW6nuWIG0kSjlRjoBkY+grZ0yy1fUreKz1DVobGzmtYbGZ4bfeyxxvuQ/UEDpWTbFYnd4iJGdlUKGGP/wBVdnorx2tuyySR/vMEDd1rl+v15dDt/s+gluOh+GOlQyXd/wD25easLjcLmSFhHu3HJDjkgk44o1bw5o+jCGXT7FUjmUFJWJd1kRhnk+oP6Vu2dyI9Qh1JE2CNTHcsflSaI9VbPGehB65AqLWJLe2sYb+6UnyQy2UbcGSRj94L6Djk16FKrKok7Hk4imqbcXK6aOV060ZQ74wXcuQPU9q37I5GO/pVDS453hCuOTy3v3rdtbbCjOK9ql7sbM+YxNpy90fChJH1q9HFmPGB6ikghx97pVxYgyHHX2pylqRGnZGr4RIg0HcGCDznkd34CLuI/pmr3npeBYBexvLxNEycMp6q6H1HNcXqWotB4P1C1tpVa7t1llCtyRnlSB3x81ecXes6osNreQ30q3OAdzsSQdvA/Ovls0xywtZRlG/Nc/SeHcilmmFlVjNR5Eul9bHplhZaRp8t3HeRzzkSO0cinlzkhg2e+7P51g6sFmuILuCExC43p5YOQm3lRn1IJ/KptM1tdage7dRHK7iQgdCSMN+vNPvhs0+7UfM0DrcoPp1/QmnhWqLVaPR/h/wzPKxsJVebCz+0mvn/AMOjJlnR4vJuE3kA4PcD0rwPxLn+0pmYAESMp/M4r3HXN1sVuY+VGHyO6n/61eZfELSTbXSapbjzLC7HzFf+Wbd1Pv3HqDXo5xDVSR5/DVb3HTk/60/Xf1OFwSRgEk8ADua6rRPBV5fRC41BxY2n96T7x+gre8F6Db6baprF6POnYExxleEHY/XGD+NWr6+mu5md3Pp+FeFq9j6iUlF2Y6z0Tw1py/NYzX8g6mV9q1t2d/psC/ufDejlRwBJya5Y46kmlDRjrnp61m6Se4KvJbHXXM3hq/8Al1TwbbKP+etlJtasqf4deF/EAI8L63Jp2oHlbLU1wrH0D1kqcEFXINXrS4lLgTBZYx/eGR/9alyOK91/18xc3M9TY+HHh/VvDUHirStdtZbaaBba7i5yj/OYyykcEHePyrokY7hipdPv3TQIY7kmeylchImbLIBgkqfTOOKiQKHYIcoOVb1HrX0WR4tSg6M9Hd2/r9D5LinAtTWJhqrJPv5P0tZFuKHzyE3EZ4ro/gP8SLjx98QL66l0tbR7LSJdqJcyTGTdLEf4+n3e3rWFp2BcKcAnOK8i+BvxIi+GfiC91KbTH1Fbm1NsI0mERU71bOSD/dq85vaC9f0I4aSbqN9OX/24+nvhImqeL/Duk+NtW8Z6pFe3V4zSWEUqLZIomKC28ojOSABnO7JHXvyB0tB8ZviDrU0QYR3FvbI2OVJiQn+lcdH8avAkXiEa9H8NI01RZftAlW+wBL/z02BNu73xmu70bUbjWr3UdSmtBZNrN0t59n8zzCiGKMAMcDn5PTvXl4aPv3PdzGdqXLfdna6BAqxhjj5uT/M14J8QboX/AIk1WYncPOVAPQKP8S1fQCt9n026lyB5cLfmeP618uX96bm6uJcgmSZ3JB65Of6mu+O54U0+TQk8Py7NatjzuBIr3qzfybQcKA8J/PGRXz9o6tJrVsFBA3DNew67qa2trpsa4XoT79qpEWNqDU9xAyMdcetXoNSATBzxXMW+n6mERvsk+1icEpjNWUtdQQ7mtpc+g4/rV8iZPMjpkv12nJx7Gql/dAW+SG27sDPfisctqWQqWxX1OcmqsseqMzFoXbIAGW6UKCQnIS91AK7Mhxx0z3rInuZry6aGDbu+8TngAYyT7U+/stS8l3kiCIq5Z3fgDPU1seHI7Lw7aNq+rB3SM7ooH+9NJ/CWHsei9vrmiT5dgprm9DZ0zSrTwzaJq+rxvLespa3tR1HHLsP72M/7o4Hc1oQeO7iO0S7fQbxbMkfNDd/vnz1KRBfmCjkkkda4bStS1DxFq2p65rs8q6csRhjjTg72+6seeCwx9B9BXW+EvEd1YRi61TTvJ+0pjysCTy1ycKDnB98YOc5rCSvudsLr4Tcd9A8XQhHijupSMmKVPIuk98H7x9xn61zWufDa6gtzJo1zvhCEBJCcp35zntxnmtzWY/Dmq6ebi2tp1udwCRwR53sTnA4yD17cYz0BNVvCN9qEMur2tzeyXlpHgwhlLNBK5J8gOeZMLzuPOCM9qmLktUOooyVpHz9PJNp32qG8j8u9FyAwPVQgJ69wSV56Vz9zem4upD94jjj1Fdl8ZdStb7xhftZlXezgSCcxsCpmGS4z3x8oPuDXm+iPvugOhI//AF1o56pEUqCUZTfQ9T+GjPcaXq2lXKExzQ+cmT/zzba2PwdPyqtHFNlogD+74z/n3zVzwRdpBPZuEBS3uVR36fu5h5Rz7bzGfyrq7HSDLe6hbrci3eGXcGZc742Hyj8CH/OqtpYwcr2nsSjHr9akI9Bio14PH41Mn3unXoa9pnjpAq8f1p5HJ70mVVGZiqxqNzOxwAPc1zeueLLWzg32roqn/l4kHBP/AEzTq/14HvWVSpGmryZtSpTqvlgrs3b26trCDzb2ZYYz0GCWc+gHU1wfiHxlPOzQaeTbxkYJU/OfYsPu/Qc+9ZcR1jxNOzWscscEnD3Exy7D0z2HsMCur0rwvpuiW4u790Zl6ySH5VPsK571a+3ux/H+v6uddqOG0fvz/Bf15/ccroug3186yLGY16+bIOnuo/qea7aGxs9FgDX1xJJMwyqsdzt9BUGo+INkBa1xZ2oHFxMPmcf7C/1NchDc32s3jx6NDI6scNcSkkn6n+gojOFP3KSu/wCv6/UJUalX95iXZf1/WvyR1ia1c3V2YYYY7a1AO6Zjlk4479enFZV74cW/2vp7zRXSgj7S7Z3k9cj0NbegeEEtSs2pTtNP1wD8o/CuoW3jjOFGF7DHaqlSjUi41Ve/9f1+ZEMROnNOg+W2z6/8H56eRxFhrd1pkiWniO3WJyNiTYzFIOmAe2fQ1rCCW3ngbRIkNvKxMkTPhUzzlfQdeK3L2yhvLZ7e5iSWFxhkYZBrk5tI1LQXMuiO13ZDlrORvnT/AHG7/Q18bi+Hq+Cq/W8plZ/y9/8AP0Z9nhOIMPjqf1XNYpr+b/Pt6r8Dq1nZXKSgq/b0NUdZQy2csYON4wT6VmHxjoNxod4l888GoxJujhYhG3+hB/pUmm3M2oadHIF4kQHke1e5kGaVswjKGJp8lSG/Z/5en3HgcQZVTy2UJ0J89Od7d1b815/ee2eGPij4b1Nre3huTa20NsswluCEDDhQuPXnP4Ven8eeD7dl/wCJp55QcLHG7gZzz0/zxXzt4M0O5/4Qqe88iaW7sr2DT2RIyePLYscYyeSn51uf8I1rGoWstumjak0bjBKwlD1z1OMV59GneN5vU+ixFRKaVNXVl+Op7PF458PPateW6X027dF5gh+f35PNZdz8QdCWF7o6Y1whcI0k5jxu7ZJ78Y+vFedpomr+E9Ea+vdIaOwW9Rot8oLJJMdjEkMflwQMY6kVkTaxM1rLayW9sI5CJHU42mQPvL4x1PA/DitlTj0Od1ZLc9H1P4klIGki8N2HlIhlBmYN8gz8wAGew/OsxvH17dRyyf2RpqhJUjKxWgkOHOFOTx9fSuP07WpbvV4rNI4LZJgxUJuKqAh+UDPQ4z9a0H00uZA8qneWJ/dnHzEE9T6gU3BLoJVGzaj8QXV75oFhaQqGK5azRCzAkHAx9Dn3rT0WTT5vBni5buxtftlnBJcJMsCmQKyHleM5BU/mKwLWzKHzZJWnySSjfKM/hRqWtHS9I1BrGytYTPAbeVvmLFGYAjJNLlUtB8zjq2c8kj3Dxyafp1xcumCs+puRGnuIx1/SpE0WW6u/tmr3T3l23G9uFUeir2FSWt81wA2cD61dikJbk8V9FGjGGqPjZ4mVTRliCzijGFGAKsCPvxSoc4zUuMY9abkxKKGgEc+1PV9tNxjOSeKM4HAqblWMbxJLFazWlzIq7VkCycclGO1v0NeVz+ba3V1ZOWWWOUszuf4Fcj16c4r1rXIRd6fNEy5yhAzXl+qXFokc8t+yxpcDbIf4mbGCB+Ir5rialenTqJXd7ff/AMMfo/h3iOWrXoSlZWUtdtNH6blzwjeEXTQnCKWKBewwa7tmGYWfJSQGJ/x4ry3Tbu2Nw9zZTs6LKCQwwRxyPfpXpVqftNjIvVhhlqMBJypKM1a6t93/AALHFxDThTxkp05Jq9000999v7yZVs7YXGnG1lOWtXa3bPcD7v6EVzF5pEtpdfYLtPN0m7dUcYyFBYf48Guqt2KatKgI23UO8f8AXROD+YI/KpfPKMiyAFSwzuH619BRtXwtp7rT7j46rfCY9Spuylr8nv8Aqcvr1sZJHeyOEDsyDp8ucD9K5i5VUJW5geJyPvDv+Fdc8ZW4u4HyGhlYD1weR+lUntTt2pLgf3WGV/I18+0rtH1jk0kcs8MWMrOuDxhhg0xoMdZI/wADXQyaZuPzQW7e4yv8jVd9Kw3Fug/7aEilbzFzeRiBFA5bP0FbGm2jIBPds1vbDsPvv7Af1NTw2DI//LOM/wCyKsi3jjzJK+fdjSkkNTaLSX5uXV9giCgJHGv3UUdAKv2zqrbzJtVTnBH51T1HS7ywitZr2zuLVLoFoGmjKeYB1xUBk3I67vmIIrSnLlacNLbGVVe0uqmt9zqrBdt4m3n5q+X16CvrLUVibU9PuIV2C5s7edkA4VjGM/qCfxr5JFermVX2tKlU7p/oeLkVD6tiMRR7NL8ZG94U0s614j0zTgMrcXCLJ7JnLH8ga+r/AAyvnajK/G0H5R6Cvn74H2Qm8SXmosgCWNqQnfEknyf+g7zX0p4Ot9tuZCBukOelc9BctO/c6sfPmq8vZfmL8SdSGkeAtQuOVaT5Bjr04P54rzG28B2Een2CXd9Kl99mSW5UxgqsjjeV65+XcF+oNdf8cZVkTQdFLHbPMrygd1J5/QVyN3qMk11cTM+S7sxreC6nBUatylSLRbXRdVgmWRblAeVGR+leg+FRouszRrraStPFu8toIyyKCfu47n3rzUXTTagu8hiqk113hS2mjtvNDEbzwvrTkh0kmz15vCXhqSFTcWtzKODukCknjvnNRf8ACF+EQ29dMnVs5DKqA/nU+jsZLCKMucBQOeoq+8RAyDXLzTTtzM6vceqijGl8GeFWzmz1DJ7hxz+tVrjwj4RtrWaa5S+htYk3ySSMAqKO55reaRYLeSWZ0jhiUvJLIcKijqSa8z8Ra0fEE+6Y/ZtFtjvRG+Uykf8ALWQf+gqenU8nAqMpt/EyZKG/KvuM26XTGupNQt7Z7TR4ebeKX/WSkdHf3J6L2+vTnpzeeLdSb70NhAQXlPKwr3UD+JzxgDrwOnNT3Fxc6/qSafa/u4l3MWcfLAneR/fH5ZwOTXW6XY29pBHbQJi3hXCg9WbHMjf7R5/3Rx653VzCVl0JbSwj2wQNCi2sQMaxlv8AVrj2GCzHq3HtwBWjLaWkc37pGt5niwDGoKkZxyvQ8nt1J9TToI1GGAODwI+ME1GNQ8jy7hY/MknylkqjaJCAcyknpGuePqT3ACeolpqclqul3Vx4ttUN2lpY6XEZPscDuHti/wB6RnHDOw425PZRwCa3pbv7Jo5LG50+GYFImhXe0CN1w2f9Yw53dvyxj3t/D4ae3GpXFvI17ckJ5zBftTgZknYnpGi9vovViaz9J1PVNVt9WWO8ZEADeaOkjNkkDtnGD+IpxSbsOo2oczPGdc02Kw1Ca1t3drdmYqzDaSM9x61VsLJYZkfDYJwSfStLXYbmK63XRZpQSrM3Un1NUYRJsDEE88UnFXKjUlKnvudRZTyeatvE2xZgbfHTlsFM/R1Q/hXqlxDJqFva6jZEp9pjDOM9OAQP/Hq8ZdZPK3qSJB8wPoRyD+de1+D9Rjk0eGRWZI3RWUKM8H5gPwDKPwrS9nc5YK8bFWPJ6DJPFUL/AFi2s/NVStxLDzKA4WOH3kc8L9OT6Cs3xLd6mJxZ2NndzK6rtEBEaPnOfMlzlVHHCjJz1FU7HwabvypPEU6XKxHMdhbgpbRfh1Y+pPJ716M6lRy5Ka+b2/4JyU6NGMVUrS+S3+fYx5tZ1PxJctDo0QvQrf691KWkXuqnlz7t+QrX0fwREtwb3WrhtQvPvMzn5B+ddRGYopotO0+1ee7K5jsrVRnHqeyL6scAVi6rqEL3bWRH9v6iP+YbprH7JD/13nGN59QCB7msWqdOV5+9P+unQ6l7WvC0LU6f9dd3/Vy4L9Nki6PDHJFCMPdSfJbQ/Vv4j7DJrkrvW1udR8rRo5te1UZHnumIIf8AdXoPqefpW2/hrUtcaOTxZfAW8fEWl2I8uCMf3eMD8q6fTbO10+Fbexgjt4F6BBim41Kv8R2Xb+v68iVUo4fSgrvu/wBP6+Zx2n+CJ725+2eKLzz5WO7yI2O0fX1ruLOzgtIEitYVjjAwFUYqVR9aeR2AwfWtYpRVonPNym+abuKqcZzk04jg9v6U3POOaXooxn6k0CQbc9xnH5UxkyOnepByMZwRyaDk4/zmpLRm3mmWl2yPc21vKynIZ4wTUrhVUEYCjoAOlWyTtyKqzfLE+CNw56UtjRLmPU/gjBt8JXNwcH7TeyuD7DCf+ymrfxg8QpoHgy52yhLq+P2SH5sHLA7iPoob8cVb+G2LTwJoqzFVklhMuMAZ3MW/qK3rmOxvgEvIba4VeQsqBwM9eor5iVTmm593c+09l7OKpfypL7lY+P8AXp2/s2z8iaRoLe7hlljDl8qr5J298VHHqFvqFw62NtqFzjklLYjaPxxX1o2geHVAT+ytMUDptgQdfoKYnhLRF3tb2fkeZgsYmK5x0rZYhdjm+rvufMmiWd3b6vbXD6LqcsUe7O0RqwyDyAWroZrrUIsY0G9IPKs9xEoP6nB9q9uvPA9hdIFW7vYwDn76t/MVyV1o2l/NHD4l1LPmtbqwtml3yKcFF2j5iMHOM9DUyxEFq3Y0p4OpO6gm/Q4MX2q+XxpUS54/eXo/opqjr9wD4W1D+0rOWK52go1rMskedwxuBAP616fY+D7+8sFudK8TRXNtLzG7QkcjIIPPBzwQRxiuW+J3hPXrHwdqV7dT2dzBCEZzG5DbdwzwVwevrVwqRk1ZkVKUoXUlscLpJXyVPAyBWzbnJA79aw9IbMIA/uitq16gf5NfTs+FS1NWI8A+1WB6/wCRUCHbgEYNSLhVGcjHSsWdKHuSDmlYkt196iLcjAz2pxPzZHT1oGJJAWUgYxXknjvRF2yLNhSsxkRwexH+I/WvXw2WNcX8RtPnu9LaS0Qs6nJUfxr3B/z2rmxcOei9LtanpZVV9liopuylo/n3+Z51Dpz6esV1JBcxWt6FlhkeJljlA+9sYjDY56V32kanb2EVst5cLF/yzLEdR0B/KszXtTvta8N6Hby6glzc2qmKCEtkoCAPmUdCAB+VRX2garK0UY025nRUCiSNd2SB3x0rxKSqSpc0Fflt/wAH9D6LMoUqddQnJe/fr81+bN7UNR0+O6ieynEwhlDDDAkjBB56dDV3V4SFLJjGMg+tcrbeE9eimWM6NdCF2yXkKqE+vNehRWTtGiXWzgAEL2r08sdR87qKydrfr+h81m0ab9n7J3cdzl76Fr2GPUrJQ9zEoS5hzgug43D3H8qoPDui8+D54u+Oq+xFdBc28+hXbXkEbS2Tn94F+8n+0v8AhUhtJEEOp6TPCIZchZFAMMnqjg/dPsfwrkxWHcJ3ietg8Sq9NKW6OUzkbgc00mt++trBrgpqEE+iXhGcqpeB/fHUD6ZFVToF9Jg2L218nUGCYEn/AICcGuS3c6TFm4TK43dq9x+FGgeEP7FttdtWfUNQRgk/2qPfJBLj7ioOF74PfjmvF7vStRh4ls50J4+ZCKPC2r694R8QRanpqbScJPBKcR3EfdWH8j2/SoaXRmlKTjLVaH09r2kReKNMk03V7QCzABVSczoccPu6KVz6n9a+Y9U0c2fie70q1vLfUQkghjuYG+STdgDnoCM4PYHPNa3i7xp4k8Xu0N/dfYtKZtsen2ZIDDsHb70h/Ie1Z0kUOlWZtDFv1W4ULCiN/wAeqZ5ZsdWI4A7VrRpym0l1Fiq0EnOSsl/X3/1sdVqM8E/iSZLVt1tbFLWNh/EI1C5HsSDXyYtfUWg2jRXFuvYHGT3r5ejCkNuJHHGBnJr0sxpqnTpU10v+h4uTVXXr16zXxNP8ZHuXwd037N4PFzj97qN0WBx/AnyL+u+vojw7b4WGJB1wK818G6R9gt9G0zAH2S3QSbf74XLf+PE167oqiEPcNwsUbSZ+gqZLkiokOftZufdni/xJujqHxJZlBaGzDouOnyIc/qVrl84U7uuKi8W6mzazIEb55PMlkPqXf/BFrBGpTICGc1tHRWOWbvI0baVH1GYkbsJhecYPrXtXhuzCaVDKyNu2joK8D0mbzbljk7mYZA/OvVBrV7FYQJHNKqKP7/H0qZSuaUo2TPYNOT5FcK4I4xtrVbAiaSX93Eilnd/lVQOSST0ArxZfEmpJGCt3PyOcOciteN9SvYI4r2eaV5sMlszkDHUO+ewxkA/U9q55U3udUJWLHijWn1udIYVKaQh8xQx2mQjnzpPRR1VT/vHnAHAX+oTa3qEGm6NAzh22xKTgyt1Mjeigc89Bya7a0t49UsXRkN5ZTHYsnINywONy4525yF9cZ6EVhXMFjaX9xpVjetD5pWLUL9lEmIxj/R4yuDjI+ZsHceCcDnWMbIlu71K+nSW1kf7P02Tz4EIa5u1H/H1KO47iNf4R36nrx10BXYqjHAq0fC/heHRJm0jxEjSQnEm90b5h/C2OVPtXP/aptPhEasIruVdxdTlbSH/nszH+Nv4B2+96VreEo2gTKEov3jYnliMdybpmeztiI51T700h+7bJ6kn75/4D/eqhrmrQ6ba3Ot644RI1COsWOn8FtF+P58k8CorExtaRTNi0sLaJntxI2BDGR80zn+8w6e31rx/xfrUnjHXAqs1vodirNAHOAifxzuP7xHQdhgDnrm1Z2Qkk9XsZHiCefxfqNzrmuIViXMEEKNhcD5kgTPQDqW+pPJr0b4T6tqc2iuNYii/s9M+U4i2ncTyAR1A9e3SvOrItq2rWzW8Hl6fbqyW0Uh+7H/EzDu7dT+Xau4jvNSs9LWysowYoo0WKNF3EKW24ABycZzWkIL4ia1XXk7fh5HOeL5Le6vb42xLCN8c/Uf41zlnds0iqi5APWtUwzTWpW5cGU71kBzuyDnB9+RWLZsUYAYHJolumZUknGSZvRIzxksea9A+GSyXOhS2yBna0maIgeh+ZT+TY/wCA1wFiWcMM++a09L8ST+F7u6a2U7boICAP7m7n/wAepy0VzGk3zOB6KvGfz5qvftMPJWNLloXLCT7KUEpPG0Bm4QHu2CR2FWFIIIGacCMYwcHrXrSV1Y4IPladrme1hNdWr2ly6WOmucvp+nOyiY+s85O+U/UgegrQs7eCxt1t7KCO2t1+7HEu0fjjrTgeD1/CnKePas4U4wVoo2qVp1nebv8A12HgjPIGKcnK55700HjBPHvSrjqfpTJJADj1z0pw4B46+lM78HjFLnp3PepGPPDdsGjvg9KjUnqRgCn5ORikO48dDikB9ByPWkDAjg5xQrHocEUrFJhggYPGapXiu1u6oVDN8qlzgDPck9B71cZiVYjBAH41nX4MlrKrHlgV6eoqJ35XY6cOlKpFPY9KsfiN4YtdMsLR3vA1rCsO1FUjhQPXnpUkfxZ8IlgYr25UkYwDH2/4FXg3hzU7PStbgutSs1vrKNWDWzMBuyMA8+hwa6ZPEHhKayZ28M6ejMXXLiJSRjIP3ef07V+e0MXOcdZpfI/aMZkuHp1PdpSknrdSR6x/wtrwose5ru5IzsJLoOf+++tOt/i34TZ1aK4nYsOMuhyP++68pj1vwnIwSDwvp4cyeVHGfLOWGPmA2nOc8fjTR4k8Jy7TJ4Y0qFSMeW5jDJ2z9z8etb+3n/z8X3M4/wCzKP8A0Dz/APAonsUfxV8ONnDXAwCefL7f8DrlLrxl4SWeaVtTuoprguxLQWhySxPcZ4yO/YZzXCS+I/CKgSP4c09x5igIrpx1zn5enHvSzeIvC8LbW8NaVIkrDHKEID/wDoMfrU+2k/inH7mWstpx+CjNf9vL/M7w/ELwvpcnkQ+I9RsY1kdltY4rQKu5g20fKeOoHOcE5JPNU/HnjDT9V+H+vWNtqWo308tuu1J4YsLiQEsTGB29eOK4iTxJ4ZREYeGdMkztyiiMkYzk58vuBXK+I9VstQ1a5udGs0060liSM20TgjsDnHqaunipRqQSknqla3mRVyenOjVnKnKLUZO7kt0uvU29JTbCvqV/pWxa54AABrKsR+7xx0ArZtkPB61+hSPxKK1NCLgj1FSjjGegPQUyMbVxj8aeDn65rFnQg4wT685pUOVBbGcdulMOD079/WlLEE4B9KLDuPAwaTcMc8YqM529/rSMRhcdetFgTsCxxqxZYolPqEAP51KLmWM/u3Kk9war7vm5JpM4bpmlylc5O13O2AZnx7mgSseSQar72Y/7tJ5hwM5p8pPMXVlIyCOMcg81TTTo4bmS40i4OnzSj99GUElvN7PGeD9RzShsg85pC+DmplBSVmVCo4Pmi7Mt2wm+z/ZpY1hjySYtovLQ+4Rv3kf4bvrWZdeHkeUmLTIGbubK6KZ+iyDNTiVhkg8U5buZQMSMMehrllhIs7IY6SMG60q5iGwQ6ooHGG5x+IqumksfnltbyRT2Lbfz4zXSSX9xnBmb6Z61Wkup2X5pGbnPJqVgYlvMZef3/wDAMhtLu1dvstvBYL0Mrku+PYZJJ+pA9qsWmk2tiWKl5pnOZJpDlmP9PpVppHOdx3A0wnncck9K66NCNPY4cRip1viZa0//AI/IjjjdXzT8O9MGseNNHs3G6IziSUHuifO36Ka+kbEkXaHPGeleO/ASx36xqepOPltrcQqfR5D/APEq351y4+PNOmvX9DsyqpyU60l2X6n0F4Vjaa+urhlJ6DOe5yTXaa3IbPwlfyIdryARKfc//rrF8H2gTTUfGDKxf/CrHxLuhZeGbVcAnc0zD1CKWH64rmm+aZtCPLE+YdemMms3snXD7V+g6VlySZQtVq8JLTM2CzOxJ/Gs8kDj1Perk9TCmk0avh5/9KjJz1rvxOfLVCfk67R61xWirCUiOMOMkmvWvDWhf2fZ2+r6hZSXt5O4TTtMzgzPnBc/7I6n1xj1wm7GlO8r9i74c0RrYQXF5AZr64x9ks+uR/z0cf3e4HfHpU+qx3WrW9zb6XMjwM+y9vyebnH3o4fVF7njceOlN1q9mT7TYxXST38uf7UvwflQd4IyOg7MR9BV/wDtQWdhbiG3EV80YNtahcCGPoshX0x91fx6URV9zSV47f1/wTDjWTw/C9npymHVJ8eaM5+yxkcLjp5rDr/dBx16VxYWxQROrQsCGEiZYK38/wCda1vaMvzXbGVyd5cnLAn39alWGII9xdk/YoiBIY/9Y7H7sSD+835AZJ4FaK0VqS25S0Of0Dwzpnh66n1a1ty1xfOyxo7FklbOWcjOPLXqfU4X1xNFGdavxM6vLZrPucn719ODyW/2V9Bx2HANOu5LnUryaN3ELFALh4elvCPuW8Xv1yT7seTVLxlqx022j0nTT5d5JEqO0YwLWDaMADJw7Dv6HPUip+EcnzabmB8RNdk1W5/sPSWea1EoFxIn/L1LnhB6op/M+wFcdeokznRrAhraN917cI2RcTL0RT/zzT9WyewrVvimlqtnbsU1S4gJ3IebSEjr7O4yB6DJ7ipvDunpbIkaRBRtwAvYVUY3MZT5dFv+XmS6bbQWcsEMhUSzAlFAJ3Y5PPat9SHaMbdjq33I1OSD0x3phs3ICspC9AOnFWrW2jaKWIhvmUpndjAI659a0bIjFIxtS0lxPcNMsjyDOA4IK+x964V7byLuSIqoZW5Ar13+y/KtooReTzxhRlpiDgjqQcd/Q9K8/wDE8MK6vI1ocIcZJPU4xUvUj4dUVrSRYEI7uCDUsyLOkZUAkDms0qQcls4NaFuC0fHrT3MJaHqKjtj/AOtTwm773JHI6daRSCR0OfQc1MAPTtXqtnGhnI4Bp69OgBPajHzAEACnBSQcDg9PWpKE2Y5H6mnAYHPI9aUA/U07GSMgEd6VykhoBII55GaUHjBFSbQcd6dj16570rjIjznvR8wdQoG3vUgHoBntSqhLZwM1I0N2kg549fenD0FOxtIHp2p2OexyKVykiEL8uCMZ/SmvaC4XBIVs8HGam8skYFOjBCFs4PINRN6HRQ+I5CXwXqRZvJOmsmM/NOQfpjbVe88HawwPlW1iUC4VTcjPv/DXbFmCDBzz+lIrSbcgEKB3r595HhL/AA/iz7lcX5k1rUX/AICv8jjE8Ia1sCG3sVdW3q4uRweP9nPpTf8AhDdZ5JtrNmzkf6Uv9RXbsZOQc59PWlG8c/Mc9sVP9iYX+V/eylxbmK+2v/AUcHJ4L1wyofsNmc5JP2pMfyp3/CH66y4eytCB3+1pkfpXeHzHZVUOzbScAZNRsk4U/JIOOflNH9iYT+V/ew/1uzL+df8AgKOFPg7XB9yzs8Y/iu1H9KY3grWvNXzILGKLcu6RboNgAgngDJrupBNuXKuCcDoaduYEgckHvWtLJcJGamo6rXdnNieLMynSlTc1Zpr4V107GXa6WlsMSEsw4OavrGExtUA1JyxOQMetIfcCvf5m9z4hxS2EGc4FAOSrZOMHj/GlIJ6Ag44oUADj1xxQSM9PQU7sRmgqcfQc0FeMH6cUCBeBjqfr3owAOw9RSj7uRyOlIAT1pgMZR7fnTCMcFcmpXwpBA4BoA4/maBEW05HNJjA44qVlO35Rgdc0xwAAcH0xTQMZjcSPxpuCDz1p+DjPQnke1NPX5jz29KYhCM5zjBx+FIQFUCnZAHt3prc9SADSGRnOOAvAySaYRn6nPNSOR6Dn0pMAjjgexqiWQEfMBz0/yKUrzgk4FPI3dOnU5NI+3JzjHc00S0FlzcRnHX1GDXBfBmzNv4TTAxNfXDP+A+Rf1BP413sOVmDZ4FZXw1sBHe6XZx8xW0a5z/sj/E5rixukov1/Q7sB8E497fqe2aPbCOOGFRwoCiuE+P8AqX2e4sbGMc/Zzu5xgEgnj6KR+Nen6NDunQEYxXhfxgnbUviDcx5zEkTIPTj5f6mvOp6zPRqK1P1PILls20ZbO4jr61lytgk9hz9K0/EWbIqr/Ku7GT9K7z4P/Dttcdde11Hj0iBgY48fNO3YAdye3oOT2BuctbGdCHu3ZqfCzweI7OLxBr0ExgLCOzslB8y6k4woH5ZPYe5GO81u/mgu7mKGQPrsoEFxND92yTtbQY4DY4Zh0/M0vi7W5rDUU0rSFU+InjEWIeU0m3I+6v8A01IPLds+/JHZ2vh3T4nuCCQCixhjukbqVB6jqCzdcEAcsKFFtXZvotI/15v+tPUz1totJtIZJoo5B/y7Wp5Ejg/ff/YU54/iOR2NPs4G8yS8uWMk8nzGV+rMe9W7CymvJ2v79cu/MaYwABwAB2UDgD2q69q8rLDEjPJIdgUfxE9vpWqstzGcubRFSOPcXLyJDGiGSW4YZSKMdWb/ADkkgd6zLm4kvbmA26mCMApaRuf9Wp+9K5/vtxn04UdKi1TUIrlfs1kfO02CRctGP+P+cdCP+manO0dzlj2wN5el20lzdMC+0PcyKM8n7sSA9+wH1J4FLm+0wcbe6tyPVLuHQ7INar5kzswtonGNz/xSMPQHkg+w+nCX94mkafcaxqI+03DOREkn/LzOecsf7o6t+AHJFbcji6ku9V1eZba2gj8yV/4YIh0RfU84A6lj71zUjReIdTW/nia4SMBbS1bKw2yDpxn5mPVjgZPtxUxTm7jk40lqU/DdhK7SajqrvLdXTNLK7DlyRjOPTPAHoK63TdqzhVTcMYweKZb27ZLSZZj1ratIhGpyD068VvolZHM7ybb6khjSTBjxnAOAc5pPKNsRuQHBweMY9at2wic71URsowTilGLhTgfKGweevrUlEeo2rzaa5gGxATlQDwOxryjWg63RDjDDqK9gulilgcl2SMDaFVsEHscV5T4jgSK7kEbs53HLMOv0pmM9jL2cEd8Vats+X2/Oq8YyOSelWIlKFlPHeqRzTelj1fGSMdaegYsR2znNRGQeuCOlSI4bnBr1GjmTJ17dzShgDxUKnAJ708MNw4OKixVyTkjp9KOQxyBgeg703IZQR92nA56EZ68/0pWKuKRgcdu1LnjGMZ61EsoZyoyWXqMEU/cAecj8KVguOVeTgU9R04qPdkAZGfenbugzyOuKTRSY9c44xTsA9vxqEtuAwSCCOlIHAbjFKw1InGTndjPtXQaBGjadl4lZvMYZKg5xXOB8YPUVvaPf2sFgkc8gRw7EqAT1PHSsa0W46HTh5JS1L4lDyMltbKwVtrSMAFU9x6k/QYpNTI+wXAWMZIAGPqKbFqWnRLsWdyNxboepJJ/nUF1qtlJbuiuxJI42Y6EVyqnK+x3OrDujQyA5yoJzxTgQBuwOeQMVSbWbHJy8n/fFIusWIUgNJj/cpezl2K9rDuvvFkdv7fjAXAW0Yk+5cCr284HHNY8mrWqagZVWSRWhCdMYO4k1MNctjyYpePoabpS7EqvBXuzQ3sXGVyO1cXcNJJf3XygAyv8Ahya6dNcs/l3JMAOT8ormGOXlYdWYt7jJJrahBxvdHPiasZW5WLhdm1sdOo703A60bxg4pjHBPP5108pxOY8jnp+VHU9MeppgbJ5Oadkg4PA9c07E3FXGDnGe9IcZP07U1m64GSOlN38c498etHKLmQ/PGO/uKdu5yMntUZcdCRnFJu5PPvT5Rcw4Ng47mkYgdeccUwvjp1PrSK2CSKfKHMOHRuRj19aTJ9wBzTTJyMnmkLkgDvmnyi5kOPLcn3NRtjPPOc800sCOSD/jTXIyc4yewppC5iT+7jJB9TTGOQTioweeDgYpC/8AD2NHKHMOJx7HNIGA755qNn4AHUU1nyMZPHFPlJ5yRzgAjH/1qY5BPIyvemPICAQfamFyQO1UokuRMDmQc5IrQ+FdmZLq5uGHCgIM+/J/pWOZW3Dpj613XwwtPJ0COcjDXDmQfTOB+ledmXuqPz/Q9HLPec/l+p6PowCSAmvmvx958HxD1fzSAFZwg77QS2T9dx/I19JWTbcN6V5d8bPChu9RttXtHWHzY3hkdgdu4qRg46Z7GvMoSSnbuepXi3BeR4bPZJ4g8c+HdIZlCXFxmTIyMDHUV9B694jOgeCtR1XT4FDWrfZtNjIyELNt8zHdsZY56mvljUNSv9B8YWWoGNo72zKt5bfrj2I6H6V9X+Fr7Q/iH4PeOB0aG5+do1I3RP1Ix6g9uo+hBrRyjzPm/pCUJqnFx/pnJeCrez07wrJqV5NK97fsWuJAczMzZIVW7uwyc9uWPA5twxXK3R1PxLZkJKCsYSQtHbjPyIc8jg5LHOWJJ5NYHiPw5q3hm5gtdYmnbTYVZNNvYRmOAscneoHJPALdcAdgBXb+H/EMawQ2msFJYWGwXSLuRhjv6j3/ADrolr761JhNL3du5rLHGU3q4CbNwJOQV9iK5TxDem6mudHtJRCAh/tGfdjyY8fNAD/eP8ZHQfIP4qXxC50a4+y+GDJLd3eGgiWQeXbISSbgZ7n+Bemcv0C5Z4D8Lw6hG15qEZj8P2B3Sckm8nHVf9oA9fU8Vnpbme35lNWdlv8AkP0zT0ttNTVLxY7eNkb7FC52hEAyZW9BgZ9gPz4yS5k1+/iFsJDaK58iNlwZHPBlb0J7D+EAD1JteP8AxPJ4m1WW2tGH2FGCSFD8rYORGpHBVSMk/wATD0VScLxFdvptkujaZJt1W9j/ANIkXrawEdPZ36ewz7VldzLUVBNszPEl5/wkGorpGlyq2j2EmZJR0u7gcFv91eQv4n0rodL04WkYG/YABn61BoGjLZWqRxxhdoxjA4rV8hJADJ5j855bAx+FdUUoo4Zyc5XJhCFJwAd3Ru9PUEgoAT3x3qwkaRovk/eHcmjqS5xkdMdCaTfYEMCAAk5LdMVPaxeWVZiBjrtPH1qOLLPtPTgHB6DPWteG1WSRw4wi/d75oEyU2Ze3kWNSrfxNjIx9a8u8aWjQ30ikLnAOB9K9xs0RotsqgHrnHOa81+JFgn2+ymj+5KDGzHjBzmmpXMpxujzWNdrKccA9KfPklWOBkYHbpWhc2qwko2FwFb8uDWfP5alfMCsxGcHoPYVdzmcXfU9PD4OTgnNKGx25oor2bHApMeJeQCvGMU9JQSAc8cYooqXFFKTHLKOQBQZcZ5GM0UVNkUm7CmYjHcHt70u/jA/Dmiik0O44NkEcc0pcKmemOnNFFKw7jSxZevOKaX2rxnpniiiiw7jlfIOCfx4qQMc4HX1oopWHew/fkZz+NG/5emPWiilYd2I0g6tn8KRXx+PWiiiwXHiTP9RSFhnrRRSsO7YM5CgCmZYKx6j+dFFCB7iKxyQQCPQU3euSOD7UUVSRDYm/JGPpg0u/qc4HoPWiiiwDOmBxxSmTGOg/GiinYVxpYbs4OOlNLE5PQYoop2EncaXyOvPpTfMycHHBzRRTsK+whcDHoetIZABnIJHeiiiwm+owuckgcfWgucH1oop2FcaZMDt+JqMygAnI6dhRRTSBsQyDtgioxJwQSQOtFFNIhtkbSdOuB2pJJMHg49MUUVaRDkyvPIdoZX2EcnjORXtmj2q2Njb20QxHEgQD6UUV5ObLSHz/AEPYyfefy/U6C1xsHJq9JFFcQSQ3ESyQyDDowyCKKK8JnvR13PL/AB98GdP8SWmy0mEciZMPnglos9lYc7fY8V5povwe8feDdWN/4duIWkyMqsm5JQOzDj8xyOxFFFXGo5aSVxShyL3W1/Xmey2uveI5tNa01/wHe3m9Qr+VcQlH45yGIwc9CK4W78Ma9BqIl8PeHNSgsC6u1jqLxyRkg5xhG+726gkHFFFbwm4axMJ+/oxNP8KeK2uppNagvWF6+++ntYv9IkBzlVJwq8YHHQAAcDFdF8QbXxNrHhOLQfB2lS6HapGIQ86sWRMEHbsz8x6ZJ7k9cEFFOc+e10KDcNmcbongnxNpUNwsthBO6Em0ARwq8fLv+XnHtVXTvA+s2c0txd2NzdXkz+ZNNg5d+/bgeg7CiirjOxnNOWjZuJpOpqQ0ujXzjHIVOhqQ2F6vTRtU9gYRx+tFFXzsz5EC2t2V2yaHqg7kiIY/nSSQTLknR9VOPSEf/FUUUczDlRFb3Diba+laooJxzCn9WrVbXbW0VRPpesblOGxaq/I/3WPFFFF2x8isJP4x012VjZ60m3v/AGe3P5HNcz4316w1my22ttqzTIwZM6dImex6iiii9mJU1JHEah9supE8jS9SY7TkG3I6nPf6mltvCPijUI/Nt9HKDubliCfoFB/nRRQ5smNCDd2f/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A) Kimura spatulas (on marking pen), glass slides, alcohol lamp to sterilize spatulas, and culture media. B) Microscope and specimen staining setup. C) Specimen staining trough for wash.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_10_22690=[""].join("\n");
var outline_f22_10_22690=null;
var title_f22_10_22691="Chronic farmers lung Light";
var content_f22_10_22691=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F56574&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F56574&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Chronic farmer's lung",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 309px; height: 205px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Low power light micrograph from a patient with chronic farmer's lung shows bronchiolitis associated with fibrosis. Cholesterol clefts (arrow) are seen in the fibrotic region.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Talmadge E King, Jr, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_10_22691=[""].join("\n");
var outline_f22_10_22691=null;
var title_f22_10_22692="Categorize chronic diarrhea";
var content_f22_10_22692=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F60860&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F60860&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 629px\">",
"   <div class=\"ttl\">",
"    Algorithm for the evaluation and classification of chronic diarrhea in children",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 609px; height: 754px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted with permission from: Fine, KD, Schiller, LR. AGA technical review on the evaluation and management of chronic diarrhea. Gastroenterology 1999; 116:1464. Copyright &copy;1999 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_10_22692=[""].join("\n");
var outline_f22_10_22692=null;
var title_f22_10_22693="Lepromatous leprosy lesions";
var content_f22_10_22693=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F71776&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F71776&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Skin lesions of lepromatous leprosy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 275px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Schmiedel S, Ehrhardt S, Moll I, Burchard GD. A Thai patient with generalised inflammatory skin disease 18 years after migration to Europe. Lancet 2006; 367:1458. Copyright &copy; 2006 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_10_22693=[""].join("\n");
var outline_f22_10_22693=null;
var title_f22_10_22694="Hematospermia";
var content_f22_10_22694=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Hematospermia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/10/22694/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/10/22694/contributors\">",
"     Barry D Weiss, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/10/22694/contributors\">",
"     Jerome P Richie, MD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/10/22694/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/10/22694/contributors\">",
"     Michael P O'Leary, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/10/22694/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/10/22694/contributors\">",
"     Fenny H Lin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/10/22694/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 30, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hematospermia, the presence of grossly bloody or blood-tinged penile (seminal) ejaculate, is an uncommon condition. While it is usually alarming to patients, the cause is almost always benign. Only a few case series have been published, nearly all of which are from urology specialty practices.",
"   </p>",
"   <p>",
"    Because of the paucity of research literature, there is little evidence on which clinicians can base their evaluation of patients with hematospermia. Searching for the rare causes that have been identified in case reports is not likely to be productive [",
"    <a class=\"abstract\" href=\"UTD.htm?22/10/22694/abstract/1\">",
"     1",
"    </a>",
"    ], and the relative frequencies of causes reported in case series from urology specialty practices may not apply to primary care practice. The most important lesson from the literature is that hematospermia is almost never a sign of cancer in younger patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common cause of hematospermia is prostate biopsy. Hematospermia occurs in more than 80 percent of men undergoing prostate biopsy and lasts for an average of three to four weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?22/10/22694/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Vasectomy can also cause hematospermia for a week or more. Because the cause of hematospermia is obvious in these instances, the remainder of this review will focus on other causes of hematospermia.",
"   </p>",
"   <p>",
"    A variety of conditions other than prostate biopsy have been reported in patients with hematospermia (",
"    <a class=\"graphic graphic_table graphicRef64639 \" href=\"UTD.htm?1/40/1677\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?22/10/22694/abstract/4-42\">",
"     4-42",
"    </a>",
"    ]. They include benign and malignant disorders of the prostate gland, seminal vesicles, spermatic cord, and ejaculatory duct system; urogenital infections including sexually transmitted infections (eg, chlamydia, herpes simplex virus, gonorrhea, trichomonas); metastatic cancers; vascular malformations; congenital and drug-induced bleeding disorders; and even frequent daily ejaculation over a period of several weeks. However, it is often impossible to know with certainty whether these conditions are the cause of hematospermia. The cause is idiopathic in a substantial proportion of patients, and the condition frequently resolves spontaneously.",
"   </p>",
"   <p>",
"    It is also difficult to know the true relative frequency of the causes listed in Table 1 because of publication bias that tends to favor reporting of new or unusual causes of hematospermia. In addition, as noted previously, there are no data on the relative prevalence of the causes of hematospermia among patients seen in primary care practice.",
"   </p>",
"   <p>",
"    The best available information on the relative frequency of the many causes of hematospermia is found in case series from urological specialty practices [",
"    <a class=\"abstract\" href=\"UTD.htm?22/10/22694/abstract/4-8\">",
"     4-8",
"    </a>",
"    ]. They suggest that hematospermia is almost always the result of a benign condition and usually resolves spontaneously. Cancers are rare and occur almost exclusively among patients over age 40 years; serious causes are virtually never found among patients under age 30 years.",
"   </p>",
"   <p>",
"    These principles were illustrated in the two largest case series:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The largest case series was from a university urology departmental in Guangzhou, China and involved 270 patients aged 15 to 75 years [",
"      <a class=\"abstract\" href=\"UTD.htm?22/10/22694/abstract/43\">",
"       43",
"      </a>",
"      ]. They had experienced hematospermia for a mean of 3.4 months (range: one day to eight years). All patients underwent transrectal ultrasound and a variety of minor abnormalities were found in the seminal vesicles, ejaculatory ducts, and prostate. No cancers were found in patients &lt;40 years old. Eight of 126 patients (6.3 percent) over 40 had cancer (five prostate, two seminal vesicle, one bladder).",
"     </li>",
"     <li>",
"      The largest case series with the longest follow-up involved 200 men with hematospermia, 150 of whom were followed for 5 to 23 years [",
"      <a class=\"abstract\" href=\"UTD.htm?22/10/22694/abstract/4\">",
"       4",
"      </a>",
"      ]. The men ranged from age 20 to 74; most were between ages 40 and 70. Approximately 85 percent of men had multiple episodes of hematospermia. Most underwent a urological work up that was standard at the time, including digital rectal examination, cystoscopy, and KUB x-rays. These studies were negative in 63 percent. In the remainder, a variety of minor abnormalities were detected, including benign prostatic hypertrophy (17 percent), prostatic calculi (7 percent), and abnormal veins (8 percent). It was not certain whether any of these abnormalities caused the bleeding or if they were simply coincidental problems. Cancer was an uncommon diagnosis; during long-term follow-up, prostate cancer developed in only 4 percent and bladder cancer in one man. It is possible that these few cases of cancer were related to the initial complaint of hematospermia, but they may also have been incidental cases related to the expected rate of such cancers among men as they age.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    No cancers were found in men in other smaller case series [",
"    <a class=\"abstract\" href=\"UTD.htm?22/10/22694/abstract/5-8\">",
"     5-8",
"    </a>",
"    ]. In two of these series that used transrectal ultrasound for evaluation, abnormalities of the seminal vesicles were common, including dilated seminal vesicles, seminal vesicle cysts, seminal vesicle amyloidosis, and calculi [",
"    <a class=\"abstract\" href=\"UTD.htm?22/10/22694/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Prostatitis was diagnosed in 28 percent of patients in the last report [",
"    <a class=\"abstract\" href=\"UTD.htm?22/10/22694/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hematospermia may be associated with an increased risk of prostate cancer in older men. In a community-based screening study involving 26,126 men ages 50 or older (or ages 40 or older if black or with a family history of prostate cancer), men were screened for prostate cancer every six or 12 months with PSA and digital rectal exam (DRE) and underwent biopsy, if these results were abnormal [",
"    <a class=\"abstract\" href=\"UTD.htm?22/10/22694/abstract/44\">",
"     44",
"    </a>",
"    ]. On an initial questionnaire, 187 men (0.7 percent) reported a history of hematospermia. Over the course of the study, prostate cancer was detected more commonly in men with than without hematospermia (13.7 versus 6.5 percent). No cases of prostate cancer were found in the 15 men with hematospermia who were younger than age 50. The interval between hematospermia and prostate cancer, as well as the duration of hematospermia, could not be assessed in this study. Also, it is unclear whether the history of hematospermia could have been known to the examiner performing the DRE and thus could have resulted in more aggressive evaluation for prostate cancer (detection bias); however, the authors of the paper report that they do not believe the examiners had this information [",
"    <a class=\"abstract\" href=\"UTD.htm?22/10/22694/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The major conclusions drawn from these and other studies are that hematospermia is almost always caused by a benign condition in younger men and, in many cases, no clear cause can be identified. In older men with hematospermia, genitourinary cancers should be considered in the differential diagnosis, but the rate of such cancers is low, even after long-term follow-up.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The etiology of hematospermia is almost always a benign condition. For patients who are otherwise asymptomatic, the initial evaluation consists of a history, physical examination, and urinalysis. Other studies are indicated only if abnormalities are suggested by these initial measures or if hematospermia persists. Although many experts recommend a more aggressive evaluation for even a single episode of hematospermia in a man over age 50, we do not believe existing evidence supports the need for this.",
"   </p>",
"   <p>",
"    Men with hematospermia and symptoms of urethritis should be tested for gonorrhea and chlamydia. Persistent unexplained hematospermia (lasting longer than one month) should be evaluated with transrectal ultrasonography and, in men over age 50, with referral to a urologist.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;The history is usually unrevealing unless the patient has an obvious history of dysuria (suggesting infection), urological symptoms suggesting prostate disease, or known urological malignancy. The clinician should ask patients about these conditions, although they are not often present. Travel history should be reviewed to determine if the patient has visited an area that is endemic for schistosomiasis, as there are multiple case reports of hematospermia due to this infection [",
"    <a class=\"abstract\" href=\"UTD.htm?22/10/22694/abstract/9,10,46,47\">",
"     9,10,46,47",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/38/15977?source=see_link\">",
"     \"Epidemiology, pathogenesis, and clinical features of schistosomiasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Questions should also be asked to assure that the patient has not recently had a biopsy of the prostate gland or vasectomy because, as mentioned, hematospermia is a well known complication of these procedures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;While the physical examination is typically normal among patients with hematospermia, examination should focus on identifying organ enlargement or masses in the scrotum, or nodularity or enlargement of the prostate gland.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Urinalysis and cultures",
"    </span>",
"    &nbsp;&mdash;&nbsp;A urinalysis should be performed on all patients with hematospermia to exclude infection; bacterial cultures are obtained as indicated by the results of the urinalysis. Pyuria without bacteriuria may be a clue to chlamydial infection, one of the reported (though uncommon) causes of hematospermia [",
"    <a class=\"abstract\" href=\"UTD.htm?22/10/22694/abstract/11,48\">",
"     11,48",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/18/18728?source=see_link\">",
"     \"Genital Chlamydia trachomatis infections in men\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Men with hematospermia and symptoms of urethritis should be tested for chlamydia and gonorrhea. If these tests are negative but symptoms of urethritis persist, infection with other agents such as trichomonas should be considered. The diagnosis of trichomonas in men is difficult and may require specimens from multiple sites (eg, urine, urethra, semen). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/18/18728?source=see_link&amp;anchor=H22#H22\">",
"     \"Genital Chlamydia trachomatis infections in men\", section on 'Differential diagnosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/35/26166?source=see_link\">",
"     \"Diagnosis of gonococcal infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In men with hematospermia who are otherwise asymptomatic we suggest not routinely testing for sexually transmitted infections. In men at very high risk for sexually transmitted infections, routine screening for gonorrhea and chlamydia is recommended even in the absence of hematospermia and so would be appropriate. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/30/490?source=see_link\">",
"     \"Screening for sexually transmitted infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Semen examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Examination of the semen is not a routine part of the evaluation of patients with hematospermia. There are, however, several situations in which semen examination can be helpful.",
"   </p>",
"   <p>",
"    The first is when there is doubt about whether the patient actually has hematospermia. In this situation, the patient can ejaculate into a condom and the ejaculate can be examined for the presence of blood.",
"   </p>",
"   <p>",
"    A second situation in which semen evaluation may be helpful is when the patient has a history of travel to an area in which schistosomiasis is endemic. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/38/15977?source=see_link&amp;anchor=H3#H3\">",
"     \"Epidemiology, pathogenesis, and clinical features of schistosomiasis\", section on 'Epidemiology'",
"    </a>",
"    .) In these cases, microscopic examination of the semen can detect Schistosoma haematobium or Schistosoma mansoni. Semen microscopy is not a useful test if there is no such travel history.",
"   </p>",
"   <p>",
"    At least one case report suggests that melanospermia can be confused with hematospermia. Melanospermia occurs when malignant melanoma, metastatic to the seminal vesicles, causes pigmentation of the semen (although melanoma can also cause true hematospermia) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/10/22694/abstract/49\">",
"     49",
"    </a>",
"    ]. While this diagnosis is quite rare, melanospermia can be distinguished from hematospermia by subjecting the semen specimen to gas chromatography.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Blood tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Routine prostate-specific antigen (PSA) is not necessary in men with hematospermia. Some studies do suggest that men over age 50 with a history of hematospermia are at a slightly higher long-term risk of prostate cancer, so it is reasonable to take this into account when making decisions about screening for prostate cancer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/8/42122?source=see_link\">",
"     \"Screening for prostate cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;When imaging is required, transrectal ultrasound is the imaging procedure of choice for patients with hematospermia [",
"    <a class=\"abstract\" href=\"UTD.htm?22/10/22694/abstract/6,7,50\">",
"     6,7,50",
"    </a>",
"    ]. It can identify structural abnormalities of the prostate gland, seminal vesicles, and spermatic cord, and guide biopsies if any suspicious abnormalities are identified in those organs. Transrectal ultrasound should be obtained when hematospermia persists for more than one month.",
"   </p>",
"   <p>",
"    Magnetic resonance imaging (MRI), particularly endorectal coil MRI, is a second-line imaging test that may occasionally be helpful when transrectal ultrasound is technically inadequate or nondiagnostic [",
"    <a class=\"abstract\" href=\"UTD.htm?22/10/22694/abstract/12,51\">",
"     12,51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based on the results of the tests discussed above, other studies may be occasionally be indicated in selected cases. These include cystoscopy, contrast studies (eg, vasography), or biopsies of the prostate, testes, or other organs. We suggest referring men over age 50 with hematospermia lasting more than one month to a urologist.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most cases, the evaluation described above will not identify a clear cause of hematospermia. Thus, there is no specific treatment for the majority of patients, and the condition usually resolves spontaneously.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Patients with identified abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Specific treatable conditions that are identified during the evaluation, such as infection or tumor, should be treated according to current practice standards. Some structural abnormalities of the urogenital tract, such as mullerian duct cysts and ejaculatory duct obstruction, may be treatable endoscopically [",
"    <a class=\"abstract\" href=\"UTD.htm?22/10/22694/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Treating for presumptive prostatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;As mentioned, 15 to 28 percent of patients with hematospermia have prostatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/10/22694/abstract/5,8\">",
"     5,8",
"    </a>",
"    ]. Some clinicians prescribe an antibiotic for treatment of \"presumptive\" prostatitis when faced with a patient presenting with a first episode of hematospermia for whom no specific diagnosis is identified. This approach is based on the rationale that prostatitis is relatively common, can cause hematospermia, and is easily treated with antibiotics [",
"    <a class=\"abstract\" href=\"UTD.htm?22/10/22694/abstract/50\">",
"     50",
"    </a>",
"    ]. However, there is no evidence that such treatment is effective. Any apparent beneficial effect may simply be due to the fact that hematospermia resolves spontaneously in most patients. Nevertheless, it may be reasonable to consider empiric treatment in patients with persistent hematospermia who have no other apparent cause. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/60/23496?source=see_link&amp;anchor=H14689296#H14689296\">",
"     \"Chronic bacterial prostatitis\", section on 'Management'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Reassurance",
"    </span>",
"    &nbsp;&mdash;&nbsp;No specific medical or surgical treatment is available for most men with hematospermia. This fact, combined with the low frequency of serious abnormalities, suggests that the most important therapeutic intervention is reassurance. Patients with hematospermia are typically anxious, and concerned that their bloody semen is a sign of cancer. In younger men, and after an appropriate evaluation in older men, reassurance can be given, with confidence, that occult cancer is an unlikely diagnosis. Patients can be further encouraged that most cases of hematospermia resolve spontaneously.",
"   </p>",
"   <p>",
"    Nevertheless, patients who have persistent hematospermia for more than one month should probably be reevaluated with transrectal ultrasound.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hematospermia is almost always a benign condition. There are multiple causes for hematospermia (",
"      <a class=\"graphic graphic_table graphicRef64639 \" href=\"UTD.htm?1/40/1677\">",
"       table 1",
"      </a>",
"      ); the most common etiology is prostate biopsy. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who are otherwise asymptomatic, the initial evaluation consists of a history, physical examination, and urinalysis. Other studies are indicated only if abnormalities are suggested by these initial measures or if hematospermia persists. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Men with hematospermia and symptoms of urethritis should be tested for gonorrhea and chlamydia. Persistent unexplained hematospermia (lasting longer than one month) should be evaluated with transrectal ultrasonography and, in men over age 50, referral to a urologist. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In most cases, the evaluation will not identify a clear cause of hematospermia. Thus, there is no specific medical or surgical treatment for the majority of patients, and the condition will usually resolve spontaneously. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When no serious abnormalities with hematospermia are found, the most important therapeutic intervention is reassurance. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Reassurance'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22694/abstract/1\">",
"      Ahmad I, Krishna NS. Hemospermia. J Urol 2007; 177:1613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22694/abstract/2\">",
"      Raaijmakers R, Kirkels WJ, Roobol MJ, et al. Complication rates and risk factors of 5802 transrectal ultrasound-guided sextant biopsies of the prostate within a population-based screening program. Urology 2002; 60:826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22694/abstract/3\">",
"      Manoharan M, Ayyathurai R, Nieder AM, Soloway MS. Hemospermia following transrectal ultrasound-guided prostate biopsy: a prospective study. Prostate Cancer Prostatic Dis 2007; 10:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22694/abstract/4\">",
"      Leary FJ. Hematospermia. J Fam Pract 1975; 2:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22694/abstract/5\">",
"      Jinza S, Noguchi K, Hosaka M. [Retrospective study of 107 patients with hematospermia]. Hinyokika Kiyo 1997; 43:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22694/abstract/6\">",
"      Furuya S, Ogura H, Saitoh N, et al. Hematospermia: an investigation of the bleeding site and underlying lesions. Int J Urol 1999; 6:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22694/abstract/7\">",
"      Worischeck JH, Parra RO. Chronic hematospermia: assessment by transrectal ultrasound. Urology 1994; 43:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22694/abstract/8\">",
"      Kochakarn W, Leenanupunth C, Ratana-Olarn K, Viseshsindh V. Hemospermia: review of the management with 5 years follow-up. J Med Assoc Thai 2001; 84:1518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22694/abstract/9\">",
"      Schwartz E, Pick N, Shazberg G, Potasman I. Hematospermia due to schistosome infection in travelers: diagnostic and treatment challenges. Clin Infect Dis 2002; 35:1420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22694/abstract/10\">",
"      Torresi J, Sheori H, Ryan N, Yung A. Usefulness of Semen Microscopy in the Diagnosis of a Difficult Case of Schistosoma haematobium Infection in a Returned Traveler. J Travel Med 1997; 4:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22694/abstract/11\">",
"      Miyata Y, Sakai H, Kanetake H, Saito Y. [Clinical study of serum antibodies specific to Chlamydia trachomatis in patients with chronic nonbacterial prostatitis and prostatodynia]. Hinyokika Kiyo 1996; 42:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22694/abstract/12\">",
"      Hasegawa N, Miki K, Kato N, et al. [Magnetic resonance images of hematospermia]. Nihon Hinyokika Gakkai Zasshi 1998; 89:956.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22694/abstract/13\">",
"      Koment RW, Poor PM. Infection by human cytomegalovirus associated with chronic hematospermia. Urology 1983; 22:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22694/abstract/14\">",
"      Walton HC. Trichomonas and haematospermia. Br Med J 1969; 2:514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22694/abstract/15\">",
"      Abdel Razic MM, el-Morsy FE. Genitourinary mycobacteria in infertile Egyptian men. Fertil Steril 1990; 54:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22694/abstract/16\">",
"      Dumas JP, Poumier-Chabanier C, Dupuis JL, et al. [Cancer of the prostate revealed by hemospermia in a young man]. Ann Urol (Paris) 1985; 19:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22694/abstract/17\">",
"      Gaudin PB, Rosai J, Epstein JI. Sarcomas and related proliferative lesions of specialized prostatic stroma: a clinicopathologic study of 22 cases. Am J Surg Pathol 1998; 22:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22694/abstract/18\">",
"      Maheshkumar P, Otite U, Gordon S, et al. Testicular tumor presenting as hematospermia. J Urol 2001; 165:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22694/abstract/19\">",
"      Meng MV, Werboff LH. Hematospermia as the presenting symptom of metastatic malignant melanoma of unknown primary origin. Urology 2000; 56:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22694/abstract/20\">",
"      Yamamoto S, Mamiya Y, Noda K, et al. [A case of metastasis to the seminal vesicle of renal cell carcinoma]. Nihon Hinyokika Gakkai Zasshi 1998; 89:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22694/abstract/21\">",
"      Lemesh RA. Case report: recurrent hematuria and hematospermia due to prostatic telangiectasia in classic von Willebrand's disease. Am J Med Sci 1993; 306:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22694/abstract/22\">",
"      Furuya S, Ogura H, Tanaka Y, et al. Hemangioma of the prostatic urethra: hematospermia and massive postejaculation hematuria with clot retention. Int J Urol 1997; 4:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22694/abstract/23\">",
"      Furuya S, Ogura H, Shimamura S, et al. [Clinical manifestations of 25 patients with prostatic-type polyps in the prostatic urethra]. Hinyokika Kiyo 2002; 48:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22694/abstract/24\">",
"      Ishigooka M, Hashimoto T, Kodama C, et al. Polyps of the prostatic urethra. Report of four cases. Urol Int 1993; 50:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22694/abstract/25\">",
"      Coppens L, Bonnet P, Andrianne R, de Leval J. Adult m&uuml;llerian duct or utricle cyst: clinical significance and therapeutic management of 65 cases. J Urol 2002; 167:1740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22694/abstract/26\">",
"      Fujisawa M, Ishigami J, Kamidono S, Yamanaka N. Adenomyosis of the seminal vesicle with hematospermia. Hinyokika Kiyo 1993; 39:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22694/abstract/27\">",
"      Botash RJ, Poster RB, Abraham JL, Makhuli ZM. Senile seminal vesicle amyloidosis associated with hematospermia: demonstration by endorectal MRI. J Comput Assist Tomogr 1997; 21:748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22694/abstract/28\">",
"      Yanagisawa N, Saegusa M, Yoshida T, Okayasu I. Squamous cell carcinoma arising from a seminal vesicular cyst: possible relationship between chronic inflammation and tumor development. Pathol Int 2002; 52:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22694/abstract/29\">",
"      Wang TM, Chuang CK, Lai MK. Seminal vesicle cyst: an unusual cause of hematospermia--a case report. Changgeng Yi Xue Za Zhi 1993; 16:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22694/abstract/30\">",
"      Mayersak JS, Viviano CJ. Unilateral seminal vesicle cyst presenting as hematospermia; diagnosis established by transrectal prostatic ultrasound. Wis Med J 1992; 91:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22694/abstract/31\">",
"      Fan K, Schaefer RF, Venable M. Urethral verumontanal polyp: evidence of prostatic origin. Urology 1984; 24:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22694/abstract/32\">",
"      Harada M, Tokuda N, Tsubaki H, et al. [Cavernous hemangioma of the spermatic cord: a case report]. Hinyokika Kiyo 1992; 38:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22694/abstract/33\">",
"      Furuya S, Ogura H, Shimamura S, et al. [Transurethral endoscopic treatment for chronic hematospermia caused by m&uuml;llerian duct cyst and ejaculatory duct obstruction]. Hinyokika Kiyo 2001; 47:839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22694/abstract/34\">",
"      Ameur A, Touiti D, Jira H, et al. [Hemospermia: diagnosis and therapeutic aspects. Seven case reports]. Ann Urol (Paris) 2002; 36:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22694/abstract/35\">",
"      Leifert S, Lurie A, Kellner J. Ectopic prostatic tissue in urethra. Urology 1985; 26:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22694/abstract/36\">",
"      Nav&iacute;o Ni&ntilde;o S, Jim&eacute;nez Cruz JF, Gonz&aacute;lez R, et al. [Hemospermia caused by proliferative papillary urethritis]. Actas Urol Esp 1981; 5:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22694/abstract/37\">",
"      Redman JF, Young JW 3rd. Massive post-ejaculation hematuria. Urology 1987; 30:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22694/abstract/38\">",
"      Bhaduri S, Riley VC. Haematospermia associated with malignant hypertension. Sex Transm Infect 1999; 75:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22694/abstract/39\">",
"      Hamburger S, Styczynski M, O'Hearne J, German G. Hemospermia and hypertension two case reports. J Kans Med Soc 1980; 81:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22694/abstract/40\">",
"      Correa-P&eacute;rez JR. Occurrence of nonpersistent hematospermia after a prolonged period of daily ejaculatory intensity longer than 3 weeks. J Assist Reprod Genet 2004; 21:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22694/abstract/41\">",
"      Najafi L, Noohi AH. Recurrent hematospermia due to aspirin. Indian J Med Sci 2009; 63:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22694/abstract/42\">",
"      Girolami A, Scarparo P, Candeo N, et al. Hemospermia in patients with congenital coagulation disorders: a study of three cases. Acta Haematol 2009; 121:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22694/abstract/43\">",
"      Zhao H, Luo J, Wang D, et al. The value of transrectal ultrasound in the diagnosis of hematospermia in a large cohort of patients. J Androl 2012; 33:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22694/abstract/44\">",
"      Han M, Brannigan RE, Antenor JA, et al. Association of hemospermia with prostate cancer. J Urol 2004; 172:2189.",
"     </a>",
"    </li>",
"    <li>",
"     Han, M, 2004, personal communication.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22694/abstract/46\">",
"      Corachan M, Valls ME, Gascon J, et al. Hematospermia: a new etiology of clinical interest. Am J Trop Med Hyg 1994; 50:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22694/abstract/47\">",
"      van Delft F, Visser L, Polderman A, van Lieshout L. Cough and alterations in semen after a tropical swim. Neth J Med 2007; 65:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22694/abstract/48\">",
"      Bamberger E, Madeb R, Steinberg J, et al. Detection of sexually transmitted pathogens in patients with hematospermia. Isr Med Assoc J 2005; 7:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22694/abstract/49\">",
"      Smith GW, Griffith DP, Pranke DW. Melanospermia: an unusual presentation of malignant melanoma. J Urol 1973; 110:314.",
"     </a>",
"    </li>",
"    <li>",
"     Anonymous. Hematospermia (Bloody Semen). In: Reinsurance Notes, Vol 1, No.9, Harvard Medical School, Boston 1998.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22694/abstract/51\">",
"      Torigian DA, Ramchandani P. Hematospermia: imaging findings. Abdom Imaging 2007; 32:29.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6888 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-125.39.66.147-BCDCD7344F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_10_22694=[""].join("\n");
var outline_f22_10_22694=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Urinalysis and cultures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Semen examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Blood tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Patients with identified abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Treating for presumptive prostatitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Reassurance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/6888\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/6888|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/40/1677\" title=\"table 1\">",
"      Causes of hematospermia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/60/23496?source=related_link\">",
"      Chronic bacterial prostatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/35/26166?source=related_link\">",
"      Diagnosis of gonococcal infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/38/15977?source=related_link\">",
"      Epidemiology, pathogenesis, and clinical features of schistosomiasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/18/18728?source=related_link\">",
"      Genital Chlamydia trachomatis infections in men",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/8/42122?source=related_link\">",
"      Screening for prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/30/490?source=related_link\">",
"      Screening for sexually transmitted infections",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_10_22695="Deferoxamine: Drug information";
var content_f22_10_22695=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Deferoxamine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?0/59/949?source=see_link\">",
"    see \"Deferoxamine: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/0/37894?source=see_link\">",
"    see \"Deferoxamine: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F157271\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Desferal&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F157272\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Desferal&reg;;",
"     </li>",
"     <li>",
"      PMS-Deferoxamine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F157313\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antidote;",
"     </li>",
"     <li>",
"      Chelating Agent",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F157274\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Acute iron toxicity:",
"     </b>",
"     <b>",
"      Note:",
"     </b>",
"     The I.V. route is used when severe toxicity is evidenced by cardiovascular collapse or systemic symptoms (coma, shock, metabolic acidosis, or gastrointestinal bleeding) or potentially severe intoxications (peak serum iron level &gt;500 mcg/dL) (Perrone, 2011). When severe symptoms are not present, the I.M. route may be used (per the manufacturer).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     I.M., I.V.: Initial: 1000 mg, may be followed by 500 mg every 4 hours for 2 doses; subsequent doses of 500 mg have been administered every 4-12 hours based on clinical response (maximum recommended dose: 6000 mg/day [per manufacturer])",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Canadian labeling:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.M.: Initial: 90 mg/kg/dose (maximum/dose: 2000 mg) followed by 45 mg/kg every 4-12 hours as needed (maximum: 6000 mg/24 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.V.: 15 mg/kg/hour up to a maximum of 80 mg/kg/dose or maximum of 6000 mg/24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Chronic iron overload:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.M.: 500-1000 mg/day (maximum: 1000 mg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: 40-50 mg/kg/day (maximum: 60 mg/kg/day) over 8-12 hours for 5-7 days per week",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     SubQ: 1000-2000 mg/day or 20-40 mg/kg/day over 8-24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Unlabeled dosing:",
"     </i>",
"     I.V., SubQ: 25-50 mg/kg over 8-10 hours 5-7 days per week (Brittenham, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Canadian labeling:",
"     </i>",
"     I.V., SubQ: 1000-4000 mg/day (20-60 mg/kg/day) over ~12 hours (may further increase iron excretion with infusion at the same dose over 24 hours). SubQ infusions are administered 4-7 days per week based on the degree of iron overload.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Diagnosis of aluminum-induced toxicity with CKD (unlabeled use; K/DOQI guidelines, 2003):",
"     </b>",
"     I.V.: Test dose: 5 mg/kg during the last hour of dialysis if serum aluminum levels are 60-200 mcg/L, or clinical signs/symptoms of toxicity, or aluminum exposure prior to parathyroid surgery. Measure aluminum just prior to deferoxamine; remeasure 2 days later (test is positive if serum aluminum is &ge;50 mcg/L). Do not use if aluminum serum levels are &gt;200 mcg/L.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Canadian labeling:",
"     </i>",
"     <b>",
"      Note:",
"     </b>",
"     Measure serum aluminum levels prior to and after administration of deferoxamine.  I.V.: Test dose: 5 mg/kg/dose (infusion rate not to exceed 15 mg/kg/hour) following hemodialysis (preferred) or during the last hour of dialysis if serum aluminum levels are &gt;60 mcg/L in association with serum ferritin levels &gt;100 mcg/L; continuous rise in serum aluminum over the next 24-48 hours suggests overload. Remeasure serum aluminum levels prior to next hemodialysis, test is considered positive if serum aluminum levels increase &gt;150 mcg/L above baseline.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Treatment of aluminum toxicity with CKD (unlabeled use; K/DOQI guidelines, 2003):",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Administer after diagnostic deferoxamine test dose.",
"     <b>",
"      Note:",
"     </b>",
"     The risk for deferoxamine-associated neurotoxicity is increased if aluminum serum levels are &gt;200 mcg/L; withhold deferoxamine and administer intensive dialysis until &lt;200 mcg/L.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Aluminum rise &ge;300 mcg/L: 5 mg/kg once a week 5 hours before dialysis for 4 months",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Aluminum rise &lt;300 mcg/L: 5 mg/kg once a week during the last hour of dialysis for 2 months",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Canadian labeling:",
"     </i>",
"     Treatment should be considered for symptomatic patients with serum aluminum levels &gt;60 mcg/L and a positive deferoxamine test dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Hemodialysis: I.V.: 5 mg/kg/dose (infusion rate not to exceed 15 mg/kg/hour) once weekly for 3 months following hemodialysis (preferred) or during the last hour of dialysis administered. Withhold treatment for 1 month then perform deferoxamine test. Further treatment is not recommended if 2 consecutive tests (performed 1 month apart) yield an increase in serum aluminum levels &lt;75 mcg/L.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Continuous ambulatory or cyclic peritoneal dialysis: Intraperitoneal (preferred), I.M., SubQ infusion (slow), or I.V. infusion (slow): 5 mg/kg/dose once weekly prior to final daily exchange",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F157293\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/0/37894?source=see_link\">",
"      see \"Deferoxamine: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Acute iron toxicity:",
"     </b>",
"     Children &ge;3 years:",
"     <b>",
"      Note:",
"     </b>",
"     The I.V. route is used when severe toxicity is evidenced by cardiovascular collapse or systemic symptoms (coma, shock, metabolic acidosis, or gastrointestinal bleeding) or potentially severe intoxications (peak serum iron level &gt;500 mcg/dL) (Perrone, 2011). When severe symptoms are not present, the I.M. route may be used (per the manufacturer).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     I.M.: 90 mg/kg/dose every 8 hours (maximum: 6000 mg/24 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     I.V.: 15 mg/kg/hour (maximum: 6000 mg/24 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Canadian labeling:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     I.M.: Initial: 90 mg/kg/dose (maximum/dose: 1000 mg) followed by 45 mg/kg every 4-12 hours as needed (maximum: 6000 mg/24 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     I.V.: 15 mg/kg/hour up to a maximum of 80 mg/kg/dose or maximum of 6000 mg/24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Chronic iron overload:",
"     </b>",
"     Children &ge;3 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     I.V.: 20-40 mg/kg/day over 8-12 hours for 5-7 days per week; dose should not exceed 40 mg/kg/day until growth has ceased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     SubQ: 20-40 mg/kg/day over 8-12 hours (maximum: 1000-2000 mg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Unlabeled dosing:",
"     </i>",
"     I.V., SubQ: 25-30 mg/kg over 8-10 hours 5-7 days per week (Brittenham, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Diagnosis of aluminum induced toxicity with CKD (unlabeled use; K/DOQI guidelines, 2003):",
"     </b>",
"     Children: I.V.: Test dose: 5 mg/kg during the last hour of dialysis if serum aluminum levels are 60-200 mcg/L, or clinical signs/symptoms of toxicity, or aluminum exposure prior to parathyroid surgery. Measure aluminum just prior to deferoxamine; remeasure 2 days later (test is positive if serum aluminum is &ge;50 mcg/L). Do not use if aluminum serum levels are &gt;200 mcg/L.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Treatment of aluminum toxicity with CKD (unlabeled use; K/DOQI guidelines, 2003):",
"     </b>",
"     Children: I.V.: Administer after diagnostic deferoxamine test dose.",
"     <b>",
"      Note:",
"     </b>",
"     The risk for deferoxamine-associated neurotoxicity is increased if aluminum serum levels are &gt;200 mcg/L; withhold deferoxamine and administer intensive dialysis until &lt;200 mcg/L.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Aluminum rise &ge;300 mcg/L: 5 mg/kg once a week 5 hours before dialysis for 4 months",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Aluminum rise &lt;300 mcg/L: 5 mg/kg once a week during the last hour of dialysis for 2 months",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F157275\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing. May initiate at the lower end of the dosing range.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F157276\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-right:0em;margin-top:0em;text-align:justify;display:inline\">",
"     Severe renal disease or anuria: Use is contraindicated in the manufacturer&rsquo;s U.S. labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     The following adjustments have been used by some clinicians (Aronoff, 2007): Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;50 mL/minute: No adjustment required",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-50 mL/minute, CRRT: Administer 25% to 50% of normal dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute, hemodialysis, peritoneal dialysis: Avoid use",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F13811880\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no dosage adjustments provided in the manufacturer&rsquo;s labeling (has not been studied).",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F157252\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution, as mesylate: 500 mg, 2 g",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Desferal&reg;: 500 mg, 2 g",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F157237\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F157255\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.V.: Urticaria, flushing of the skin, hypotension, and shock have occurred following rapid I.V. administration; limiting infusion rate to 15mg/kg/hour may help avoid infusion-related adverse effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Acute iron toxicity: The manufacturer states that the I.M. route is preferred; however, the I.V. route is generally preferred in patients with severe toxicity (ie, patients in shock). For the first 1000 mg, infuse at 15 mg/kg/hour. Subsequent doses may be given over 4-12 hours at a rate not to exceed 125 mg/hour.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Chronic iron overload: Administer over 8-12 hours for 5-7 days per week; rate not to exceed 15 mg/kg/hour. In patients with poor compliance, deferoxamine may be administered on the same day of blood transfusion, either prior to or following transfusion; do not administer concurrently with transfusion. Longer infusion times (24 hours) and I.V. administration may be required in patients with severe cardiac iron deposition (Brittenham, 2011).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Diagnosis or treatment of aluminum-induced toxicity with CKD: Administer dose over 1 hour, during the last hour of dialysis (K/DOQI guidelines, 2003).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     SubQ: When administered for chronic iron overload, administration over 8-12 hours using a portable infusion pump is generally recommended; however, longer infusion times (24 hours) may also be used. Topical anesthetic or glucocorticoid creams may be used for induration or erythema (Brittenham, 2011).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.M.: I.M. administration may be used for patients with acute iron toxicity that do not exhibit severe symptoms (per the manufacturer); may also be used in the treatment of chronic iron toxicity.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F157319\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W, LR, NS, sterile water for injection.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F157253\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adjunct in the treatment of acute iron intoxication; treatment of chronic iron overload secondary to multiple transfusions",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Canadian labeling (unlabeled use in the U.S.): Diagnosis of aluminum overload; treatment of chronic aluminum overload in patients with end-stage renal failure undergoing maintenance dialysis",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F157310\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Diagnosis or treatment of aluminum induced toxicity associated with chronic kidney disease (CKD)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F157321\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Deferoxamine may be confused with cefuroxime, deferasirox, deferiprone",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Desferal&reg; may be confused with desflurane, Desyrel&reg;, Dexferrum&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Desferal [U.S., Canada, and multiple international markets] may be confused with Deseril brand name for methysergide [Australia, Belgium, Great Britain, Netherlands]; Disophrol brand name for dexbrompheniramine and pseudoephedrine [Czech Republic, Poland, Turkey]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F157311\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Flushing, hypotension, shock, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Dizziness, encephalopathy (aluminum toxicity/dialysis-related), fever, headache, seizure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Angioedema, rash,  urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Growth retardation (children), hyperparathyroidism (aggravated), hypocalcemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal discomfort, abdominal pain, diarrhea, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Dysuria, urine discoloration (reddish  color)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Leukopenia, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic:  Hepatic dysfunction, transaminases increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Injection site: Burning, crust, edema, erythema, eschar, induration, infiltration, irritation, pain, pruritus, swelling, vesicles, wheal formation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, metaphyseal dysplasia (children &lt;3 years; dose related), muscle spasms, myalgia, neuropathy (peripheral, sensory, motor, or mixed), paresthesia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision, cataract, corneal opacities, dyschromatopsia, loss of vision, night blindness, optic neuritis, peripheral vision impaired, retinal pigment abnormalities, scotoma, visual acuity decreased, visual field defects",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Hearing loss, tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Acute renal failure, renal tubular disorders, serum creatinine increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Acute respiratory distress syndrome (dyspnea, cyanosis, and/or interstitial infiltrates), asthma",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylaxis (with or without shock), hypersensitivity reaction, infections (",
"     <i>",
"      Yersinia",
"     </i>",
"     , mucormycosis)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F157258\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to deferoxamine or any component of the formulation; patients with severe renal disease or anuria",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Canadian labeling does not include severe renal disease or anuria as contraindications.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F157241\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Acute respiratory distress syndrome (ARDS): Deferoxamine has been associated with ARDS following excessively high-dose I.V. treatment of acute iron intoxication or thalassemia; has been reported in children and adults.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Auditory effects: Auditory disturbances (tinnitus and high frequency hearing loss) have been reported following prolonged administration, at high doses, or in patients with low ferritin levels; effects are generally reversible with early detection and immediate discontinuation. Elderly patients are at increased risk for hearing loss. Audiology exams are recommended with long-term treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Growth retardation: High deferoxamine doses and concurrent low ferritin levels are also associated with growth retardation. Growth velocity may partially resume to pretreatment rates after deferoxamine dose reduction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Infection: Patients with iron overload are at increased susceptibility to infection with",
"     <i>",
"      Yersinia enterocolitica",
"     </i>",
"     and",
"     <i>",
"      Yersinia pseudotuberculosis;",
"     </i>",
"     treatment with deferoxamine may enhance this risk; if infection develops, discontinue therapy until resolved.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Infusion reactions: Flushing of the skin, hypotension, urticaria and shock are associated with rapid I.V. infusion; administer I.M., by slow subcutaneous infusion, or slow I.V. infusion only.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Mucormycosis: Rare and serious cases of mucormycosis (including fatalities) have been reported with use; withhold treatment with signs and symptoms of mucormycosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ocular effects: Ocular disturbances (blurred vision, cataracts, corneal opacities, decreased visual acuity, impaired peripheral, color, and night vision, optic neuritis, retinal pigment abnormalities, scotoma, visual loss/defect)  have been reported following prolonged administration, at high doses, or in patients with low ferritin levels; effects are generally reversible with early detection and immediate discontinuation. Elderly patients are at increased risk for ocular disorders. Periodic ophthalmic exams are recommended with long-term treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal effects: Increases in serum creatinine, acute renal failure and renal tubular disorders have been reported; monitor for changes in renal function. Deferoxamine is readily dialyzable. When iron is chelated with deferoxamine, the chelate is excreted renally.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Urine discoloration: Patients should be informed that urine may have a reddish color.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Aluminum toxicity: Treatment with deferoxamine in patients with aluminum toxicity may cause hypocalcemia and aggravate hyperparathyroidism. Deferoxamine may cause neurological symptoms (including seizure) in patients with aluminum-related encephalopathy receiving dialysis and may precipitate dialysis dementia onset.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hemochromatosis: Deferoxamine is",
"     <b>",
"      not",
"     </b>",
"     indicated for the treatment of primary hemochromatosis (treatment of choice is phlebotomy).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ascorbic acid: Combination treatment with ascorbic acid (&gt;500 mg/day in adults) and deferoxamine may impair cardiac function (rare), effects are reversible upon discontinuation of ascorbic acid. If combination treatment is warranted, initiate ascorbic acid only after one month of regular deferoxamine treatment, do not exceed ascorbic acid dose of 200 mg/day for adults (in divided doses), 100 mg/day for children &ge;10 years of age, or 50 mg/day in children &lt;10 years of age; monitor cardiac function. Do not administer deferoxamine in combination with ascorbic acid in patients with pre-existing cardiac failure.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299129\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F157246\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ascorbic Acid: May enhance the adverse/toxic effect of Deferoxamine. Left ventricular dysfunction is of particular concern. Management: Avoid ascorbic acid doses greater than 200 mg/day.  Lower doses may be given to patients without cardiac failure, after one month of regular treatment with deferoxamine alone, ideally soon after setting up the infusion pump.  Monitor cardiac function.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the adverse/toxic effect of Deferoxamine. Left ventricular dysfunction is of particular concern. Management: Avoid ascorbic acid doses greater than 200 mg/day.  Lower doses may be given to patients without cardiac failure, after one month of regular treatment with deferoxamine alone, ideally soon after setting up the infusion pump.  Monitor cardiac function.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prochlorperazine: Deferoxamine may enhance the adverse/toxic effect of Prochlorperazine. Specifically, prolonged loss of consciousness has been reported.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F157248\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F802788\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-right:0em;margin-top:0em;text-align:justify;display:inline\">",
"     Skeletal anomalies and delayed ossification were observed in some but not all animal reproduction studies. Toxic amounts of iron or deferoxamine have not been noted to cross the placenta. In case of acute iron toxicity, treatment during pregnancy should not be withheld.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F157280\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F13811879\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if deferoxamine is excreted in human milk; the manufacturer recommends that caution be used if administered to a breast-feeding woman.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F802790\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-right:0em;margin-top:0em;text-align:justify;display:inline\">",
"     Vitamin C supplements may need to be limited. The manufacturer recommends a maximum ascorbic acid dose of 200 mg/day in adults (given in divided doses), 100 mg/day in children &ge;10 years of age, or 50 mg/day in children &lt;10 years of age. Avoid concurrent use with ascorbic acid in patients with heart failure.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F157260\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Deferoxamine Mesylate Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 g (1): $61.80",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (1): $9.39",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Desferal Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 g (1): $113.94",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (1): $29.32",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F157250\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serum iron, ferritin, total iron-binding capacity, CBC with differential, renal function tests (serum creatinine), liver function tests, serum chemistries; ophthalmologic exam (visual acuity tests, fundoscopy, slit-lamp exam) and audiometry with long-term treatment; growth and body weight in children (every 3 months)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Dialysis patients: Serum aluminum (yearly; every 3 months in patients on aluminum-containing medications)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Aluminum-induced bone disease: Serum aluminum 2 days following test dose; test is considered positive if serum aluminum increases &ge;50 mcg/L",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F802987\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Iron, serum: Normal: 50-160 mcg/dL; peak levels &gt;500 mcg/dL associated with toxicity. Consider treatment in  symptomatic patients with levels &ge;350 mcg/dL; toxicity cannot be excluded with serum iron levels &lt;350 mcg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Aluminum, serum: &lt;20 mcg/L recommended baseline level in dialysis patients  (K/DOQI, 2003)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F157261\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Desferal (AE, AR, AT, AU, BB, BE, BF, BG, BH, BJ, BM, BR, BS, BZ, CH, CI, CL, CN, CY, CZ, DE, DK, EE, EG, ES, ET, FI, FR, GB, GH, GM, GN, GR, GY, HK, HN, ID, IE, IL, IN, IQ, IR, IT, JM, JO, KE, KP, KW, LB, LR, LU, LY, MA, ML, MR, MT, MU, MW, MX, MY, NE, NG, NL, NO, OM, PH, PK, PL, PT, QA, RU, SA, SC, SD, SE, SG, SK, SL, SN, SR, SY, TH, TN, TR, TT, TW, TZ, UG, UY, VE, YE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Talifer (TH)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F157240\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Complexes with trivalent ions (ferric ions) to form ferrioxamine, which is removed by the kidneys, slows accumulation of hepatic iron and retards or eliminates progression of hepatic fibrosis.  Also known to inhibit DNA synthesis",
"     <i>",
"      in vitro",
"     </i>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F157257\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: I.M., SubQ: Well absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Distributed throughout body fluids",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: &lt;10%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Plasma enzymes; binds with iron to form ferrioxamine (iron complex)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 14 hours (plasma half-life: 20-30 minutes)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Primarily urine (as unchanged drug and ferrioxamine); feces (via bile)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Allain P, Mauras Y, Chaleil D, et al, &ldquo;Pharmacokinetics and Renal Elimination of Desferrioxamine and Ferrioxamine in Healthy Subjects and Patients With Haemochromatosis,&rdquo;",
"      <i>",
"       Br J Clin Pharmacol",
"      </i>",
"      , 1987, 24(2):207-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/10/22695/abstract-text/3620295/pubmed\" id=\"3620295\" target=\"_blank\">",
"        3620295",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Aronoff GR, Bennett WM, Berns JS, et al,",
"      <i>",
"       Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children",
"      </i>",
"      , 5th ed. Philadelphia, PA: American College of Physicians; 2007, p 116.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bacon BR, Adams PC, Kowdley KV, et al, &ldquo;Diagnosis and Management of Hemochromatosis: 2011 Practice Guideline by the American Association for the Study of Liver Disease,&rdquo;",
"      <i>",
"       Hepatology",
"      </i>",
"      , 2011, 54(1):328-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/10/22695/abstract-text/21452290/pubmed\" id=\"21452290\" target=\"_blank\">",
"        21452290",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Brittenham GM. &ldquo;Iron-Chelating Therapy for Transfusional Iron Overload,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2011, 364(2):146-56.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/10/22695/abstract-text/21226580/pubmed\" id=\"21226580\" target=\"_blank\">",
"        21226580",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chang TPY and Rangan C, &ldquo;Iron Poisoning-A Literature-Based Review of Epidemiology, Diagnosis, and Management,&rdquo;",
"      <i>",
"       Pediatr Emerg Care",
"      </i>",
"      , 2011, 27(!0):978-85.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/10/22695/abstract-text/21975503/pubmed\" id=\"21975503\" target=\"_blank\">",
"        21975503",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease, Guideline 6. Serum Calcium and Calcium-Phosphorus Product.&rdquo; Available at  file://www.kidney.org/professionals/KDOQI/guidelines_bone/Guide11.htm",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/10/22695/abstract-text/14520607/pubmed\" id=\"14520607\" target=\"_blank\">",
"        14520607",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Comprehensive Cancer Network&reg; (NCCN), &ldquo;Clinical Practice Guidelines in Oncology&trade;: Myelodysplastic Syndromes,&rdquo; Version 1.2012. Available at  file://www.nccn.org/professionals/physician_gls/PDF/mds.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Perrone J, &ldquo;Iron,&rdquo;",
"      <i>",
"       Goldfrank's Toxicologic Emergencies",
"      </i>",
"      , 9th ed, Nelson LS, Hoffman RS, Lewin NA, et al, eds, New York, NY: McGraw-Hill Companies, Inc, 2011.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Stiles ML, Allen LV, and Prince SJ, &ldquo;Stability of Deferoxamine Mesylate, Floxuridine, Fluorouracil, Hydromorphone Hydrochloride, Lorazepam, and Midazolam Hydrochloride in Polypropylene Infusion-Pump Syringes,&rdquo;",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 1996, 53(13):1583-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/10/22695/abstract-text/8809281/pubmed\" id=\"8809281\" target=\"_blank\">",
"        8809281",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Valentine K, Mastropietro C, and Sarnaik AP, &ldquo;Infantile Iron Poisoning: Challenges in Diagnosis and Management,&rdquo;",
"      <i>",
"       Pediatr Crit Care Med",
"      </i>",
"      , 2009, 10(3):e31-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/10/22695/abstract-text/19433938/pubmed\" id=\"19433938\" target=\"_blank\">",
"        19433938",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9327 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-85.214.214.87-1759BFA714-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_10_22695=[""].join("\n");
var outline_f22_10_22695=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157271\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157272\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157313\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157274\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157293\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157275\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157276\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13811880\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157252\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157237\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157255\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157319\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157253\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157310\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157321\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157311\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157258\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157241\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299129\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157246\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157248\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F802788\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157280\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13811879\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F802790\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157260\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157250\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F802987\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157261\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157240\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157257\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9327\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9327|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?0/59/949?source=related_link\">",
"      Deferoxamine: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/0/37894?source=related_link\">",
"      Deferoxamine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_10_22696="Overview of hypertrophic cardiomyopathy management including treatment of special problems";
var content_f22_10_22696=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of hypertrophic cardiomyopathy management including treatment of special problems",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/10/22696/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/10/22696/contributors\">",
"     Martin S. Maron, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/10/22696/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/10/22696/contributors\">",
"     William J McKenna, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/10/22696/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/10/22696/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/10/22696/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 6, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypertrophic cardiomyopathy (HCM) is a genetically determined heart muscle disease most often (60 to 70 percent) caused by mutations in one of several sarcomere genes which encode components of the contractile apparatus. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/44/29386?source=see_link\">",
"     \"Genetics of hypertrophic cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    HCM is characterized by left ventricular hypertrophy of various morphologies, with a wide array clinical manifestations and hemodynamic abnormalities. Depending in part upon the site and extent of cardiac hypertrophy, HCM patients can develop one or more of the following abnormalities:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      LV outflow obstruction (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/59/28600?source=see_link\">",
"       \"Types and pathophysiology of obstructive hypertrophic cardiomyopathy\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Diastolic dysfunction",
"     </li>",
"     <li>",
"      Myocardial ischemia",
"     </li>",
"     <li>",
"      Mitral regurgitation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These structural and functional abnormalities can produce a variety of symptoms, including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Fatigue",
"     </li>",
"     <li>",
"      Dyspnea",
"     </li>",
"     <li>",
"      Chest pain",
"     </li>",
"     <li>",
"      Palpitations",
"     </li>",
"     <li>",
"      Presyncope or syncope",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In broad terms, the symptoms related to HCM can be categorized as those related to heart failure (HF), chest pain, or arrhythmias. Patients with HCM have an increased incidence of both supraventricular and ventricular arrhythmias and are at an increased risk for sudden cardiac death (SCD). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/34/28199?source=see_link\">",
"     \"Atrial fibrillation and other atrial tachyarrhythmias in hypertrophic cardiomyopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/3/22586?source=see_link\">",
"     \"Ventricular arrhythmias and sudden cardiac arrest in hypertrophic cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For the majority of patients with HCM, LVH is not progressive, and the clinical course is relatively benign. A small subset of patients, however, will progress to an advanced form of the disease that is characterized by relative LV dilation and wall thinning and systolic dysfunction. Such patients are managed according to the standard approach to patients with HF due to systolic dysfunction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=see_link\">",
"     \"Overview of the therapy of heart failure due to systolic dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic will provide a brief overview of management of patients with HCM (",
"    <a class=\"graphic graphic_algorithm graphicRef86793 \" href=\"UTD.htm?29/22/30048\">",
"     algorithm 1",
"    </a>",
"    ) and also discuss special problems and issues that may arise. Issues such as the clinical manifestations, natural history, and detailed discussions of the treatment of this disorder are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/4/32841?source=see_link\">",
"     \"Natural history of hypertrophic cardiomyopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/55/10105?source=see_link\">",
"     \"Medical therapy in hypertrophic cardiomyopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/21/7514?source=see_link\">",
"     \"Nonpharmacologic treatment of outflow obstruction in hypertrophic cardiomyopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/42/36522?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and evaluation of hypertrophic cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following are the major components of management of hypertrophic cardiomyopathy, most of which are discussed in detail separately:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Avoidance of volume depletion &ndash; In HCM patients, volume depletion tends to decrease stroke volume and increase or precipitate the left ventricular outflow gradient, and may lead to hypotension, lightheadedness and syncope. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Perioperative management'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Activity restriction &ndash; Since exercise may increase the risk of arrhythmias and sudden cardiac death in HCM patients, avoidance of intense physical exertion and most competitive sports is important. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/36/13898?source=see_link&amp;anchor=H13#H13\">",
"       \"Risk of sudden cardiac death in athletes\", section on 'Hypertrophic cardiomyopathy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Control of cardiovascular symptoms &ndash; Treatment of dyspnea and chest pain generally begins with medical therapy. If medical therapy fails to adequately control these symptoms, then nonpharmacologic therapy should be considered for those patients with LV outflow tract obstruction (eg, alcohol septal ablation or septal myectomy). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/55/10105?source=see_link\">",
"       \"Medical therapy in hypertrophic cardiomyopathy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/21/7514?source=see_link\">",
"       \"Nonpharmacologic treatment of outflow obstruction in hypertrophic cardiomyopathy\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Management of syncope is discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/3/22586?source=see_link&amp;anchor=H13#H13\">",
"       \"Ventricular arrhythmias and sudden cardiac arrest in hypertrophic cardiomyopathy\", section on 'High-risk clinical features'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/21/7514?source=see_link&amp;anchor=H4#H4\">",
"       \"Nonpharmacologic treatment of outflow obstruction in hypertrophic cardiomyopathy\", section on 'Syncope or presyncope'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/42/36522?source=see_link\">",
"       \"Clinical manifestations, diagnosis, and evaluation of hypertrophic cardiomyopathy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Treatment of arrhythmias &ndash; HCM is the most common cause of sudden death in young patients, while all HCM patients are susceptible to atrial and ventricular arrhythmias. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/34/28199?source=see_link\">",
"       \"Atrial fibrillation and other atrial tachyarrhythmias in hypertrophic cardiomyopathy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/3/22586?source=see_link\">",
"       \"Ventricular arrhythmias and sudden cardiac arrest in hypertrophic cardiomyopathy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Screening of first-degree relatives &ndash; HCM is an autosomal dominant genetic disorder with a high degree of penetrance. First-degree family members of an affected individual should be evaluated for possible inheritance of the disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/42/36522?source=see_link&amp;anchor=H31#H31\">",
"       \"Clinical manifestations, diagnosis, and evaluation of hypertrophic cardiomyopathy\", section on 'Screening of first-degree relatives'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     SPECIAL PROBLEMS AND ISSUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following problems and issues may arise in HCM patients and are discussed below.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Left ventricular outflow tract (LVOT) obstruction associated with acute hemodynamic collapse",
"     </li>",
"     <li>",
"      Management during pregnancy and birth",
"     </li>",
"     <li>",
"      Differential diagnosis and management in children",
"     </li>",
"     <li>",
"      Anticoagulation",
"     </li>",
"     <li>",
"      Endocarditis prophylaxis",
"     </li>",
"     <li>",
"      Perioperative management",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     LEFT VENTRICULAR OUTFLOW TRACT OBSTRUCTION ASSOCIATED WITH ACUTE HEMODYNAMIC COLLAPSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Occasional patients with HCM and LVOT obstruction present with acute hemodynamic collapse (ie, severe hypotension) precipitated by a variety of potential external causes. This presentation may also include patients experiencing chest pain, palpitation, lightheadedness, postural presyncope, or syncope.",
"   </p>",
"   <p>",
"    Physical examination may elicit the following signs: sinus tachycardia; thready double-impulse peripheral arterial pulse; hypotension; low jugular venous pressure; auscultatory and radiographic evidence of cardiac failure; and systolic murmurs of LV obstruction and mitral regurgitation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/37/26202?source=see_link\">",
"     \"Auscultation of cardiac murmurs\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/56/22410?source=see_link\">",
"     \"Auscultation of heart sounds\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/15/33013?source=see_link\">",
"     \"Examination of the arterial pulse\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/59/33719?source=see_link\">",
"     \"Examination of the jugular venous pulse\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    LVOT obstruction is confirmed by 2-D echocardiography, which characteristically demonstrates hyperdynamic LV function with a small (underfilled) LV cavity, and systolic anterior motion (SAM) with prolonged SAM-septal contact associated with mitral regurgitation (usually posteriorly directed).",
"   </p>",
"   <p>",
"    This syndrome is usually precipitated by events that acutely increase outflow obstruction, including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Withdrawal of a beta blocker or calcium blocker",
"     </li>",
"     <li>",
"      Decreased preload due to dehydration, diuretics, or an acute reduction in blood volume (eg, hemorrhage, sepsis, peripheral venous pooling, post epidural)",
"     </li>",
"     <li>",
"      Decreased afterload due to administration of a vasodilator",
"     </li>",
"     <li>",
"      Supraventricular tachycardia,",
"      <span class=\"nowrap\">",
"       AF/flutter",
"      </span>",
"      or sinus tachycardia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Conventional treatment of heart failure with nitrates, diuretics, and vasodilators may result in further hemodynamic deterioration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Less severe cases can be managed with oral fluids and administration of a beta blocker.",
"   </p>",
"   <p>",
"    Severe obstruction usually resolves rapidly with the institution of the following regimen:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Increase preload with elevation of the legs and administration of intravenous fluids; in addition, anemia, if present, should be corrected.",
"     </li>",
"     <li>",
"      Intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/36/39488?source=see_link\">",
"       phenylephrine",
"      </a>",
"      to increase blood pressure. Phenylephrine can be given in a solution that contains 10 mg (1 mL of 1 percent phenylephrine) of phenylephrine in 500 mL of dextrose in water. This solution is administration at a rate of 5 to 9",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      (or 100 to 180",
"      <span class=\"nowrap\">",
"       drops/min",
"      </span>",
"      if there are 20",
"      <span class=\"nowrap\">",
"       drops/mL).",
"      </span>",
"      It provides phenylephrine at a rate of 100 to 180",
"      <span class=\"nowrap\">",
"       mcg/min.",
"      </span>",
"      When the blood pressure is stabilized, the rate may be reduced to 2 to 3",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      (40 to 60",
"      <span class=\"nowrap\">",
"       drops/min).",
"      </span>",
"     </li>",
"     <li>",
"      Intravenous administration of a beta blocker (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"       propranolol",
"      </a>",
"      1 mg, or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/37/40536?source=see_link\">",
"       esmolol",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Administration of intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/49/35607?source=see_link\">",
"       disopyramide",
"      </a>",
"      50 mg over one to five minutes. (Intravenous disopyramide is not available in United States.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     PREGNANCY AND DELIVERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;While patients with HCM should generally be followed by an obstetrician experienced with high-risk patients, pregnancy is generally tolerated well in such patients [",
"    <a class=\"abstract\" href=\"UTD.htm?22/10/22696/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. This includes patients with obstructive HCM who, prior to pregnancy, have no symptoms or only mild and stable symptoms. Most pregnant women with HCM increase cardiac output adequately in response to the enhanced physiologic demands of pregnancy. Fluid retention with a subsequent increase in plasma volume appears to offset the characteristic vasodilation that occurs in the setting. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/40/20105?source=see_link\">",
"     \"Maternal cardiovascular and hemodynamic adaptations to pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The data supporting these conclusions were provided in a report of 100 women with HCM who had a total of 199 births [",
"    <a class=\"abstract\" href=\"UTD.htm?22/10/22696/abstract/2\">",
"     2",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among the 40 patients evaluated in close proximity to pregnancy, only one of 28 previously asymptomatic patients progressed to NYHA class III or IV during pregnancy. In comparison, such progression occurred in 5 of 12 previously symptomatic patients.",
"     </li>",
"     <li>",
"      One patient had atrial fibrillation and one had syncope; in both cases, the problem was not new, having occurred repeatedly prior to pregnancy.",
"     </li>",
"     <li>",
"      Two deaths occurred, both sudden and both in patients at particularly high risk. One patient had massive left ventricular hypertrophy and a resting outflow gradient of 115 mmHg. The other patient had a family history of eight deaths in young patients, five of which were sudden.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Beta blockers and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    can be used as necessary to alleviate symptoms, but the doses should be kept as low as possible to avoid fetal bradycardia, hypoglycemia, and growth retardation. Beta blockers are probably preferred since there is greater experience with these agents in pregnant women. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/7/13434?source=see_link\">",
"     \"Management of hypertension in pregnant and postpartum women\"",
"    </a>",
"    .) Judicious use of diuretics may be helpful to control fluid retention towards the end of pregnancy.",
"   </p>",
"   <p>",
"    Normal vaginal delivery is the preferred delivery method and is almost always successful. Epidural anesthesia with risk of peripheral venous pooling, prolonged labor, and hypovolemia should be avoided if possible. Precautions at the time of delivery to prepare for massive blood loss include prior placement of a venous cannula and rapid access to volume replacement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CHILDREN WITH HCM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among children diagnosed with HCM, there are unique diagnostic and management issues.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Presentation and diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among children with familial HCM, left ventricular hypertrophy can develop in infancy and childhood, but for the vast majority increases in LV wall thickness typically occur during puberty, with little change in adulthood. [",
"    <a class=\"abstract\" href=\"UTD.htm?22/10/22696/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Children and adolescents with HCM are often asymptomatic and diagnosed during family screening. However, since echocardiography may be normal during childhood, a single negative screening examination may not exclude the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?22/10/22696/abstract/3\">",
"     3",
"    </a>",
"    ]. We suggest that for asymptomatic family members, echocardiography should be repeated annually until approximately age 20, and then every five years. The presence of abnormalities on 12-lead ECG (pathological Q waves, left axis deviation, inferior or lateral T wave inversion) may precede the development of LV hypertrophy and identify family members who may potentially develop clinical disease. [",
"    <a class=\"abstract\" href=\"UTD.htm?22/10/22696/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An exception to these observations can occur in infants diagnosed in the first year of life [",
"    <a class=\"abstract\" href=\"UTD.htm?22/10/22696/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Detection of a heart murmur is often the initial sign of heart disease. Death is primarily due to heart failure rather than sudden death.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of cases of hypertrophic obstructive cardiomyopathy in children are due to the familial disorder associated with mutations in cardiac sarcomere proteins [",
"    <a class=\"abstract\" href=\"UTD.htm?22/10/22696/abstract/7\">",
"     7",
"    </a>",
"    ]. However, similar phenotypes can be caused by several other disorders, including the following [",
"    <a class=\"abstract\" href=\"UTD.htm?22/10/22696/abstract/5,7\">",
"     5,7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Inborn errors of metabolism (eg, Fabry disease and Danon disease)",
"     </li>",
"     <li>",
"      Neuromuscular disorders, including mitochondrial disease",
"     </li>",
"     <li>",
"      Congenital malformation syndromes, such as Noonan syndrome [",
"      <a class=\"abstract\" href=\"UTD.htm?22/10/22696/abstract/5\">",
"       5",
"      </a>",
"      ] (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/62/39910?source=see_link\">",
"       \"Clinical manifestations and diagnosis of pulmonic stenosis\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a series of 855 HCM patients in the Pediatric Cardiomyopathy Registry, the following incidence of each cause was noted [",
"    <a class=\"abstract\" href=\"UTD.htm?22/10/22696/abstract/7\">",
"     7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Idiopathic HCM &ndash; 74 percent",
"     </li>",
"     <li>",
"      Malformation syndromes &ndash; 9 percent",
"     </li>",
"     <li>",
"      Inborn errors of metabolism &ndash; 9 percent",
"     </li>",
"     <li>",
"      Neuromuscular disorders &ndash; 7 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Children in this registry defined as having \"idiopathic HCM\" included those patients with the conventionally defined clinical diagnosis of HCM who did not have one of the other listed etiologies for hypertrophy.",
"   </p>",
"   <p>",
"    It has been suggested that Danon disease (glycogen storage disease IIb due to mutations in lysosome associated membrane protein 2 [LAMP2]) may be an underrecognized cause of HCM in childhood, primarily in boys. This was illustrated in a review of an unselected population of 50 children with HCM (mean age at diagnosis 7 years) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/10/22696/abstract/8\">",
"     8",
"    </a>",
"    ]. Two (4 percent) had LAMP2 mutations; both had the characteristic features of skeletal myopathy and Wolff-Parkinson-White syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/19/43315?source=see_link\">",
"     \"Lysosome-associated membrane protein 2 deficiency (glycogen storage disease IIb, Danon disease)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Genetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;A report of 84 children diagnosed with isolated unexplained left ventricular hypertrophy before 15 years of age found mutations in genes associated with HCM in adults in about half (25 of 51) of presumed sporadic cases and in nearly two-thirds (21 of 33) of familial cases [",
"    <a class=\"abstract\" href=\"UTD.htm?22/10/22696/abstract/9\">",
"     9",
"    </a>",
"    ]. Among 11 of 25 children with presumed sporadic disease, four carried new mutations and seven inherited the mutations. In &gt;75 percent of the children, mutations occurred in the cardiac beta-myosin heavy chain gene or the cardiac myosin binding protein-C gene. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/44/29386?source=see_link\">",
"     \"Genetics of hypertrophic cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Given these findings, the diagnosis of childhood-onset HCM (as for HCM in adults) should prompt family evaluations including clinical assessment (and consideration of genetic testing) of all first-degree relatives. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/42/36522?source=see_link&amp;anchor=H31#H31\">",
"     \"Clinical manifestations, diagnosis, and evaluation of hypertrophic cardiomyopathy\", section on 'Screening of first-degree relatives'",
"    </a>",
"    .) Issues related to genetic testing are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/44/29386?source=see_link&amp;anchor=H24#H24\">",
"     \"Genetics of hypertrophic cardiomyopathy\", section on 'Genetic testing and screening'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mortality is often due to sudden death and is frequently unheralded by symptoms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/3/22586?source=see_link&amp;anchor=H9#H9\">",
"     \"Ventricular arrhythmias and sudden cardiac arrest in hypertrophic cardiomyopathy\", section on 'Sudden cardiac death'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a series of 855 patients from the Pediatric Cardiomyopathy Registry without inborn errors of metabolism, malformation syndromes, or neuromuscular disorders (ie, those with a conventional clinical diagnosis of HCM), the following findings were noted [",
"    <a class=\"abstract\" href=\"UTD.htm?22/10/22696/abstract/7\">",
"     7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The age of death had a bimodal distribution, with a large peak in infancy and a smaller peak in adolescence.",
"     </li>",
"     <li>",
"      Among those diagnosed in infancy, the one year survival rate was 86 percent.",
"     </li>",
"     <li>",
"      Among children who were alive beyond one year of age, annual morality was much lower at 1 percent. This group includes patients diagnosed in infancy who survived past one year (annual mortality beyond one year of age 0.7 percent), and patients diagnosed after one year of age (annual morality 1.1 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Children with inborn errors of metabolism, malformation syndromes, and neuromuscular disorders had one year survival rates of 54, 82, and 98 percent, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Mechanisms",
"    </span>",
"    &nbsp;&mdash;&nbsp;A pathologic study in asymptomatic children and young adults with HCM who died suddenly found that increased thickness of the septum is due to myocyte hypertrophy and an expanded extracellular matrix of collagen (both interstitial and replacement fibrosis) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/10/22696/abstract/10\">",
"     10",
"    </a>",
"    ]. The mechanism of sudden death in HCM is considered to be due to ventricular tachyarrhythmias emanating from a structurally abnormal myocardial substrate of myocyte disarray and myocardial fibrosis.",
"   </p>",
"   <p>",
"    One possible cause for myocardial ischemia in children with HCM is myocardial bridging. However, the data are conflicting as to whether myocardial bridging is a predictor of ventricular tachyarrhythmias and sudden death [",
"    <a class=\"abstract\" href=\"UTD.htm?22/10/22696/abstract/11-13\">",
"     11-13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/47/12023?source=see_link\">",
"     \"Myocardial bridging of the coronary arteries\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Management of LV outflow obstruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;LV outflow tract obstruction resulting in symptom limitation is uncommon in young HCM patients. If patients do experience limiting heart failure symptoms, negative inotropic drugs beginning with a beta-blocker and alternatively calcium channel blocker can be used. Although",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/49/35607?source=see_link\">",
"     disopyramide",
"    </a>",
"    is used in select adult patients, its utility in children is limited by anticholinergic side effects and the fact that it does not often provide long-term relief of symptoms. If drugs are ineffective or not tolerated and limiting heart failure symptoms persist, consideration should be given to permanent relief of obstruction with surgical myectomy. A number of uncertainties regarding the long term effects of alcohol ablation (ventricular arrhythmia, LV impairment) preclude its use in children and adolescents [",
"    <a class=\"abstract\" href=\"UTD.htm?22/10/22696/abstract/14-17\">",
"     14-17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The general consensus is that the operative risks, hemodynamic benefits, and initial improvement in symptoms are similar with the two procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?22/10/22696/abstract/18\">",
"     18",
"    </a>",
"    ]. However, the long-term survival benefits noted with surgical myectomy have not yet been demonstrated with ethanol ablation. Alcohol ablation is also associated with a higher risk of needing a pacemaker due to high-degree AV block induced by the procedure and a higher repeat procedure rate (due to unsuccessful initial ablation) compared with myectomy. As a result, surgery remains the preferred option in patients with HCM [",
"    <a class=\"abstract\" href=\"UTD.htm?22/10/22696/abstract/17-19\">",
"     17-19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/21/7514?source=see_link&amp;anchor=H25#H25\">",
"     \"Nonpharmacologic treatment of outflow obstruction in hypertrophic cardiomyopathy\", section on 'Patient selection'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     ANTICOAGULATION AND ENDOCARDITIS PROPHYLAXIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with obstructive HCM who develop paroxysmal or chronic atrial fibrillation are at high risk for thromboembolism. Such patients require long term anticoagulation [",
"    <a class=\"abstract\" href=\"UTD.htm?22/10/22696/abstract/20-22\">",
"     20-22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42506?source=see_link\">",
"     \"Antithrombotic therapy to prevent embolization in atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Infective endocarditis of the mitral valve has been reported in patients with obstructive HCM [",
"    <a class=\"abstract\" href=\"UTD.htm?22/10/22696/abstract/23\">",
"     23",
"    </a>",
"    ]. However, revisions to guidelines for endocarditis prophylaxis state that patients with HCM are among those who are no longer considered to require routine prophylaxis, although HCM expert opinion continues to favor antimicrobial bacterial endocarditis prophylaxis before dental procedures. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/36/585?source=see_link\">",
"     \"Antimicrobial prophylaxis for bacterial endocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     PERIOPERATIVE MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limited data are available on perioperative risk in patients with HCM. In small series, adverse cardiac events included heart failure, myocardial ischemia, arrhythmias, and hypotension [",
"    <a class=\"abstract\" href=\"UTD.htm?22/10/22696/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. The duration and magnitude (major versus minor) of the surgical procedure were predictors of adverse cardiac outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?22/10/22696/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Perioperative hemodynamic fluctuations (such as may accompany induction, hemorrhage, and other perioperative stressors) may be poorly tolerated by patients with HCM [",
"    <a class=\"abstract\" href=\"UTD.htm?22/10/22696/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Conditions that reduce LV volumes and may increase outflow obstruction include reduction in blood volume, decrease in systemic vascular resistance, and increased venous capacitance.",
"     </li>",
"     <li>",
"      In the setting of impaired LV diastolic filling, reduced filling pressures may lead to a fall in stroke volume.",
"     </li>",
"     <li>",
"      Increases in contractility may worsen outflow obstruction and may provoke ischemia.",
"     </li>",
"     <li>",
"      Tachycardia may further impair diastolic filling.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Invasive monitoring of arterial blood pressure and LV filling pressure has been advocated [",
"    <a class=\"abstract\" href=\"UTD.htm?22/10/22696/abstract/26\">",
"     26",
"    </a>",
"    ]. However, pulmonary capillary wedge pressure measurements should be interpreted with caution in the presence of diastolic dysfunction, since relatively high filling pressures may be required to maintain adequate stroke volume while excessive fluid administration may cause pulmonary edema.",
"   </p>",
"   <p>",
"    Transesophageal echocardiography (TEE) may help guide intraoperative management. TEE enables dynamic assessment of outflow obstruction, LV cavity size, mitral regurgitation, diastolic dysfunction, and regional wall motion (which may be impaired by ischemia) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/10/22696/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/59/13240?source=see_link\">",
"     \"Transesophageal echocardiography in the evaluation of the left ventricle\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following maneuvers may help preserve LV stroke volume in the perioperative period [",
"    <a class=\"abstract\" href=\"UTD.htm?22/10/22696/abstract/26\">",
"     26",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Preservation of LV",
"      <span class=\"nowrap\">",
"       volumes/preload",
"      </span>",
"      via careful hydration and avoidance of high airway pressures with mechanical ventilation (smaller tidal volumes with higher respiratory rates are favored).",
"     </li>",
"     <li>",
"      Treatment of hypotension with volume and augmentation of afterload via administration of alpha-1 agonists (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/36/39488?source=see_link\">",
"       phenylephrine",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Limiting contractility, tachycardia and oxygen demand. This can be achieved by avoidance of beta adrenergic agonists and by administration of beta blockers (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/37/40536?source=see_link\">",
"       esmolol",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"       metoprolol",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Avoidance of vasodilators (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"       nitroglycerin",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21302?source=see_link\">",
"       nitroprusside",
"      </a>",
"      ) since they decrease preload and systemic vascular resistance.",
"     </li>",
"     <li>",
"      Maintenance of sinus rhythm. Atrial fibrillation is frequently poorly tolerated if adequate rate control cannot be achieved with pharmacologic therapy, and may require cardioversion.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?34/28/35266?source=see_link\">",
"       \"Patient information: Hypertrophic cardiomyopathy in adults (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?35/24/36226?source=see_link\">",
"       \"Patient information: Hypertrophic cardiomyopathy in children (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?17/49/18197?source=see_link\">",
"       \"Patient information: Hypertrophic cardiomyopathy (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6427826\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The major components of management of hypertrophic cardiomyopathy include avoidance of volume depletion, restriction from intense physical activities such as most competitive sports, controlling heart failure symptoms and chest pain, arrhythmia treatment, and screening of first-degree relatives. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      LV outflow tract obstruction associated with acute hemodynamic collapse may present with clinical features of heart failure and severe hypotension. Conventional heart failure therapies with nitrates, diuretics, and vasodilators may result in further hemodynamic deterioration and should be avoided. Instead, treatment includes increasing preload, hydration, and beta blockers. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Left ventricular outflow tract obstruction associated with acute hemodynamic collapse'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pregnancy is not associated with any increased risk in the majority of HCM patients. This includes patients with obstructive HCM who, prior to pregnancy, have no symptoms or only mild and stable symptoms. Most pregnant women with HCM increase cardiac output adequately in response to the enhanced physiologic demands of pregnancy. Fluid retention with a subsequent increase in plasma volume appears to offset the characteristic vasodilation that occurs in the setting. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Pregnancy and delivery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Among children diagnosed with HCM, there are unique diagnostic and management issues. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Children with HCM'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In HCM patients undergoing non-cardiac surgery, close monitoring of intraoperative hemodynamics, particularly during induction, hemorrhage, and other perioperative stressors, is critical. Invasive monitoring of arterial blood pressure and LV filling pressure has been advocated. Transesophageal echocardiography (TEE) may help guide intraoperative management. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Perioperative management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22696/abstract/1\">",
"      Oakley GD, McGarry K, Limb DG, Oakley CM. Management of pregnancy in patients with hypertrophic cardiomyopathy. Br Med J 1979; 1:1749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22696/abstract/2\">",
"      Autore C, Conte MR, Piccininno M, et al. Risk associated with pregnancy in hypertrophic cardiomyopathy. J Am Coll Cardiol 2002; 40:1864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22696/abstract/3\">",
"      Maron BJ, Spirito P, Wesley Y, Arce J. Development and progression of left ventricular hypertrophy in children with hypertrophic cardiomyopathy. N Engl J Med 1986; 315:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22696/abstract/4\">",
"      Ryan MP, Cleland JG, French JA, et al. The standard electrocardiogram as a screening test for hypertrophic cardiomyopathy. Am J Cardiol 1995; 76:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22696/abstract/5\">",
"      Nugent AW, Daubeney PE, Chondros P, et al. Clinical features and outcomes of childhood hypertrophic cardiomyopathy: results from a national population-based study. Circulation 2005; 112:1332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22696/abstract/6\">",
"      Maron BJ, Tajik AJ, Ruttenberg HD, et al. Hypertrophic cardiomyopathy in infants: clinical features and natural history. Circulation 1982; 65:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22696/abstract/7\">",
"      Colan SD, Lipshultz SE, Lowe AM, et al. Epidemiology and cause-specific outcome of hypertrophic cardiomyopathy in children: findings from the Pediatric Cardiomyopathy Registry. Circulation 2007; 115:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22696/abstract/8\">",
"      Yang Z, McMahon CJ, Smith LR, et al. Danon disease as an underrecognized cause of hypertrophic cardiomyopathy in children. Circulation 2005; 112:1612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22696/abstract/9\">",
"      Morita H, Rehm HL, Menesses A, et al. Shared genetic causes of cardiac hypertrophy in children and adults. N Engl J Med 2008; 358:1899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22696/abstract/10\">",
"      Shirani J, Pick R, Roberts WC, Maron BJ. Morphology and significance of the left ventricular collagen network in young patients with hypertrophic cardiomyopathy and sudden cardiac death. J Am Coll Cardiol 2000; 35:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22696/abstract/11\">",
"      Yetman AT, Hamilton RM, Benson LN, McCrindle BW. Long-term outcome and prognostic determinants in children with hypertrophic cardiomyopathy. J Am Coll Cardiol 1998; 32:1943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22696/abstract/12\">",
"      Yetman AT, McCrindle BW, MacDonald C, et al. Myocardial bridging in children with hypertrophic cardiomyopathy--a risk factor for sudden death. N Engl J Med 1998; 339:1201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22696/abstract/13\">",
"      Mohiddin SA, Begley D, Shih J, Fananapazir L. Myocardial bridging does not predict sudden death in children with hypertrophic cardiomyopathy but is associated with more severe cardiac disease. J Am Coll Cardiol 2000; 36:2270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22696/abstract/14\">",
"      Dilsizian V, Bonow RO, Epstein SE, Fananapazir L. Myocardial ischemia detected by thallium scintigraphy is frequently related to cardiac arrest and syncope in young patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 1993; 22:796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22696/abstract/15\">",
"      Ostman-Smith I, Wettrell G, Riesenfeld T. A cohort study of childhood hypertrophic cardiomyopathy: improved survival following high-dose beta-adrenoceptor antagonist treatment. J Am Coll Cardiol 1999; 34:1813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22696/abstract/16\">",
"      Rishi F, Hulse JE, Auld DO, et al. Effects of dual-chamber pacing for pediatric patients with hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 1997; 29:734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22696/abstract/17\">",
"      Stone CD, McIntosh CL, Hennein HA, et al. Operative treatment of pediatric obstructive hypertrophic cardiomyopathy: a 26-year experience. Ann Thorac Surg 1993; 56:1308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22696/abstract/18\">",
"      Watkins H, McKenna WJ. The prognostic impact of septal myectomy in obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 2005; 46:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22696/abstract/19\">",
"      Yetman AT, McCrindle BW. Management of pediatric hypertrophic cardiomyopathy. Curr Opin Cardiol 2005; 20:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22696/abstract/20\">",
"      Hardarson T, De la Calzada CS, Curiel R, Goodwin JF. Prognosis and mortality of hypertrophic obstructive cardiomyopathy. Lancet 1973; 2:1462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22696/abstract/21\">",
"      Shah PM, Adelman AG, Wigle ED, et al. The natural (and unnatural) history of hypertrophic obstructive cardiomyopathy. Circ Res 1974; 35:suppl II:179.",
"     </a>",
"    </li>",
"    <li>",
"     Pasquale G Di, Andreoli A, Lusa AM, et al. Cerebral embolic risk in hypertrophic cardiomyopathy. In: Advances in Cardiomyopathies, Baroldi G, Camerini F, Goodwin JF (Eds), Springer-Verlag, 1990. p.90.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22696/abstract/23\">",
"      Spirito P, Rapezzi C, Bellone P, et al. Infective endocarditis in hypertrophic cardiomyopathy: prevalence, incidence, and indications for antibiotic prophylaxis. Circulation 1999; 99:2132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22696/abstract/24\">",
"      Thompson RC, Liberthson RR, Lowenstein E. Perioperative anesthetic risk of noncardiac surgery in hypertrophic obstructive cardiomyopathy. JAMA 1985; 254:2419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22696/abstract/25\">",
"      Haering JM, Comunale ME, Parker RA, et al. Cardiac risk of noncardiac surgery in patients with asymmetric septal hypertrophy. Anesthesiology 1996; 85:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22696/abstract/26\">",
"      Poliac LC, Barron ME, Maron BJ. Hypertrophic cardiomyopathy. Anesthesiology 2006; 104:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22696/abstract/27\">",
"      Fleisher LA, Beckman JA, Brown KA, et al. 2009 ACCF/AHA focused update on perioperative beta blockade incorporated into the ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery: a report of the American college of cardiology foundation/American heart association task force on practice guidelines. Circulation 2009; 120:e169.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4951 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-122.72.80.101-9C98E7F444-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_10_22696=[""].join("\n");
var outline_f22_10_22696=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H6427826\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      SPECIAL PROBLEMS AND ISSUES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      LEFT VENTRICULAR OUTFLOW TRACT OBSTRUCTION ASSOCIATED WITH ACUTE HEMODYNAMIC COLLAPSE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      PREGNANCY AND DELIVERY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CHILDREN WITH HCM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Presentation and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Genetics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Mortality",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Mechanisms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Management of LV outflow obstruction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      ANTICOAGULATION AND ENDOCARDITIS PROPHYLAXIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      PERIOPERATIVE MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6427826\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/4951\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/4951|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?29/22/30048\" title=\"algorithm 1\">",
"      HCM treatment algorithm",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/36/585?source=related_link\">",
"      Antimicrobial prophylaxis for bacterial endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42506?source=related_link\">",
"      Antithrombotic therapy to prevent embolization in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/34/28199?source=related_link\">",
"      Atrial fibrillation and other atrial tachyarrhythmias in hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/37/26202?source=related_link\">",
"      Auscultation of cardiac murmurs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/56/22410?source=related_link\">",
"      Auscultation of heart sounds",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/62/39910?source=related_link\">",
"      Clinical manifestations and diagnosis of pulmonic stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/42/36522?source=related_link\">",
"      Clinical manifestations, diagnosis, and evaluation of hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/15/33013?source=related_link\">",
"      Examination of the arterial pulse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/59/33719?source=related_link\">",
"      Examination of the jugular venous pulse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/44/29386?source=related_link\">",
"      Genetics of hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/19/43315?source=related_link\">",
"      Lysosome-associated membrane protein 2 deficiency (glycogen storage disease IIb, Danon disease)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/7/13434?source=related_link\">",
"      Management of hypertension in pregnant and postpartum women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/40/20105?source=related_link\">",
"      Maternal cardiovascular and hemodynamic adaptations to pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/55/10105?source=related_link\">",
"      Medical therapy in hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/47/12023?source=related_link\">",
"      Myocardial bridging of the coronary arteries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/4/32841?source=related_link\">",
"      Natural history of hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/21/7514?source=related_link\">",
"      Nonpharmacologic treatment of outflow obstruction in hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=related_link\">",
"      Overview of the therapy of heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?17/49/18197?source=related_link\">",
"      Patient information: Hypertrophic cardiomyopathy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?34/28/35266?source=related_link\">",
"      Patient information: Hypertrophic cardiomyopathy in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/24/36226?source=related_link\">",
"      Patient information: Hypertrophic cardiomyopathy in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/36/13898?source=related_link\">",
"      Risk of sudden cardiac death in athletes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/59/13240?source=related_link\">",
"      Transesophageal echocardiography in the evaluation of the left ventricle",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/59/28600?source=related_link\">",
"      Types and pathophysiology of obstructive hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/3/22586?source=related_link\">",
"      Ventricular arrhythmias and sudden cardiac arrest in hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_10_22697="Digital clubbing";
var content_f22_10_22697=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F85718%7EDERM%2F80452%7EDERM%2F61526&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F85718%7EDERM%2F80452%7EDERM%2F61526&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Digital clubbing",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 322px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hypertrophic osteoarthropathy - digital clubbing",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Bulbous swelling of the distal phalanx of the finger with increased nail curvature is present.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hypertrophic osteoarthropathy - digital clubbing",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Bulbous swelling of the distal phalanges of the fingers with increased nail curvature is present.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_10_22697=[""].join("\n");
var outline_f22_10_22697=null;
var title_f22_10_22698="Management of unscheduled bleeding in women using contraception";
var content_f22_10_22698=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of unscheduled bleeding in women using contraception",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/10/22698/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/10/22698/contributors\">",
"     Alison Edelman, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/10/22698/contributors\">",
"     Bliss Kaneshiro, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/10/22698/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/10/22698/contributors\">",
"     Mimi Zieman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/10/22698/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/10/22698/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/10/22698/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 15, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A common reason women choose to discontinue hormonal contraception is dissatisfaction with its effects on uterine bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?22/10/22698/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The bleeding pattern most bothersome to women is probably unscheduled bleeding and spotting, which can occur with all hormonal methods of contraception, as well as the copper intrauterine device. The frequency of unscheduled bleeding is highest in the first few months of use, and then begins to diminish. Interventions that prevent or treat unscheduled bleeding could improve contraceptive acceptability and increase compliance, and thus lead to fewer unplanned pregnancies. These interventions are discussed below and summarized in the figure (",
"    <a class=\"graphic graphic_algorithm graphicRef69054 \" href=\"UTD.htm?35/4/35906\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following terminology has been suggested for standardizing the description of bleeding in women in contraceptive trials [",
"    <a class=\"abstract\" href=\"UTD.htm?22/10/22698/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bleeding &ndash; Blood loss that requires the use of a tampon, pad or panty liner.",
"     </li>",
"     <li>",
"      Spotting &ndash; Minimal blood loss that does not require use of any type of protection.",
"     </li>",
"     <li>",
"      Episode of",
"      <span class=\"nowrap\">",
"       bleeding/spotting",
"      </span>",
"      &ndash;",
"      <span class=\"nowrap\">",
"       Bleeding/spotting",
"      </span>",
"      days bounded on either end by two days of no bleeding or spotting.",
"     </li>",
"     <li>",
"      Scheduled bleeding or withdrawal bleeding &ndash; Any bleeding or spotting that occurs during contraceptive hormone-free intervals; bleeding may continue through days 1 to 4 of the subsequent active cycle.",
"     </li>",
"     <li>",
"      Unscheduled bleeding and unscheduled spotting &ndash; Any bleeding that occurs while taking active contraceptive hormones, except bleeding that begins in the hormone-free interval and continues through days 1 to 4 of the subsequent active cycle.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18877011\">",
"    <span class=\"h1\">",
"     MECHANISM",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of unscheduled bleeding in women using hormonal contraception is poorly understood. Upon initiation of the method, unscheduled bleeding is thought to be due to a relatively thick endometrium transitioning to a relatively thin endometrium as a result of the progestin-dominant component of all hormonal contraceptives [",
"    <a class=\"abstract\" href=\"UTD.htm?22/10/22698/abstract/1\">",
"     1",
"    </a>",
"    ]. With continuing use, it is thought to be the final step in a complex process activated by continuous exposure to exogenous sex steroids, particularly progestins [",
"    <a class=\"abstract\" href=\"UTD.htm?22/10/22698/abstract/4\">",
"     4",
"    </a>",
"    ]. In this environment, the endometrium develops a dense network of small, thin-walled, dilated, superficial veins and capillaries, which are fragile and prone to focal bleeding. The fragility of these vessels is due to alterations in their basement membranes and pericytes, as well as reduced structural support from the endometrial stroma and glands, which are also altered [",
"    <a class=\"abstract\" href=\"UTD.htm?22/10/22698/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Altered matrix metalloproteinase (MMP) activity appears to have a major role in this remodeling. Changes in endometrial perfusion, local vascular hemostasis, pro- and anti-oxidant processes, and migratory cells also appear to play a role.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     GENERAL APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to initiating contraception, women should be thoroughly counseled about the range of bleeding patterns associated with various contraceptive options and informed that there is no evidence that unscheduled bleeding is associated with decreased contraceptive efficacy or other harmful effects. Providing this information as a component of standard contraception counseling helps patients choose the method that best suits their needs. If warned of the frequency, course, and significance of unscheduled bleeding, they may be more willing to adhere to the method if bleeding irregularities occur and can be reassured that the method is effective, thus reducing the risk of unintended pregnancy. Users of short-acting hormonal methods like oral contraceptive pills, the contraceptive patch, or the vaginal ring should understand that missed or delayed ingestion, application, or placement can lead to unscheduled withdrawal bleeding.",
"   </p>",
"   <p>",
"    Even with the most effective contraceptive methods, pregnancy should be considered and excluded if a woman experiences a significant change in her bleeding pattern or if she develops pregnancy-type symptoms (breast tenderness, nausea, urinary frequency, fatigue). Both pregnancy (intrauterine and ectopic) and hormonal contraceptives share many of the same signs and symptoms. In particular, absence of uterine bleeding and unscheduled bleeding are not only signs of early pregnancy, but also common occurrences with hormonal methods of birth control, both combined and progestin-only.",
"   </p>",
"   <p>",
"    In addition to a full medical history, the following questions can help guide further evaluation when a woman is experiencing unscheduled bleeding or spotting:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      What are the patient&rsquo;s main concerns?",
"     </li>",
"     <li>",
"      What was her bleeding pattern prior to her current method of contraception? How has it changed?",
"     </li>",
"     <li>",
"      How many days does she bleed each month, how heavy is the bleeding, and how many bleeding episodes occur?",
"     </li>",
"     <li>",
"      Does the bleeding occur during or after sex or is it associated with pain or urinary symptoms? Bleeding associated with sex, pain, or urinary symptoms is unlikely to be related to contraception.",
"     </li>",
"     <li>",
"      What drugs or medications is she taking? Some drugs may affect bleeding patterns in contraceptive users [",
"      <a class=\"abstract\" href=\"UTD.htm?22/10/22698/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Has she been consistent in her use of contraception? Missing pills or taking them late affects hormone levels, which can cause unscheduled bleeding.",
"     </li>",
"     <li>",
"      Does she smoke? Smoking may affect bleeding patterns in contraceptive users [",
"      <a class=\"abstract\" href=\"UTD.htm?22/10/22698/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Has she had a new partner or is she at increased risk of a sexually transmitted infection? Cervicitis can cause unscheduled bleeding. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/4/64?source=see_link\">",
"       \"Acute cervicitis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      When was her last cervical cancer screening?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Beyond pregnancy testing, the decision to initiate a more detailed evaluation will depend on the answers to these questions and the type of contraceptive the patient is using. Unscheduled bleeding is common and expected with the use of progestin methods (contraceptive implants, progestin only pills, DMPA, and the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/47/25336?source=see_link\">",
"     levonorgestrel",
"    </a>",
"    -releasing IUD); further evaluation is not necessary unless indicated based on history (bleeding pattern was abnormal prior to contraceptive use), symptoms (menorrhagia, pain, vaginal discharge) or national cervical cancer screening guidelines, even if the unscheduled bleeding persists for the duration of contraceptive use. With the initiation of other contraceptive methods, including combined estrogen-progestin methods (pill, patch, ring) and the copper-releasing IUD, unscheduled bleeding is common and usually resolves over time, thus, further evaluation is not routinely necessary in the first six months of use.",
"   </p>",
"   <p>",
"    A patient with additional symptoms, such as pelvic pain or vaginal discharge, should have a pelvic examination. Depending on the findings and her symptoms, a pelvic ultrasound may be helpful to evaluate for possible uterine pathology. Cervical cancer screening should be performed according to national screening guidelines. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/16/38154?source=see_link\">",
"     \"Screening for cervical cancer: Rationale and recommendations\"",
"    </a>",
"    .) An endometrial biopsy is reasonable in women over the age of 35 who had abnormal uterine bleeding for more than three months prior to starting contraception, women with a history of endometrial hyperplasia, or women with prolonged periods of unopposed estrogen stimulation secondary to chronic anovulation. Otherwise, the decision to biopsy the endometrium for women who are experiencing unscheduled bleeding while using contraception will depend on the method they are using. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/25/20887?source=see_link\">",
"     \"Initial approach to the premenopausal woman with abnormal uterine bleeding\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Drug therapy has been used in an attempt to prevent or treat unscheduled bleeding. Most trials have been small",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    had design flaws; thus, it is difficult to determine whether the medical therapies discussed below result in a statistically significant reduction in symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15719109\">",
"    <span class=\"h1\">",
"     ESTROGEN-PROGESTIN CONTRACEPTIVES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15719137\">",
"    <span class=\"h2\">",
"     Bleeding pattern",
"    </span>",
"    &nbsp;&mdash;&nbsp;Combined estrogen-progestin contraceptives include oral contraceptive pills (OCs), the transdermal contraceptive patch, and the vaginal contraceptive ring. An injectable combined estrogen-progestin contraceptive (Cyclofemina&reg;, Lunelle&reg;) is available in some countries.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Estrogen-progestin contraceptive pills",
"      </strong>",
"      &ndash; Unscheduled bleeding occurs in up to 30 percent of women initiating OCs, but decreases to less than 10 percent by the third month of use [",
"      <a class=\"abstract\" href=\"UTD.htm?22/10/22698/abstract/1,9\">",
"       1,9",
"      </a>",
"      ]. Randomized trials have shown that unscheduled bleeding is slightly higher with the lowest dose OCs (20 mcg ethinyl estradiol [EE] component) than with 30 to 35 mcg EE pills [",
"      <a class=\"abstract\" href=\"UTD.htm?22/10/22698/abstract/10-12\">",
"       10-12",
"      </a>",
"      ]. There is no evidence that unscheduled bleeding is associated with decreased efficacy, even with the lowest dose products, as long as the woman takes her pills consistently (ie, no missed days and at the same time every day) [",
"      <a class=\"abstract\" href=\"UTD.htm?22/10/22698/abstract/1\">",
"       1",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/5/18522?source=see_link\">",
"       \"Overview of the use of estrogen-progestin contraceptives\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Continuous and extended administration of OCs to avoid all scheduled uterine bleeding is an increasingly popular method of contraception. Continuous use involves taking hormonally active pills indefinitely, without an induced withdrawal bleed. Extended use involves taking hormonally active pills for intervals of several months, thus minimizing scheduled bleeds to only a few times per year.",
"      <br/>",
"      <br/>",
"      Compared to the traditional monthly regimen, continuous and extended use of OCs decreases the overall number of scheduled bleeding days; however, they are associated with a high frequency of unscheduled bleeding and spotting, particularly during the first three months of use [",
"      <a class=\"abstract\" href=\"UTD.htm?22/10/22698/abstract/13-16\">",
"       13-16",
"      </a>",
"      ]. In randomized trials, absence of all uterine bleeding and spotting during months 0 to 3 was achieved in less than 50 percent of continuous OC users, but this rate increased to 80 to 90 percent by months 10 to 12 [",
"      <a class=\"abstract\" href=\"UTD.htm?22/10/22698/abstract/13-15\">",
"       13-15",
"      </a>",
"      ]. The duration of unscheduled bleeding appears to be higher in women using continuous OCs that contain",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/47/25336?source=see_link\">",
"       levonorgestrel",
"      </a>",
"      (LNG) than in those that contain",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/52/16199?source=see_link\">",
"       norethindrone acetate",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?22/10/22698/abstract/17\">",
"       17",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/47/3832?source=see_link\">",
"       \"Hormonal contraception for suppression of menstruation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Patch and ring",
"      </strong>",
"      &ndash; The frequency of unscheduled bleeding upon initiation of the contraceptive patch and ring is generally similar to that with OCs. Neither is approved for extended or continuous use. Although the ring and patch are not approved for",
"      <span class=\"nowrap\">",
"       continuous/extended",
"      </span>",
"      use, a randomized trial comparing extended versus cyclic vaginal ring regimens found that skipping the hormone-free interval increased unscheduled bleeding and reduced the amount of",
"      <span class=\"nowrap\">",
"       scheduled/withdrawal",
"      </span>",
"      bleeding [",
"      <a class=\"abstract\" href=\"UTD.htm?22/10/22698/abstract/18\">",
"       18",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/10/41127?source=see_link\">",
"       \"Transdermal contraceptive patch\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15719144\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;For women experiencing unscheduled bleeding while taking combined estrogen-progestin contraceptives (pill, patch, ring), reinforcing consistent use (reducing the number of missed doses, taking the pill at the same time each day) can improve the bleeding pattern [",
"    <a class=\"abstract\" href=\"UTD.htm?22/10/22698/abstract/9,19\">",
"     9,19",
"    </a>",
"    ]. Inconsistent pill use is associated with a 60 to 70 percent increase in the relative risk of unscheduled bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?22/10/22698/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Smokers are more likely than nonsmokers to experience unscheduled bleeding and spotting when taking OCs [",
"    <a class=\"abstract\" href=\"UTD.htm?22/10/22698/abstract/9,20\">",
"     9,20",
"    </a>",
"    ]. Bleeding is also more likely to persist through subsequent cycles [",
"    <a class=\"abstract\" href=\"UTD.htm?22/10/22698/abstract/9\">",
"     9",
"    </a>",
"    ]. Smoking cessation may result in improved cycle control, and has other major health benefits [",
"    <a class=\"abstract\" href=\"UTD.htm?22/10/22698/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Women with new or persistent bleeding for six months should be evaluated for cervicitis and other gynecological disorders associated with bleeding (eg, cervical or endometrial polyps) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/10/22698/abstract/9,21,22\">",
"     9,21,22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/4/64?source=see_link\">",
"     \"Acute cervicitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/10/7336?source=see_link\">",
"     \"Endometrial polyps\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15719151\">",
"    <span class=\"h3\">",
"     Women using a cyclic estrogen-progestin regimen",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with other methods, reassurance and encouragement is the best long-term management for unscheduled bleeding associated with OC use. Unscheduled bleeding will cease by the third cycle in the majority of women [",
"    <a class=\"abstract\" href=\"UTD.htm?22/10/22698/abstract/1\">",
"     1",
"    </a>",
"    ]. If bleeding is prolonged and the woman desires intervention, experts have recommended a short course of estrogen (1.25 mg conjugated estrogen or 2 mg estradiol for seven days) to decrease the duration of the bleeding episode [",
"    <a class=\"abstract\" href=\"UTD.htm?22/10/22698/abstract/1\">",
"     1",
"    </a>",
"    ]. Supplemental estrogen can be used any time during the pill cycle. Estrogen supplementation is thought to promote tissue repair and coagulation. However, there are no studies demonstrating the benefit of this approach.",
"   </p>",
"   <p>",
"    Some clinicians manage bothersome unscheduled bleeding related to OCs by switching the woman to the estrogen-progestin vaginal ring. Theoretically, this approach has two potential benefits: (1) the woman is less likely to have unscheduled bleeding related to a \"missed pill,\" and (2) the vaginal ring is associated with more constant hormone levels than OCs. Although there are no studies evaluating this approach, the resulting elimination of wide swings in serum estrogen and progestin concentrations may reduce bothersome unscheduled bleeding. The ring has excellent cycle control under normal circumstances; however, this may not be the case in a woman experiencing unscheduled bleeding.",
"   </p>",
"   <p>",
"    There is no evidence that monophasic OCs are associated with less unscheduled bleeding than biphasic OCs, or that discontinuation due to dissatisfaction with bleeding patterns is different for the two formulations [",
"    <a class=\"abstract\" href=\"UTD.htm?22/10/22698/abstract/9,23\">",
"     9,23",
"    </a>",
"    ]. Some studies have found that triphasic OCs have a lower incidence of unscheduled bleeding than monophasic OCs [",
"    <a class=\"abstract\" href=\"UTD.htm?22/10/22698/abstract/24-27\">",
"     24-27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is also no evidence that pill products by different manufacturers or different formulations of estrogen or progestin result in improved bleeding patterns [",
"    <a class=\"abstract\" href=\"UTD.htm?22/10/22698/abstract/9\">",
"     9",
"    </a>",
"    ]. Although uncontrolled studies have reported decreased bleeding after changing formulations, bleeding would have probably stopped with continued use of the initial OC regardless of the type of product used [",
"    <a class=\"abstract\" href=\"UTD.htm?22/10/22698/abstract/1\">",
"     1",
"    </a>",
"    ]. However, if the patient requests another OC product, allowing her to switch is unlikely to worsen bleeding patterns and can improve overall satisfaction with OC use. Women on OCs containing &le;20 mcg estrogen can be switched to an OC with a higher estrogen dose [",
"    <a class=\"abstract\" href=\"UTD.htm?22/10/22698/abstract/12\">",
"     12",
"    </a>",
"    ] or the progestin can be switched to a different progestin (1",
"    <sup>",
"     st",
"    </sup>",
"    generation:",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/52/16199?source=see_link\">",
"     norethindrone acetate",
"    </a>",
"    , ethynodiol diacetate, lynestrenol, norethynodrel; 2",
"    <sup>",
"     nd",
"    </sup>",
"    generation: dl-norgestrel,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/47/25336?source=see_link\">",
"     levonorgestrel",
"    </a>",
"    ; 3",
"    <sup>",
"     rd",
"    </sup>",
"    generation: desogestrel, gestodene, norgestimate) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/10/22698/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients who use a 21-day estrogen-progestin pill may have fewer unscheduled days of bleeding than women using a 24-day regimen. Two studies have addressed this topic. One reported less unscheduled bleeding in women using a 21-day compared to a 24-day hormonally active pill (mean 4.6 versus 6.1 days) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/10/22698/abstract/29\">",
"     29",
"    </a>",
"    ], and the other showed no difference between the two regimens in unscheduled bleeding days [",
"    <a class=\"abstract\" href=\"UTD.htm?22/10/22698/abstract/30\">",
"     30",
"    </a>",
"    ]. Of note, the total days of bleeding (scheduled plus unscheduled) will be higher for women using a 21-day estrogen-progestin pill (mean 15.8 versus 13.2 days) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/10/22698/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Doubling or tripling the daily dose of OCs is not recommended to decrease unscheduled bleeding. While it may work for some women, it has not been studied and may increase the risk of adverse events.",
"   </p>",
"   <p>",
"    As discussed above, it is important to exclude gynecological disease in women with new or persistent unscheduled bleeding.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15719158\">",
"    <span class=\"h3\">",
"     Women using continuous or extended pill regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most women, unscheduled bleeding will decrease over time with continuous or extended use of all OC products. However, estrogen dose and progestin type appear to play a role in the amount of unscheduled bleeding women experience with method initiation. In one randomized trial, use of an OC pill containing 30 mcg of EE during the first year of use resulted in significantly less unscheduled bleeding than a pill containing 20 mcg of EE (35.5 versus 47.4 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/10/22698/abstract/31\">",
"     31",
"    </a>",
"    ]. In another randomized trial, continuous use of OCs containing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/52/16199?source=see_link\">",
"     norethindrone acetate",
"    </a>",
"    resulted in significantly more bleeding-free days than use of pills containing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/47/25336?source=see_link\">",
"     levonorgestrel",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?22/10/22698/abstract/17\">",
"     17",
"    </a>",
"    ]. However, the levonorgestrel dose (90 versus 100 mcg) does not seem to make a difference [",
"    <a class=\"abstract\" href=\"UTD.htm?22/10/22698/abstract/32\">",
"     32",
"    </a>",
"    ]. In women using continuous or extended OCs who experience problematic unscheduled bleeding, consideration should be given to using a different estrogen dose or progestin type.",
"   </p>",
"   <p>",
"    If troublesome unscheduled bleeding occurs after the first 21 days of hormone use, one approach is to stop the OC for three days to allow withdrawal bleeding and then resume the pill for at least 21 days of continuous use [",
"    <a class=\"abstract\" href=\"UTD.htm?22/10/22698/abstract/33\">",
"     33",
"    </a>",
"    ]. This approach of scheduling a short hormone-free interval can be repeated whenever bothersome breakthrough bleeding occurs, as long as the patient has had at least 21 days of active pills before taking a hormone-free interval. Over time, breakthrough bleeding episodes will become spaced out and stop. As an example, in one study where subjects were given the option of stopping the OC for four days if they had taken at least 24 days of active pills, the mean number of days of",
"    <span class=\"nowrap\">",
"     bleeding/spotting",
"    </span>",
"    decreased from 19 days in the first 3 months of the study to 10 days in months 9 to 12 [",
"    <a class=\"abstract\" href=\"UTD.htm?22/10/22698/abstract/34\">",
"     34",
"    </a>",
"    ]. This technique should not be used more frequently than every three weeks in order to maintain contraceptive effectiveness.",
"   </p>",
"   <p>",
"    The use of the antibiotic",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    was not effective in decreasing unscheduled bleeding in continuous combined oral contraceptive users when taken at the onset of unscheduled bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?22/10/22698/abstract/35\">",
"     35",
"    </a>",
"    ]. Doxycycline was studied because it inhibits matrix metalloproteinases [",
"    <a class=\"abstract\" href=\"UTD.htm?22/10/22698/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. Matrix metalloproteinases play a role in endometrial degradation and are thought to be upregulated by the progestin dominant effect of hormonal contraceptives [",
"    <a class=\"abstract\" href=\"UTD.htm?22/10/22698/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. However, coadministration of doxycycline (40 mg daily) for the first 84 days after beginning continuous oral contraceptive pills resulted in a significant reduction in the length of time needed to achieve amenorrhea (62 versus 85 days) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/10/22698/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15719165\">",
"    <span class=\"h3\">",
"     Women using a patch or ring",
"    </span>",
"    &nbsp;&mdash;&nbsp;For women using the vaginal ring continuously, a randomized trial found that when unscheduled bleeding persisted for five or more days, women who removed the ring for four days and then reinserted it generally had fewer subsequent days of bleeding than those who continued use of the ring [",
"    <a class=\"abstract\" href=\"UTD.htm?22/10/22698/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15719890\">",
"    <span class=\"h1\">",
"     PROGESTIN ONLY CONTRACEPTIVES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Depot medroxyprogesterone acetate (DMPA)",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Bleeding pattern",
"    </span>",
"    &nbsp;&mdash;&nbsp;Menstrual changes occur in most women using DMPA (subcutaneous or intramuscular formulations) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/10/22698/abstract/1,42\">",
"     1,42",
"    </a>",
"    ]. Amenorrhea occurs in 12 percent of women during the first three months of use, but by one year, 46 percent of users will be amenorrheic [",
"    <a class=\"abstract\" href=\"UTD.htm?22/10/22698/abstract/1,43\">",
"     1,43",
"    </a>",
"    ]. Although bleeding is rarely heavy, 25 percent of users will discontinue DMPA in the first year because of dissatisfaction with bleeding patterns [",
"    <a class=\"abstract\" href=\"UTD.htm?22/10/22698/abstract/44\">",
"     44",
"    </a>",
"    ]. Structured counseling prior to DMPA use increases continuation rates at one year of use, and decreases discontinuation due to bleeding. With continued use, the most common bleeding pattern is no bleeding; absence of all bleeding and spotting after one and five years of use is 50 and 80 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?22/10/22698/abstract/45-47\">",
"     45-47",
"    </a>",
"    ]. Therefore, women who are uncomfortable with cessation of uterine bleeding should be advised to use another method. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/45/34522?source=see_link\">",
"     \"Depot medroxyprogesterone acetate for contraception\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The etiology of unscheduled bleeding in DMPA users is not clearly understood. Based on endometrial biopsy studies, atrophy and chronic endometritis appear to play a role [",
"    <a class=\"abstract\" href=\"UTD.htm?22/10/22698/abstract/1,48\">",
"     1,48",
"    </a>",
"    ]. Biopsy studies also suggest that the endometritis is related to atrophic endometrium rather than an infectious process [",
"    <a class=\"abstract\" href=\"UTD.htm?22/10/22698/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since the frequency and duration of unscheduled bleeding decrease with continued administration of DMPA, many women find it acceptable to wait for spontaneous resolution of the problem. For women who want an intervention, medication may help with cessation of bleeding and spotting; however, there is no evidence to support routine use of this approach. Options include:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H728294250\">",
"    <span class=\"h4\">",
"     Supplemental estrogen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Estrogen supplementation is thought to promote tissue repair and coagulation. The addition of estrogen does not affect the contraceptive efficacy of DMPA, but does put the patient at risk for estrogen related side effects [",
"    <a class=\"abstract\" href=\"UTD.htm?22/10/22698/abstract/1\">",
"     1",
"    </a>",
"    ]. The efficacy of supplemental estrogen for prevention or treatment of active unscheduled bleeding in DMPA users is unclear. Trials have reported discordant findings and some were flawed by high discontinuation rates by study participants [",
"    <a class=\"abstract\" href=\"UTD.htm?22/10/22698/abstract/36,50-53\">",
"     36,50-53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Treatment of unscheduled bleeding",
"      </strong>",
"      &mdash; If estrogen supplementation is used for treatment of unscheduled bleeding, we suggest 7 to 14 days of oral estrogen (1.25 mg conjugated estrogen or 2 mg of micronized estradiol) or transdermal estrogen (a patch releasing 0.1 mg",
"      <span class=\"nowrap\">",
"       estradiol/24",
"      </span>",
"      hours), if there are no contraindications to exogenous estrogen administration.",
"      <br/>",
"      <br/>",
"      In the largest therapeutic trial of this approach, 278 DMPA users with unscheduled bleeding were assigned to receive either EE 50 mcg, estrone sulfate 2.5 mg, or placebo for 14 days [",
"      <a class=\"abstract\" href=\"UTD.htm?22/10/22698/abstract/51\">",
"       51",
"      </a>",
"      ]. EE was significantly more effective than placebo in stopping bleeding during treatment, but estrone sulfate was not (bleeding stopped in 93, 76, and 74 percent of EE, estrone sulfate, and placebo groups, respectively). Bleeding tended to recur after discontinuation of estrogen.",
"     </li>",
"     <li>",
"      <strong>",
"       Prevention of unscheduled bleeding in new users",
"      </strong>",
"      &mdash; A few trials have studied use of supplemental estrogen for prevention of unscheduled bleeding in new DMPA users because unscheduled bleeding is especially common in this population and the reason many women do not return for a second injection. There is no high quality evidence of efficacy, but some promising trends have been observed that require further study [",
"      <a class=\"abstract\" href=\"UTD.htm?22/10/22698/abstract/50,52,53\">",
"       50,52,53",
"      </a>",
"      ] . At this time, we do not recommend prophylactic use of estrogen to prevent unscheduled bleeding in new DMPA users.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H728294257\">",
"    <span class=\"h4\">",
"     Valdecoxib",
"    </span>",
"    &nbsp;&mdash;&nbsp;Valdecoxib (40 mg orally once per day for five days) decreases the duration of bleeding episodes and increases the number of days the woman is free of bleeding before another episode occurs. In the only placebo-controlled randomized trial evaluating valdecoxib, a significantly higher percentage of subjects in the active treatment group had cessation of bleeding during the first week of treatment (77 versus 33 percent with placebo), and this group had a significantly higher mean number of bleeding-free days during 28 days of follow-up (17.8 versus 11.5 days) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/10/22698/abstract/54\">",
"     54",
"    </a>",
"    ]. This was a small trial over only one treatment cycle; long-term treatment cannot be recommended at this time based on this trial alone. Valdecoxib is not available in the United States.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H728294264\">",
"    <span class=\"h4\">",
"     Mefenamic acid",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/63/41976?source=see_link\">",
"     Mefenamic acid",
"    </a>",
"    (500 mg twice per day for five days) was reported to be effective in control of bleeding during the first week of DMPA use, but was not statistically more effective than placebo by week 4 [",
"    <a class=\"abstract\" href=\"UTD.htm?22/10/22698/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H728294275\">",
"    <span class=\"h4\">",
"     Tranexamic acid",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/58/14248?source=see_link\">",
"     Tranexamic acid",
"    </a>",
"    is an antifibrinolytic used primarily during operative procedures in patients with hemophilia. A randomized placebo-controlled trial of 100 DMPA users with unscheduled bleeding found that tranexamic acid 250 mg orally four times per day for five days was effective in halting bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?22/10/22698/abstract/56\">",
"     56",
"    </a>",
"    ]. The tranexamic acid group had a significantly higher percentage of subjects in whom unscheduled bleeding stopped during the first week of treatment (88 versus 8.2 percent with placebo), and during the four-week follow-up period (68 versus 0 percent with placebo). The mean number of",
"    <span class=\"nowrap\">",
"     bleeding/spotting",
"    </span>",
"    days was also significantly different between the groups (5.7 versus 17.5 days).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H728294282\">",
"    <span class=\"h4\">",
"     Mifepristone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Low doses of the antiprogestin",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/45/1753?source=see_link\">",
"     mifepristone",
"    </a>",
"    (50 mg orally once every two weeks) decrease the number of days of unscheduled bleeding in women initiating DMPA. In a randomized placebo-controlled trial involving 20 new starters of DMPA, 15 percent of women taking mifepristone experienced unscheduled bleeding during the first three months of use compared with 36 percent of women taking placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?22/10/22698/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/45/1753?source=see_link\">",
"     Mifepristone",
"    </a>",
"    administration does not lead to ovulation in DMPA users and thus should not reduce DMPA&rsquo;s contraceptive efficacy.",
"   </p>",
"   <p>",
"    Although a promising approach, a low dose formulation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/45/1753?source=see_link\">",
"     mifepristone",
"    </a>",
"    is not available in the US. The 200 mg dose is used for termination of pregnancy and has not been studied in this context.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H728294289\">",
"    <span class=\"h4\">",
"     Shortening the interval between DMPA injections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increasing the frequency of DMPA injections is another approach to treatment of unscheduled bleeding. Although widely used, there are no studies evaluating the efficacy of this practice. We do",
"    <strong>",
"     not",
"    </strong>",
"    suggest shortening the interval between DMPA injections to treat unscheduled bleeding.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5574966\">",
"    <span class=\"h4\">",
"     Doxycycline",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a double-blind placebo-controlled randomized trial in 68 DMPA users with a current bleeding episode,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    100 mg twice daily for five days was not more effective than placebo for stopping a current episode of bleeding or for improving bleeding characteristics in the three months following treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?22/10/22698/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Contraceptive implants",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Bleeding pattern",
"    </span>",
"    &nbsp;&mdash;&nbsp;All contraceptive implants are associated with significant uterine bleeding disturbances [",
"    <a class=\"abstract\" href=\"UTD.htm?22/10/22698/abstract/36\">",
"     36",
"    </a>",
"    ]. A single rod",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/1/35863?source=see_link\">",
"     etonogestrel",
"    </a>",
"    releasing system is available in many countries and the only contraceptive implant available for use in the United States.",
"   </p>",
"   <p>",
"    Over a three-month period, 22 percent of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/1/35863?source=see_link\">",
"     etonogestrel",
"    </a>",
"    implant users will experience absence of all",
"    <span class=\"nowrap\">",
"     bleeding/spotting,",
"    </span>",
"    while the remainder experience some form of unscheduled bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?22/10/22698/abstract/59-61\">",
"     59-61",
"    </a>",
"    ]. A literature review found that 6 to 23 percent of etonogestrel implant users worldwide discontinued the method because of bleeding issues [",
"    <a class=\"abstract\" href=\"UTD.htm?22/10/22698/abstract/62\">",
"     62",
"    </a>",
"    ]. The bleeding pattern is unpredictable and, unlike other progestin-only methods, amenorrhea may not be sustained [",
"    <a class=\"abstract\" href=\"UTD.htm?22/10/22698/abstract/60\">",
"     60",
"    </a>",
"    ]. However, a favorable bleeding pattern within the first three months appears to predict a continued favorable pattern during the remainder of use, whereas those with unfavorable patterns have a 50 percent chance of improving [",
"    <a class=\"abstract\" href=\"UTD.htm?22/10/22698/abstract/60\">",
"     60",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/27/3512?source=see_link\">",
"     \"Etonogestrel contraceptive implant\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Norplant is a six rod LNG releasing system that is still used in some parts of the world. After one year of use, 20 to 25 percent of Norplant users have regular monthly bleeding, the remainder experience anything from absence of all bleeding and spotting to frequent, prolonged bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?22/10/22698/abstract/36,63\">",
"     36,63",
"    </a>",
"    ]. After five years, only 33 percent of users experience unscheduled bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?22/10/22698/abstract/63\">",
"     63",
"    </a>",
"    ]. Bleeding abnormalities are the primary reason for method discontinuation [",
"    <a class=\"abstract\" href=\"UTD.htm?22/10/22698/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Management",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H110850442\">",
"    <span class=\"h4\">",
"     Etonogestrel implant",
"    </span>",
"    &nbsp;&mdash;&nbsp;There have been few studies examining interventions to decrease bleeding in",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/1/35863?source=see_link\">",
"     etonogestrel",
"    </a>",
"    implant users. A randomized trial that compared five regimens ((i)",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/45/1753?source=see_link\">",
"     mifepristone",
"    </a>",
"    25 mg given twice on day 1 followed by four days of ethinyl estradiol 20 microg; (ii)",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    100 mg twice daily for five days; (iii) mifepristone 25 mg given twice on day 1 plus doxycycline 100 mg twice daily for five days; (iv) doxycycline 100 mg twice daily with ethinyl estradiol 20 microg daily; and (v) placebo twice daily for five days) showed that the regimens containing mifepristone were more effective than the other regimens [",
"    <a class=\"abstract\" href=\"UTD.htm?22/10/22698/abstract/65\">",
"     65",
"    </a>",
"    ]. The mifepristone regimens resulted in four days of unscheduled bleeding as compared to six days with the other regimens. These low doses of mifepristone are not commercially available.",
"   </p>",
"   <p>",
"    For women with unscheduled bleeding related to progestin implants, our preference is expectant management rather than medical therapy. After reviewing the literature, one group described their pragmatic approach to management of unacceptable bleeding patterns in",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/1/35863?source=see_link\">",
"     etonogestrel",
"    </a>",
"    implant users [",
"    <a class=\"abstract\" href=\"UTD.htm?22/10/22698/abstract/66\">",
"     66",
"    </a>",
"    ]. The following options are listed in order of preference (first choice to fifth choice), and are based primarily on anecdotal evidence and extrapolation of data from studies in women using Norplant (see",
"    <a class=\"local\" href=\"#H110850387\">",
"     'Norplant'",
"    </a>",
"    below): &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Estrogen-progestin oral contraceptive pills taken daily for 21 days followed by a seven-day break for up to three months",
"     </li>",
"     <li>",
"      High-dose cyclical progestin for up to three months (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/24/1417?source=see_link\">",
"       medroxyprogesterone acetate",
"      </a>",
"      10 mg twice daily or norethisterone 5 mg twice daily for 21 days with a seven-day break)",
"     </li>",
"     <li>",
"      Progestin-only pills taken for up to three months",
"     </li>",
"     <li>",
"      Nonsteroidal antiinflammatory drugs (NSAIDS), especially COX-2 inhibitors, taken daily for 5 to 10 days [",
"      <a class=\"abstract\" href=\"UTD.htm?22/10/22698/abstract/67\">",
"       67",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/58/14248?source=see_link\">",
"       Tranexamic acid",
"      </a>",
"      500 mg twice daily for five days",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H110850387\">",
"    <span class=\"h4\">",
"     Norplant",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with DMPA, many users of Norplant are willing to go without intervention and wait for bleeding patterns to improve with continued use. For Norplant users who desire intervention, options include:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H728294296\">",
"    <span class=\"h5\">",
"     Supplemental estrogen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Administration of exogenous estrogen (conjugated estrogen 1.25 mg or estradiol 2 mg administered once per day for seven days) shortens episodes of unscheduled bleeding associated with Norplant use [",
"    <a class=\"abstract\" href=\"UTD.htm?22/10/22698/abstract/68-70\">",
"     68-70",
"    </a>",
"    ]. This benefit is observed for both unscheduled bleeding soon after initiating Norplant and unscheduled bleeding after several months of use. Use of estrogen may also increase the interval between bleeding episodes [",
"    <a class=\"abstract\" href=\"UTD.htm?22/10/22698/abstract/68\">",
"     68",
"    </a>",
"    ]. Transdermal estrogen (estradiol 0.1",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    may have the same benefits [",
"    <a class=\"abstract\" href=\"UTD.htm?22/10/22698/abstract/71\">",
"     71",
"    </a>",
"    ]. As expected, estrogen related side effects occur while taking the supplements. Supplemental estrogen should be avoided in women with contraindications to use of estrogen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H728294303\">",
"    <span class=\"h5\">",
"     Combined estrogen-progestin oral contraceptive pills",
"    </span>",
"    &nbsp;&mdash;&nbsp;OCs have also been used to treat bleeding abnormalities associated with Norplant use. Women may find it convenient to cycle on OCs for one to three months [",
"    <a class=\"abstract\" href=\"UTD.htm?22/10/22698/abstract/1\">",
"     1",
"    </a>",
"    ]. While the efficacy of OCs is similar to estrogen supplementation, OCs are more readily available in family planning facilities. Two pill formulations have been studied (EE 50",
"    <span class=\"nowrap\">",
"     mcg/LNG",
"    </span>",
"    250 mcg and EE 30",
"    <span class=\"nowrap\">",
"     mcg/LNG",
"    </span>",
"    150 mcg) and both decrease the duration of bleeding episodes [",
"    <a class=\"abstract\" href=\"UTD.htm?22/10/22698/abstract/36,68,70\">",
"     36,68,70",
"    </a>",
"    ]. In a placebo controlled randomized trial, women who received OCs for three weeks had fewer days of bleeding than those in the control group (mean 2.6 days after starting the OC versus 12.3 days after starting a placebo) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/10/22698/abstract/68\">",
"     68",
"    </a>",
"    ]. In another trial, OCs significantly decreased the total number of",
"    <span class=\"nowrap\">",
"     bleeding/spotting",
"    </span>",
"    days, but not the number of",
"    <span class=\"nowrap\">",
"     bleeding/spotting",
"    </span>",
"    episodes [",
"    <a class=\"abstract\" href=\"UTD.htm?22/10/22698/abstract/70\">",
"     70",
"    </a>",
"    ].",
"    <br/>",
"    <br/>",
"    The cyclic OCs promote scheduled bleeding during the hormone-free interval and reduce unscheduled bleeding. The number of days of scheduled bleeding may total more days than the unscheduled bleeding would have been, but women tend to prefer scheduled to unscheduled bleeding. While it is true that the first several months of cyclic OC use are associated with unscheduled bleeding, it occurs less often than the unscheduled bleeding that occurs with a progestin only method.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H728294310\">",
"    <span class=\"h5\">",
"     Mifepristone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Low doses of the progesterone receptor modulator",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/45/1753?source=see_link\">",
"     mifepristone",
"    </a>",
"    (50 to 100 mg) appear to be effective in reducing unscheduled bleeding in Norplant users [",
"    <a class=\"abstract\" href=\"UTD.htm?22/10/22698/abstract/72,73\">",
"     72,73",
"    </a>",
"    ]. Mifepristone, however, is not commercially available in low doses and theoretically may counteract the contraceptive efficacy of progestin implants.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H728294317\">",
"    <span class=\"h5\">",
"     Selective estrogen receptor modulators",
"    </span>",
"    &nbsp;&mdash;&nbsp;An early trial of the selective estrogen receptor modulator (SERM)",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    showed promise in reducing unscheduled bleeding over three months [",
"    <a class=\"abstract\" href=\"UTD.htm?22/10/22698/abstract/74\">",
"     74",
"    </a>",
"    ]. These results need to be confirmed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H728294324\">",
"    <span class=\"h5\">",
"     NSAIDs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although pilot studies suggested that NSAIDs including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"     ibuprofen",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/63/41976?source=see_link\">",
"     mefenamic acid",
"    </a>",
"    , and the cox-2 inhibitor valdecoxib might be effective in decreasing unscheduled bleeding in Norplant users, larger studies failed to replicate these results [",
"    <a class=\"abstract\" href=\"UTD.htm?22/10/22698/abstract/36,69,75,76\">",
"     36,69,75,76",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H728294339\">",
"    <span class=\"h5\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vitamin E is ineffective [",
"    <a class=\"abstract\" href=\"UTD.htm?22/10/22698/abstract/75\">",
"     75",
"    </a>",
"    ]. Studies on progestin supplementation were inconclusive [",
"    <a class=\"abstract\" href=\"UTD.htm?22/10/22698/abstract/69\">",
"     69",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/58/14248?source=see_link\">",
"     Tranexamic acid",
"    </a>",
"    , an antifibrinolytic [",
"    <a class=\"abstract\" href=\"UTD.htm?22/10/22698/abstract/77\">",
"     77",
"    </a>",
"    ], shows promise for Norplant users and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?22/10/22698/abstract/37\">",
"     37",
"    </a>",
"    ], shows promise for Implanon users, but results need to be confirmed with longer trials and longer periods of follow-up.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Progestin pills",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Bleeding pattern",
"    </span>",
"    &nbsp;&mdash;&nbsp;Progestin contraceptive pills are taken every day, without interruption for a scheduled withdrawal bleed. They have an unpredictable effect on ovulation. Approximately 40 to 50 percent of women who use progestin pills have normal menstrual cycles; 40 percent have irregular cycles or spotting and 10 percent have amenorrhea [",
"    <a class=\"abstract\" href=\"UTD.htm?22/10/22698/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/52/9031?source=see_link\">",
"     \"Progestin-only pills (minipills) for contraception\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Taking progestin pills at the same time every day and eliminating missed doses will minimize the frequency of unscheduled bleeding.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H728294375\">",
"    <span class=\"h4\">",
"     Estrogen supplementation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many women taking progestin pills do so because of contraindications to estrogen therapy. If there are no contraindications to estrogen supplementation, it can be an effective intervention. A study with 12 participants reported short term estrogen administration decreased unscheduled bleeding associated with progestin pills [",
"    <a class=\"abstract\" href=\"UTD.htm?22/10/22698/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H728294382\">",
"    <span class=\"h4\">",
"     Mifepristone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Low doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/45/1753?source=see_link\">",
"     mifepristone",
"    </a>",
"    can decrease the number and duration of unscheduled bleeding episodes in progestin pill users, especially in initial cycles [",
"    <a class=\"abstract\" href=\"UTD.htm?22/10/22698/abstract/79\">",
"     79",
"    </a>",
"    ]. However, as discussed above, mifepristone is not readily available for this purpose.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     INTRAUTERINE CONTRACEPTION (IUD)",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two general types of IUD: copper-releasing and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/47/25336?source=see_link\">",
"     levonorgestrel",
"    </a>",
"    -releasing. The levonorgestrel-releasing IUD is available as a device that releases levonorgestrel at a rate of 20",
"    <span class=\"nowrap\">",
"     mcg/day",
"    </span>",
"    (LNG20; total levonorgestrel content: 52 mg) and as a lower dose device (LNG14; total levonorgestrel content: 13.5 mg). Because of sparse data on the LNG14, the following discussion applies primarily to the LNG20.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Bleeding pattern",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both the copper and the LNG20-releasing IUDs are associated with changes in uterine bleeding. Unscheduled bleeding and spotting are common in the first three to six months with the LNG20-IUD and irregular spotting and heavier periods can occur in the first few months of use of the copper IUD. During the initial three months after insertion of the LNG20-IUD, 35 percent of users experienced frequent or prolonged bleeding, decreasing to 4 percent by one year [",
"    <a class=\"abstract\" href=\"UTD.htm?22/10/22698/abstract/80\">",
"     80",
"    </a>",
"    ]. In addition, two-thirds of users experienced unscheduled bleeding in the first three months, decreasing to one fifth by one year. Over time, however, LNG20-IUD users are likely to experience cessation of menstrual bleeding: 40 to 50 percent of users will have amenorrhea after two years of use and the remainder will have oligomenorrhea [",
"    <a class=\"abstract\" href=\"UTD.htm?22/10/22698/abstract/81\">",
"     81",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/19/32058?source=see_link\">",
"     \"Overview of intrauterine contraception\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A long-term, seven-year, randomized trial of the copper T-380AG IUD and LNG20-IUD reported termination rates for menstrual problems in 5.9 per 100 users of the LNG20-IUD (mostly because of amenorrhea) and 3.0 per 100 copper IUD users [",
"    <a class=\"abstract\" href=\"UTD.htm?22/10/22698/abstract/82\">",
"     82",
"    </a>",
"    ]. The annual incidence of menstrual complaints diminished markedly with time for both IUDs. Continuation rates at seven years were comparable: 22.8 per 100 women for the LNG20-IUD and 27.2 per 100 women for the copper IUD.",
"   </p>",
"   <p>",
"    In clinical trials of the LNG14, unscheduled bleeding was common in the first 90 days of use: 42 percent of women had irregular bleeding, 59 percent had prolonged bleeding, and 31 percent had frequent bleeding; however, these rates decreased to 23, 9, and 8 percent, respectively, at the end of one year and 6 percent of women were amenorrheic at that time [",
"    <a class=\"abstract\" href=\"UTD.htm?22/10/22698/abstract/83\">",
"     83",
"    </a>",
"    ]. Further improvement occurred through year three, when 12 percent of women were amenorrheic. Approximately 5 percent of women in the trials discontinued the method due to bleeding complaints.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the first three to six months of use, providing reassurance and education is appropriate for management of patients with unscheduled bleeding and cramping associated with IUD use. For women who desire medical intervention, NSAIDs can be effective for reducing menstrual blood loss [",
"    <a class=\"abstract\" href=\"UTD.htm?22/10/22698/abstract/84\">",
"     84",
"    </a>",
"    ], but do not significantly reduce unscheduled bleeding or discontinuation rates [",
"    <a class=\"abstract\" href=\"UTD.htm?22/10/22698/abstract/85-87\">",
"     85-87",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A systematic review of 15 randomized trials involving 2702 participants evaluated the effect of a variety of NSAIDS on bleeding or pain associated with IUD use [",
"      <a class=\"abstract\" href=\"UTD.htm?22/10/22698/abstract/84\">",
"       84",
"      </a>",
"      ]. NSAIDs were generally effective in reducing menstrual blood loss in IUD users; several trials reported a 40 to 50 percent reduction from baseline. Unscheduled bleeding was not evaluated. The optimum NSAID and dose could not be determined and meta-analysis of the data was not possible due to wide ranges in study designs.",
"     </li>",
"     <li>",
"      A systematic review that included both randomized trials and comparative studies in copper IUD users found limited evidence that NSAIDs taken at the start of menses were useful in the treatment of bleeding irregularities and heavy blood loss during menses [",
"      <a class=\"abstract\" href=\"UTD.htm?22/10/22698/abstract/85\">",
"       85",
"      </a>",
"      ].&nbsp;One included trial addressed the use of prophylactic ibuprofen administration and found it had no impact on copper IUD continuation rates over the first year of use, despite significant reduction in IUD-related bleeding [",
"      <a class=\"abstract\" href=\"UTD.htm?22/10/22698/abstract/88\">",
"       88",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In two placebo-controlled randomized trials of women initiating the LNG20-IUD, use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/58/14248?source=see_link\">",
"       tranexamic acid",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/63/41976?source=see_link\">",
"       mefenamic acid",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/43/43705?source=see_link\">",
"       naproxen",
"      </a>",
"      over a 90-day treatment period did not significantly reduce nuisance bleeding and spotting compared with placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?22/10/22698/abstract/86,87\">",
"       86,87",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If bleeding is accompanied by significant abdominal pain or cramping, the location of the IUD should be assessed by physical examination and ultrasound. IUDs that are embedded in the myometrium or those in the process of being expelled can be associated with unscheduled bleeding. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/27/19898?source=see_link\">",
"     \"Management of problems related to intrauterine contraception\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Persistent unscheduled bleeding in IUD users warrants an evaluation for infection, as well as endometrial and cervical pathology. The endometrium can be biopsied with the IUD in place. However, if the sample is not adequate after one or two attempts, the IUD should be removed and the endometrium resampled. In copper IUD users with continued heavy bleeding, treatment with NSAIDs can be beneficial. In fact, a copper IUD available in China releases a small amount of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/50/36649?source=see_link\">",
"     indomethacin",
"    </a>",
"    and this device is associated with significantly less bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?22/10/22698/abstract/89\">",
"     89",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Practitioners have also attempted to reduce unscheduled bleeding in women using IUDs by cycling them with one- to three-month courses of OCs. However, there is no high quality evidence supporting this practice.",
"   </p>",
"   <p>",
"    A 7- to 14-day course of the antibiotic",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    has also been given as empiric treatment of nonspecific endometritis. Although there is no high quality evidence supporting this practice, doxycycline may be effective because it inhibits matrix metalloproteinases, which play a role in endometrial degradation and are thought to be upregulated by the progestin dominant effect of hormonal contraceptives [",
"    <a class=\"abstract\" href=\"UTD.htm?22/10/22698/abstract/36-39\">",
"     36-39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    After three to six months, bleeding patterns with both LNG20- and copper-IUDs are relatively stable. If a patient is markedly dissatisfied with her bleeding pattern at that time, another method of contraception should be offered.",
"   </p>",
"   <p>",
"    Even though eventual cessation of bleeding occurs in about 20 percent of users of the LNG20-IUD, pregnancy testing should be performed in any IUD user who has pregnancy-related symptoms or is concerned about the possibility of pregnancy. A pregnancy test should also be performed if proper placement of the IUD cannot be confirmed. Once pregnancy is excluded, further pregnancy testing is not required unless pregnancy is suspected because of symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18877109\">",
"    <span class=\"h1\">",
"     RETURN OF NORMAL MENSES AFTER DISCONTINUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The woman&rsquo;s bleeding pattern should return to its pre-contraception pattern after discontinuation of the method. This can take as little as one cycle for estrogen-progestin contraceptives (pill, patch, ring) and most progestin-only methods (pill, implant, IUD); however, it may take a year to 18 months in DMPA users. Except for DMPA, the bleeding pattern usually returns to its pre-contraception baseline within three months.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?21/32/22021?source=see_link\">",
"       \"Patient information: Hormonal methods of birth control (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?4/16/4355?source=see_link\">",
"       \"Patient information: Long-term methods of birth control (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Dissatisfaction with bleeding pattern represents one of the most common reasons women discontinue their method of contraception. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The unscheduled bleeding that occurs with contraceptive use is not associated with decreased contraceptive effectiveness. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'General approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Women should be provided with information about the frequency, course, and significance of uterine bleeding associated with various contraceptive methods. Proper counseling prior to method initiation allows women to choose the method that best suits their needs, prepares them for known side effects, and improves patient satisfaction and continuation (thus may reduce the risk of unintended pregnancy). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'General approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In women with unscheduled bleeding, the possibility of pregnancy, cervicitis, or endometrial or cervical pathology should be considered and excluded by appropriate laboratory tests and physical examination. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'General approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women with unscheduled bleeding related to depot",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/24/1417?source=see_link\">",
"       medroxyprogesterone acetate",
"      </a>",
"      , we suggest expectant management rather than medical intervention (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Unscheduled bleeding episodes will usually decrease over time: absence of all bleeding and spotting after one and five years of use occurs in 50 and 80 percent of users, respectively. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Depot medroxyprogesterone acetate (DMPA)'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      For women who desire treatment to stop a current bleeding episode, we suggest use of estrogen-progestin oral contraceptive pills for one month over other medical therapies (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      For women with unscheduled bleeding related to progestin implants, we suggest expectant management rather than medical therapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Unscheduled bleeding episodes will become lighter in",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/1/35863?source=see_link\">",
"       etonogestrel",
"      </a>",
"      implant users, and decrease over time in Norplant users. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Contraceptive implants'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      For women who desire treatment to stop a current bleeding episode, we suggest one to three cycles of estrogen-progestin contraceptive pills rather than estrogen supplements alone (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Unscheduled bleeding occurs in up to 50 percent of women initiating estrogen-progestin contraceptive pills, but decreases to less than 10 percent by the third month of use. Taking the pills consistently and cessation of smoking may reduce unscheduled bleeding. (See",
"      <a class=\"local\" href=\"#H15719109\">",
"       'Estrogen-progestin contraceptives'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Women experiencing unscheduled bleeding while using a cyclic estrogen-progestin contraceptive can be given reassurance that bleeding patterns will improve over time. Those who would like to switch to another pill or another cyclic method, such as the contraceptive patch or the contraceptive ring, can do so, even though this has not been demonstrated to decrease unscheduled bleeding.",
"      <br/>",
"      <br/>",
"      For women using continuous or extended cycle regimens with unscheduled bleeding, there are three options:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      If the ethinyl estradiol dose is 20 mcg, increase to a 30 mcg formulation",
"     </li>",
"     <li>",
"      If the progestin is",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/47/25336?source=see_link\">",
"       levonorgestrel",
"      </a>",
"      , switch to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/52/16199?source=see_link\">",
"       norethindrone acetate",
"      </a>",
"      formulation",
"     </li>",
"     <li>",
"      Stop the contraceptive pill for three days to allow withdrawal bleeding and then resume use for at least 21 days",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Progestin-only pills should be taken at the same time each day to minimize unscheduled bleeding. For women with persistent bothersome bleeding, we suggest switching to another method rather than providing estrogen supplementation (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Progestin pills'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women who desire treatment of unscheduled bleeding related to intrauterine contraception, we suggest nonsteroidal antiinflammatory drugs rather than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      or hormone supplements (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). We use either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"       ibuprofen",
"      </a>",
"      400 mg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/43/43705?source=see_link\">",
"       naproxen",
"      </a>",
"      250 mg, or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/63/41976?source=see_link\">",
"       mefenamic acid",
"      </a>",
"      500 mg three times per day for five to seven days.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Speroff L, Darney PD. A Clinical Guide For Contraception, 54th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2011.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22698/abstract/2\">",
"      Moreau C, Cleland K, Trussell J. Contraceptive discontinuation attributed to method dissatisfaction in the United States. Contraception 2007; 76:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22698/abstract/3\">",
"      Mishell DR Jr, Guillebaud J, Westhoff C, et al. Recommendations for standardization of data collection and analysis of bleeding in combined hormone contraceptive trials. Contraception 2007; 75:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22698/abstract/4\">",
"      Hickey M, d'Arcangues C. Vaginal bleeding disturbances and implantable contraceptives. Contraception 2002; 65:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22698/abstract/5\">",
"      ESHRE Capri Workshop Group. Ovarian and endometrial function during hormonal contraception. Hum Reprod 2001; 16:1527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22698/abstract/6\">",
"      Steroids and endometrial breakthrough bleeding. Proceedings of a meeting. Melbourne, Australia, 4-5 May 1999. Hum Reprod 2000; 15 Suppl 3:i.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22698/abstract/7\">",
"      Crawford P. Interactions between antiepileptic drugs and hormonal contraception. CNS Drugs 2002; 16:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22698/abstract/8\">",
"      Grossman MP, Nakajima ST. Menstrual cycle bleeding patterns in cigarette smokers. Contraception 2006; 73:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22698/abstract/9\">",
"      Thorneycroft IH. Cycle control with oral contraceptives: A review of the literature. Am J Obstet Gynecol 1999; 180:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22698/abstract/10\">",
"      Rosenberg MJ, Meyers A, Roy V. Efficacy, cycle control, and side effects of low- and lower-dose oral contraceptives: a randomized trial of 20 micrograms and 35 micrograms estrogen preparations. Contraception 1999; 60:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22698/abstract/11\">",
"      Akerlund M, R&oslash;de A, Westergaard J. Comparative profiles of reliability, cycle control and side effects of two oral contraceptive formulations containing 150 micrograms desogestrel and either 30 micrograms or 20 micrograms ethinyl oestradiol. Br J Obstet Gynaecol 1993; 100:832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22698/abstract/12\">",
"      Gallo MF, Nanda K, Grimes DA, Schulz KF. 20 mcg versus &gt;20 mcg estrogen combined oral contraceptives for contraception. Cochrane Database Syst Rev 2005; :CD003989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22698/abstract/13\">",
"      Miller L, Hughes JP. Continuous combination oral contraceptive pills to eliminate withdrawal bleeding: a randomized trial. Obstet Gynecol 2003; 101:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22698/abstract/14\">",
"      Anderson FD, Hait H. A multicenter, randomized study of an extended cycle oral contraceptive. Contraception 2003; 68:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22698/abstract/15\">",
"      Archer DF, Jensen JT, Johnson JV, et al. Evaluation of a continuous regimen of levonorgestrel/ethinyl estradiol: phase 3 study results. Contraception 2006; 74:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22698/abstract/16\">",
"      Legro RS, Pauli JG, Kunselman AR, et al. Effects of continuous versus cyclical oral contraception: a randomized controlled trial. J Clin Endocrinol Metab 2008; 93:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22698/abstract/17\">",
"      Edelman AB, Koontz SL, Nichols MD, Jensen JT. Continuous oral contraceptives: are bleeding patterns dependent on the hormones given? Obstet Gynecol 2006; 107:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22698/abstract/18\">",
"      Miller L, Verhoeven CH, Hout Ji. Extended regimens of the contraceptive vaginal ring: a randomized trial. Obstet Gynecol 2005; 106:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22698/abstract/19\">",
"      Rosenberg MJ, Waugh MS, Higgins JE. The effect of desogestrel, gestodene, and other factors on spotting and bleeding. Contraception 1996; 53:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22698/abstract/20\">",
"      Rosenberg MJ, Waugh MS, Stevens CM. Smoking and cycle control among oral contraceptive users. Am J Obstet Gynecol 1996; 174:628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22698/abstract/21\">",
"      Bontis J, Vavilis D, Panidis D, et al. Detection of Chlamydia trachomatis in asymptomatic women: relationship to history, contraception, and cervicitis. Adv Contracept 1994; 10:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22698/abstract/22\">",
"      Krettek JE, Arkin SI, Chaisilwattana P, Monif GR. Chlamydia trachomatis in patients who used oral contraceptives and had intermenstrual spotting. Obstet Gynecol 1993; 81:728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22698/abstract/23\">",
"      Van Vliet HA, Grimes DA, Helmerhorst FM, Schulz KF. Biphasic versus monophasic oral contraceptives for contraception: a Cochrane review. Hum Reprod 2002; 17:870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22698/abstract/24\">",
"      Hampton RM, Fisher AC, Pagano S, LaGuardia KD. Scheduled and unscheduled bleeding patterns with two combined hormonal contraceptives: application of new recommendations for standardization. Fertil Steril 2009; 92:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22698/abstract/25\">",
"      Poindexter AN, Burkman R, Fisher AC, LaGuardia KD. Cycle control, tolerability, and satisfaction among women switching from 30-35 microg ethinyl estradiol-containing oral contraceptives to the triphasic norgestimate/25 microg ethinyl estradiol-containing oral contraceptive Ortho Tri-Cyclen LO. Int J Fertil Womens Med 2003; 48:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22698/abstract/26\">",
"      Sulak P, Lippman J, Siu C, et al. Clinical comparison of triphasic norgestimate/35 micrograms ethinyl estradiol and monophasic norethindrone acetate/20 micrograms ethinyl estradiol. Cycle control, lipid effects, and user satisfaction. Contraception 1999; 59:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22698/abstract/27\">",
"      Hampton RM, Short M, Bieber E, et al. Comparison of a novel norgestimate/ethinyl estradiol oral contraceptive (Ortho Tri-Cyclen Lo) with the oral contraceptive Loestrin Fe 1/20. Contraception 2001; 63:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22698/abstract/28\">",
"      Lawrie TA, Helmerhorst FM, Maitra NK, et al. Types of progestogens in combined oral contraception: effectiveness and side-effects. Cochrane Database Syst Rev 2011; :CD004861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22698/abstract/29\">",
"      Kaunitz AM, Burkman RT, Fisher AC, Laguardia KD. Cycle control with a 21-day compared with a 24-day oral contraceptive pill: a randomized controlled trial. Obstet Gynecol 2009; 114:1205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22698/abstract/30\">",
"      Anttila L, Kunz M, Marr J. Bleeding pattern with drospirenone 3 mg+ethinyl estradiol 20 mcg 24/4 combined oral contraceptive compared with desogestrel 150 mcg+ethinyl estradiol 20 mcg 21/7 combined oral contraceptive. Contraception 2009; 80:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22698/abstract/31\">",
"      Endrikat J, M&uuml;ller U, D&uuml;sterberg B. A twelve-month comparative clinical investigation of two low-dose oral contraceptives containing 20 micrograms ethinylestradiol/75 micrograms gestodene and 30 micrograms ethinylestradiol/75 micrograms gestodene, with respect to efficacy, cycle control, and tolerance. Contraception 1997; 55:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22698/abstract/32\">",
"      Kaneshiro B, Edelman A, Carlson NE, et al. Unscheduled bleeding with continuous oral contraceptive pills: a comparison of progestin dose. Contraception 2012; 86:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22698/abstract/33\">",
"      Sulak PJ, Kuehl TJ, Coffee A, Willis S. Prospective analysis of occurrence and management of breakthrough bleeding during an extended oral contraceptive regimen. Am J Obstet Gynecol 2006; 195:935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22698/abstract/34\">",
"      Jensen JT, Garie SG, Trummer D, Elliesen J. Bleeding profile of a flexible extended regimen of ethinylestradiol/drospirenone in US women: an open-label, three-arm, active-controlled, multicenter study. Contraception 2012; 86:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22698/abstract/35\">",
"      Kaneshiro B, Edelman A, Carlson N, et al. Treatment of unscheduled bleeding in continuous oral contraceptive users with doxycycline: a randomized controlled trial. Obstet Gynecol 2010; 115:1141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22698/abstract/36\">",
"      Abdel-Aleem H, d'Arcangues C, Vogelsong K, G&uuml;lmezoglu AM. Treatment of vaginal bleeding irregularities induced by progestin only contraceptives. Cochrane Database Syst Rev 2007; :CD003449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22698/abstract/37\">",
"      Weisberg E, Hickey M, Palmer D, et al. A pilot study to assess the effect of three short-term treatments on frequent and/or prolonged bleeding compared to placebo in women using Implanon. Hum Reprod 2006; 21:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22698/abstract/38\">",
"      Chegini N, Rhoton-Vlasak A, Williams RS. Expression of matrix metalloproteinase-26 and tissue inhibitor of matrix metalloproteinase-3 and -4 in endometrium throughout the normal menstrual cycle and alteration in users of levonorgestrel implants who experience irregular uterine bleeding. Fertil Steril 2003; 80:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22698/abstract/39\">",
"      Vincent AJ, Zhang J, Ostor A, et al. Matrix metalloproteinase-1 and -3 and mast cells are present in the endometrium of women using progestin-only contraceptives. Hum Reprod 2000; 15:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22698/abstract/40\">",
"      Kaneshiro B, Edelman A, Carlson NE, et al. A randomized controlled trial of subantimicrobial-dose doxycycline to prevent unscheduled bleeding with continuous oral contraceptive pill use. Contraception 2012; 85:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22698/abstract/41\">",
"      Sulak PJ, Smith V, Coffee A, et al. Frequency and management of breakthrough bleeding with continuous use of the transvaginal contraceptive ring: a randomized controlled trial. Obstet Gynecol 2008; 112:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22698/abstract/42\">",
"      Jain J, Jakimiuk AJ, Bode FR, et al. Contraceptive efficacy and safety of DMPA-SC. Contraception 2004; 70:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22698/abstract/43\">",
"      Hubacher D, Lopez L, Steiner MJ, Dorflinger L. Menstrual pattern changes from levonorgestrel subdermal implants and DMPA: systematic review and evidence-based comparisons. Contraception 2009; 80:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22698/abstract/44\">",
"      Cromer BA, Smith RD, Blair JM, et al. A prospective study of adolescents who choose among levonorgestrel implant (Norplant), medroxyprogesterone acetate (Depo-Provera), or the combined oral contraceptive pill as contraception. Pediatrics 1994; 94:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22698/abstract/45\">",
"      Belsey EM. Vaginal bleeding patterns among women using one natural and eight hormonal methods of contraception. Contraception 1988; 38:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22698/abstract/46\">",
"      Gardner JM, Mishell DR Jr. Analysis of bleeding patterns and resumption of fertility following discontinuation of a long acting injectable contraceptive. Fertil Steril 1970; 21:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22698/abstract/47\">",
"      Berenson AB, Odom SD, Breitkopf CR, Rahman M. Physiologic and psychologic symptoms associated with use of injectable contraception and 20 microg oral contraceptive pills. Am J Obstet Gynecol 2008; 199:351.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22698/abstract/48\">",
"      Fraser IS. A survey of different approaches to management of menstrual disturbances in women using injectable contraceptives. Contraception 1983; 28:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22698/abstract/49\">",
"      Thurman AR, Livengood CH, Soper DE. Chronic endometritis in DMPA users and Chlamydia trachomatis endometritis. Contraception 2007; 76:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22698/abstract/50\">",
"      Dempsey A, Roca C, Westhoff C. Vaginal estrogen supplementation during Depo-Provera initiation: a randomized controlled trial. Contraception 2010; 82:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22698/abstract/51\">",
"      Said S, Sadek W, Rocca M, et al. Clinical evaluation of the therapeutic effectiveness of ethinyl oestradiol and oestrone sulphate on prolonged bleeding in women using depot medroxyprogesterone acetate for contraception. World Health Organization, Special Programme of Research, Development and Research Training in Human Reproduction, Task Force on Long-acting Systemic Agents for Fertility Regulation. Hum Reprod 1996; 11 Suppl 2:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22698/abstract/52\">",
"      el-Habashy MA, Mishell DR Jr, Moyer DL. Effect of supplementary oral estrogen on long-acting injectable progestogen contraception. Obstet Gynecol 1970; 35:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22698/abstract/53\">",
"      Goldberg AB, Cardenas LH, Hubbard AE, Darney PD. Post-abortion depot medroxyprogesterone acetate continuation rates: a randomized trial of cyclic estradiol. Contraception 2002; 66:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22698/abstract/54\">",
"      Nathirojanakun P, Taneepanichskul S, Sappakitkumjorn N. Efficacy of a selective COX-2 inhibitor for controlling irregular uterine bleeding in DMPA users. Contraception 2006; 73:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22698/abstract/55\">",
"      Tantiwattanakul P, Taneepanichskul S. Effect of mefenamic acid on controlling irregular uterine bleeding in DMPA users. Contraception 2004; 70:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22698/abstract/56\">",
"      Senthong AJ, Taneepanichskul S. The effect of tranexamic acid for treatment irregular uterine bleeding secondary to DMPA use. J Med Assoc Thai 2009; 92:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22698/abstract/57\">",
"      Jain JK, Nicosia AF, Nucatola DL, et al. Mifepristone for the prevention of breakthrough bleeding in new starters of depo-medroxyprogesterone acetate. Steroids 2003; 68:1115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22698/abstract/58\">",
"      Abdel-Aleem H, Shaaban OM, Abdel-Aleem MA, Fetih GN. Doxycycline in the treatment of bleeding with DMPA: a double-blinded randomized controlled trial. Contraception 2012; 86:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22698/abstract/59\">",
"      Zheng SR, Zheng HM, Qian SZ, et al. A randomized multicenter study comparing the efficacy and bleeding pattern of a single-rod (Implanon) and a six-capsule (Norplant) hormonal contraceptive implant. Contraception 1999; 60:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22698/abstract/60\">",
"      Mansour D, Korver T, Marintcheva-Petrova M, Fraser IS. The effects of Implanon on menstrual bleeding patterns. Eur J Contracept Reprod Health Care 2008; 13 Suppl 1:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22698/abstract/61\">",
"      Darney P, Patel A, Rosen K, et al. Safety and efficacy of a single-rod etonogestrel implant (Implanon): results from 11 international clinical trials. Fertil Steril 2009; 91:1646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22698/abstract/62\">",
"      Casey PM, Long ME, Marnach ML, Bury JE. Bleeding related to etonogestrel subdermal implant in a US population. Contraception 2011; 83:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22698/abstract/63\">",
"      Shoupe D, Mishell DR Jr, Bopp BL, Fielding M. The significance of bleeding patterns in Norplant implant users. Obstet Gynecol 1991; 77:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22698/abstract/64\">",
"      Datey S, Gaur LN, Saxena BN. Vaginal bleeding patterns of women using different contraceptive methods (implants, injectables, IUDs, oral pills)--an Indian experience. An ICMR Task Force Study. Indian Council of Medical Research. Contraception 1995; 51:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22698/abstract/65\">",
"      Weisberg E, Hickey M, Palmer D, et al. A randomized controlled trial of treatment options for troublesome uterine bleeding in Implanon users. Hum Reprod 2009; 24:1852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22698/abstract/66\">",
"      Mansour D, Bahamondes L, Critchley H, et al. The management of unacceptable bleeding patterns in etonogestrel-releasing contraceptive implant users. Contraception 2011; 83:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22698/abstract/67\">",
"      Phaliwong P, Taneepanichskul S. The effect of mefenamic acid on controlling irregular uterine bleeding second to Implanon use. J Med Assoc Thai 2004; 87 Suppl 3:S64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22698/abstract/68\">",
"      Alvarez-Sanchez F, Brache V, Thevenin F, et al. Hormonal treatment for bleeding irregularities in Norplant implant users. Am J Obstet Gynecol 1996; 174:919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22698/abstract/69\">",
"      D&iacute;az S, Croxatto HB, Pavez M, et al. Clinical assessment of treatments for prolonged bleeding in users of Norplant implants. Contraception 1990; 42:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22698/abstract/70\">",
"      Witjaksono J, Lau TM, Affandi B, Rogers PA. Oestrogen treatment for increased bleeding in Norplant users: preliminary results. Hum Reprod 1996; 11 Suppl 2:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22698/abstract/71\">",
"      Boonkasemsanti W, Reinprayoon D, Pruksananonda K, et al. The effect of transdermal oestradiol on bleeding pattern, hormonal profiles and sex steroid receptor distribution in the endometrium of Norplant users. Hum Reprod 1996; 11 Suppl 2:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22698/abstract/72\">",
"      Cheng L, Zhu H, Wang A, et al. Once a month administration of mifepristone improves bleeding patterns in women using subdermal contraceptive implants releasing levonorgestrel. Hum Reprod 2000; 15:1969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22698/abstract/73\">",
"      Massai MR, Pavez M, Fuentealba B, et al. Effect of intermittent treatment with mifepristone on bleeding patterns in Norplant implant users. Contraception 2004; 70:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22698/abstract/74\">",
"      Abdel-Aleem H, Shaaban OM, Amin AF, Abdel-Aleem AM. Tamoxifen treatment of bleeding irregularities associated with Norplant use. Contraception 2005; 72:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22698/abstract/75\">",
"      d'Arcangues C, Piaggio G, Brache V, et al. Effectiveness and acceptability of vitamin E and low-dose aspirin, alone or in combination, on Norplant-induced prolonged bleeding. Contraception 2004; 70:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22698/abstract/76\">",
"      Kaewrudee S, Taneepanichskul S, Jaisamraun U, Reinprayoon D. The effect of mefenamic acid on controlling irregular uterine bleeding secondary to Norplant use. Contraception 1999; 60:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22698/abstract/77\">",
"      Phupong V, Sophonsritsuk A, Taneepanichskul S. The effect of tranexamic acid for treatment of irregular uterine bleeding secondary to Norplant use. Contraception 2006; 73:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22698/abstract/78\">",
"      Johannisson E, Landgren BM, Diczfalusy E. Endometrial morphology and peripheral steroid levels in women with and without intermenstrual bleeding during contraception with the 300 microgram norethisterone (NET) minipill. Contraception 1982; 25:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22698/abstract/79\">",
"      Gemzell-Danielsson K, van Heusden AM, Killick SR, et al. Improving cycle control in progestogen-only contraceptive pill users by intermittent treatment with a new anti-progestogen. Hum Reprod 2002; 17:2588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22698/abstract/80\">",
"      Bachmann G, Korner P. Bleeding patterns associated with non-oral hormonal contraceptives: a review of the literature. Contraception 2009; 79:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22698/abstract/81\">",
"      Hidalgo M, Bahamondes L, Perrotti M, et al. Bleeding patterns and clinical performance of the levonorgestrel-releasing intrauterine system (Mirena) up to two years. Contraception 2002; 65:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22698/abstract/82\">",
"      Sivin I, Stern J. Health during prolonged use of levonorgestrel 20 micrograms/d and the copper TCu 380Ag intrauterine contraceptive devices: a multicenter study. International Committee for Contraception Research (ICCR). Fertil Steril 1994; 61:70.",
"     </a>",
"    </li>",
"    <li>",
"     Package insert. SKYLA (levonorgestrel-releasing intrauterine system) file://labeling.bayerhealthcare.com/html/products/pi/Skyla_PI.pdf (Accessed on April 15, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22698/abstract/84\">",
"      Grimes DA, Hubacher D, Lopez LM, Schulz KF. Non-steroidal anti-inflammatory drugs for heavy bleeding or pain associated with intrauterine-device use. Cochrane Database Syst Rev 2006; :CD006034.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22698/abstract/85\">",
"      Godfrey EM, Folger SG, Jeng G, et al. Treatment of bleeding irregularities in women with copper-containing IUDs: a systematic review. Contraception 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22698/abstract/86\">",
"      Madden T, Proehl S, Allsworth JE, et al. Naproxen or estradiol for bleeding and spotting with the levonorgestrel intrauterine system: a randomized controlled trial. Am J Obstet Gynecol 2012; 206:129.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22698/abstract/87\">",
"      Sordal T, Inki P, Draeby J, et al. Management of Initial Bleeding or Spotting After Levonorgestrel-Releasing Intrauterine System Placement. Obstet Gynecol 2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22698/abstract/88\">",
"      Hubacher D, Reyes V, Lillo S, et al. Preventing copper intrauterine device removals due to side effects among first-time users: randomized trial to study the effect of prophylactic ibuprofen. Hum Reprod 2006; 21:1467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/10/22698/abstract/89\">",
"      Zhao G, Li M, Zhu P, et al. A preliminary morphometric study on the endometrium from patients treated with indomethacin-releasing copper intrauterine device. Hum Reprod 1997; 12:1563.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5474 Version 18.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-222.190.118.195-806F72AFFC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_10_22698=[""].join("\n");
var outline_f22_10_22698=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18877011\">",
"      MECHANISM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      GENERAL APPROACH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15719109\">",
"      ESTROGEN-PROGESTIN CONTRACEPTIVES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15719137\">",
"      Bleeding pattern",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15719144\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15719151\">",
"      - Women using a cyclic estrogen-progestin regimen",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15719158\">",
"      - Women using continuous or extended pill regimens",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15719165\">",
"      - Women using a patch or ring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15719890\">",
"      PROGESTIN ONLY CONTRACEPTIVES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Depot medroxyprogesterone acetate (DMPA)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Bleeding pattern",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H728294250\">",
"      Supplemental estrogen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H728294257\">",
"      Valdecoxib",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H728294264\">",
"      Mefenamic acid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H728294275\">",
"      Tranexamic acid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H728294282\">",
"      Mifepristone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H728294289\">",
"      Shortening the interval between DMPA injections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H5574966\">",
"      Doxycycline",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Contraceptive implants",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Bleeding pattern",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H110850442\">",
"      Etonogestrel implant",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H110850387\">",
"      Norplant",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H728294296\">",
"      - Supplemental estrogen",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H728294303\">",
"      - Combined estrogen-progestin oral contraceptive pills",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H728294310\">",
"      - Mifepristone",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H728294317\">",
"      - Selective estrogen receptor modulators",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H728294324\">",
"      - NSAIDs",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H728294339\">",
"      - Other",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Progestin pills",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Bleeding pattern",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H728294375\">",
"      Estrogen supplementation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H728294382\">",
"      Mifepristone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      INTRAUTERINE CONTRACEPTION (IUD)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Bleeding pattern",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18877109\">",
"      RETURN OF NORMAL MENSES AFTER DISCONTINUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/5474\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/5474|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?35/4/35906\" title=\"algorithm 1\">",
"      Management of unscheduled bleeding in women using contraception",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/4/64?source=related_link\">",
"      Acute cervicitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/45/34522?source=related_link\">",
"      Depot medroxyprogesterone acetate for contraception",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/10/7336?source=related_link\">",
"      Endometrial polyps",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/27/3512?source=related_link\">",
"      Etonogestrel contraceptive implant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/47/3832?source=related_link\">",
"      Hormonal contraception for suppression of menstruation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/25/20887?source=related_link\">",
"      Initial approach to the premenopausal woman with abnormal uterine bleeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/27/19898?source=related_link\">",
"      Management of problems related to intrauterine contraception",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/19/32058?source=related_link\">",
"      Overview of intrauterine contraception",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/5/18522?source=related_link\">",
"      Overview of the use of estrogen-progestin contraceptives",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/32/22021?source=related_link\">",
"      Patient information: Hormonal methods of birth control (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?4/16/4355?source=related_link\">",
"      Patient information: Long-term methods of birth control (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/52/9031?source=related_link\">",
"      Progestin-only pills (minipills) for contraception",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/16/38154?source=related_link\">",
"      Screening for cervical cancer: Rationale and recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/10/41127?source=related_link\">",
"      Transdermal contraceptive patch",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_10_22699="Predictors repeat ulcer bleed";
var content_f22_10_22699=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F78607&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F78607&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Endoscopic predictors of recurrent peptic ulcer hemorrhage",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Endoscopic stigmata of recent hemorrhage",
"       </td>",
"       <td class=\"subtitle1\">",
"        Prevalence, percent",
"       </td>",
"       <td class=\"subtitle1\">",
"        Risk of rebleeding on medical management, percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Active arterial bleeding (Forrest Ia)",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        90",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Oozing without visible vessel (Forrest Ib)",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        10 to 20",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Non-bleeding visible vessel (Forrest IIa)",
"       </td>",
"       <td>",
"        25",
"       </td>",
"       <td>",
"        50",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Adherent clot (Forrest IIb)",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        25 to 30",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Flat spot (Forrest IIc)",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        7 to 10",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Clean ulcer base (Forrest (III)",
"       </td>",
"       <td>",
"        35",
"       </td>",
"       <td>",
"        3 to 5",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Katschinski B, Logan R, Davies J, et al. Dig Dis Sci 1994; 39:706.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_10_22699=[""].join("\n");
var outline_f22_10_22699=null;
var title_f22_10_22700="Comparison between EME and EIEE";
var content_f22_10_22700=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F76108&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F76108&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Comparison of early myoclonic encephalopathy (EME) and early infantile epileptic encephalopathy (EIEE)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        EME",
"       </td>",
"       <td class=\"subtitle1\">",
"        EIEE",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Age of onset",
"       </td>",
"       <td>",
"        Neonatal period",
"       </td>",
"       <td>",
"        Within first three months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neurologic status at onset",
"       </td>",
"       <td>",
"        Abnormal at birth or at seizure onset",
"       </td>",
"       <td>",
"        Always abnormal, even prior to seizure onset",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Characteristic seizure type",
"       </td>",
"       <td>",
"        Erratic or fragmentary myoclonus",
"       </td>",
"       <td>",
"        Tonic spasm",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Additional seizure types",
"       </td>",
"       <td>",
"        Massive myoclonus",
"        <br/>",
"        Simple partial seizures",
"        <br/>",
"        Infantile spasms (tonic)",
"       </td>",
"       <td>",
"        Focal motor seizures",
"        <br/>",
"        Hemiconvulsions",
"        <br/>",
"        Generalized seizures",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Background EEG",
"       </td>",
"       <td>",
"        Suppression-burst",
"       </td>",
"       <td>",
"        Suppression-burst",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Etiology",
"       </td>",
"       <td>",
"        Inborn errors of metabolism",
"        <br/>",
"        Familial",
"        <br/>",
"        Cryptogenic",
"       </td>",
"       <td>",
"        Cerebral dysgenesis",
"        <br/>",
"        Anoxia",
"        <br/>",
"        Cryptogenic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Natural course",
"       </td>",
"       <td>",
"        Progressive impairment",
"       </td>",
"       <td>",
"        Static impairment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Incidence of death",
"       </td>",
"       <td>",
"        Very high, occurring in infancy",
"       </td>",
"       <td>",
"        High, occurring in infancy, childhood or adolescence",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Status of survivors",
"       </td>",
"       <td>",
"        Vegetative state",
"       </td>",
"       <td>",
"        Severe mental retardation",
"        <br/>",
"        Quadriplegia and bedridden",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Long-term seizure evolution",
"       </td>",
"       <td>",
"        Infantile spasms",
"       </td>",
"       <td>",
"        West syndrome",
"        <br/>",
"        Lennox-Gastaut",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Based upon data from: 1. Aicardi, J. Epileptic encephalopathies of early childhood. Curr Opin Neurol Neurosurg 1992; 5:344.",
"     <br>",
"      2. Ohtahara, S, Yamatogi, Y. Epileptic encephalopathies in early infancy with suppression-burst. J Clin Neurophysiol. 2003; 20:398.",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_10_22700=[""].join("\n");
var outline_f22_10_22700=null;
var title_f22_10_22701="TLS risk stratification";
var content_f22_10_22701=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F57607&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F57607&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Tumor lysis syndrome (TLS) prophylaxis recommendations based on TLS risk",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Low risk disease (LRD)",
"       </td>",
"       <td class=\"subtitle1_single\">",
"        Intermediate risk disease (IRD)",
"       </td>",
"       <td class=\"subtitle1_single\">",
"        High risk disease (HRD)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Most solid tumors",
"       </td>",
"       <td>",
"        Rare, highly chemotherapy sensative solid tumors (eg, neuroblastoma, germ cell tumor, small cell lung cancer) with bulky or advanced stage disease",
"       </td>",
"       <td>",
"        N/A",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        MM",
"       </td>",
"       <td>",
"        N/A",
"       </td>",
"       <td>",
"        N/A",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CML",
"       </td>",
"       <td>",
"        N/A",
"       </td>",
"       <td>",
"        N/A",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Indolent NHL",
"       </td>",
"       <td>",
"        N/A",
"       </td>",
"       <td>",
"        N/A",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        HL",
"       </td>",
"       <td>",
"        N/A",
"       </td>",
"       <td>",
"        N/A",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CLL and WBC &lt;50 x 10",
"        <sup>",
"         9",
"        </sup>",
"        /L treated only with alkylating agents",
"       </td>",
"       <td>",
"        CLL treated with fludarabine, rituximab, or lenalidomide, and/or those with high WBC &ge;50 x 10",
"        <sup>",
"         9",
"        </sup>",
"        /L",
"       </td>",
"       <td>",
"        N/A",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        AML and WBC &lt;25 x 10",
"        <sup>",
"         9",
"        </sup>",
"        /L and LDH &lt;2 x ULN",
"       </td>",
"       <td>",
"        AML with WBC 25 to 100 x 10",
"        <sup>",
"         9",
"        </sup>",
"        /L",
"       </td>",
"       <td rowspan=\"2\">",
"        AML and WBC &ge;100 x 10",
"        <sup>",
"         9",
"        </sup>",
"        /L",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        AML and WBC &lt;25 x 10",
"        <sup>",
"         9",
"        </sup>",
"        /L and LDH &ge;2 x ULN",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Adult intermediate grade NHL and LDH within normal limits",
"       </td>",
"       <td>",
"        Adult&nbsp;T cell leukemia/lymphoma, diffuse large B-cell,&nbsp;transformed, and mantle cell lymphomas with&nbsp;LDH &gt; ULN, non bulky",
"       </td>",
"       <td>",
"        Adult&nbsp;T cell leukemia/lymphoma, diffuse large B-cell,&nbsp;transformed, and mantle cell lymphomas with bulky disease and LDH &ge;2 x ULN",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Adult ALCL",
"       </td>",
"       <td>",
"        Childhood ALCL stage III/IV",
"       </td>",
"       <td>",
"        N/A",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        N/A",
"       </td>",
"       <td>",
"        Childhood intermediate grade NHL stage III/IV with LDH &lt;2 x ULN",
"       </td>",
"       <td>",
"        Stage III/IV childhood diffuse large B cell lymphoma with LDH &ge;2 x ULN",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        N/A",
"       </td>",
"       <td>",
"        ALL and WBC &lt;100 x 10",
"        <sup>",
"         9",
"        </sup>",
"        /L and LDH &lt;2 x ULN",
"       </td>",
"       <td>",
"        <p>",
"         Burkitt's leukemia",
"        </p>",
"        <p>",
"         Other ALL and WBC &ge;100 x 10",
"         <sup>",
"          9",
"         </sup>",
"         /L and/or LDH &ge;2 x ULN",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        N/A",
"       </td>",
"       <td>",
"        Burkitt lymphoma&nbsp;and LDH &lt;2 x ULN",
"       </td>",
"       <td>",
"        Burkitt lymphoma&nbsp;stage III/IV and/or LDH &ge;2 x ULN",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        N/A",
"       </td>",
"       <td>",
"        Lymphoblastic lymphoma&nbsp;stage I/II and LDH &lt;2 x ULN",
"       </td>",
"       <td>",
"        Lymphoblastic lymphoma stage III/IV and/or LDH &ge;2 x ULN",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        N/A",
"       </td>",
"       <td rowspan=\"2\">",
"        N/A",
"       </td>",
"       <td>",
"        IRD with renal dysfunction and/or renal involvement",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        IRD with uric acid, potassium and/or phosphate &gt;ULN",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"3\">",
"        Prophylaxis recommendations",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Monitoring",
"       </td>",
"       <td>",
"        Monitoring",
"       </td>",
"       <td>",
"        Monitoring",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hydration",
"       </td>",
"       <td>",
"        Hydration",
"       </td>",
"       <td>",
"        Hydration",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &plusmn;Allopurinol",
"       </td>",
"       <td>",
"        Allopurinol",
"       </td>",
"       <td>",
"        Rasburicase*",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     MM: multiple myeloma; CML: chronic myeloid leukaemia; NHL: non-Hodgkin lymphoma; HL: Hodgkin lymphoma; CLL: chronic lymphoid leukaemia; AML: acute myeloid leukaemia; WBC: white blood cell count; LDH: lactate dehydrogenase; ULN: upper limit of normal; ALCL: anaplastic large cell lymphoma; N/A: not applicable; ALL: acute lymphoblastic leukaemia.",
"     <br>",
"      * Contraindicated in patients with a history consistent with glucose-6 phosphate dehydrogenase. In these patients, rasburicase should be substituted with allopurinol.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Cairo MS, Coiffier B, Reiter A. Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus. Br J Haematol 2010; 149:578. Copyright &copy; 2010. Modified with permission of Blackwell Publishing Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_10_22701=[""].join("\n");
var outline_f22_10_22701=null;
var title_f22_10_22702="Action potentials in early repolarization";
var content_f22_10_22702=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F83884&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F83884&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 542px\">",
"   <div class=\"ttl\">",
"    Action potentials in early repolarization",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 522px; height: 307px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A disproportionately abbreviated epicardial action potential compared with the endocardial action potential&nbsp;causes J-point elevation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_10_22702=[""].join("\n");
var outline_f22_10_22702=null;
var title_f22_10_22703="Contents: Skin, hair, and nails";
var content_f22_10_22703=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?18/22/18798\">",
"       Patient Information",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Skin, hair, and nails",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Skin, hair, and nails",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Acne",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/40/20099\">",
"           Patient information: Acne (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/12/1218\">",
"           Patient information: Acne (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Angioedema",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/31/1523\">",
"           Patient information: Angioedema (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Blisters",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/60/5058\">",
"           Patient information: Blisters (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/11/3250\">",
"           Patient information: Bullous pemphigoid (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Chickenpox and shingles",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/57/27538\">",
"           Patient information: Chickenpox (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/40/2691\">",
"           Patient information: Chickenpox prevention and treatment (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/12/13507\">",
"           Patient information: Shingles (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/0/14338\">",
"           Patient information: Shingles (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Corns and calluses",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/52/834\">",
"           Patient information: Corns and calluses (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Dermatitis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/38/32354\">",
"           Patient information: Contact dermatitis (including latex dermatitis) (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/53/1874\">",
"           Patient information: Dermatitis (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Discoid lupus",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/5/16466\">",
"           Patient information: Discoid lupus (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Eczema",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/23/15730\">",
"           Patient information: Atopic dermatitis (eczema) (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/30/6626\">",
"           Patient information: Eczema (atopic dermatitis) (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Erythema multiforme",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/3/21553\">",
"           Patient information: Erythema multiforme (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Erythema nodosum",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/24/20866\">",
"           Patient information: Erythema nodosum (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Excess hair growth",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/24/13698\">",
"           Patient information: Hirsutism (excess hair growth in women) (Beyond the Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Granuloma annulare",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/23/35185\">",
"           Patient information: Granuloma annulare (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Hair loss",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/15/24817\">",
"           Patient information: Alopecia areata (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/18/7458\">",
"           Patient information: Hair loss in men and women (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/56/17282\">",
"           Patient information: Hair loss in men and women (androgenetic alopecia) (Beyond the Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Heat rash",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/21/22865\">",
"           Patient information: Heat rash (prickly heat) (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Hidradenitis suppurativa",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/23/22897\">",
"           Patient information: Hidradenitis suppurativa (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Hives",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/45/2772\">",
"           Patient information: Hives (urticaria) (Beyond the Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Ingrown nail",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/3/19505\">",
"           Patient information: Ingrown toenail (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Insects and parasites",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/30/14817\">",
"           Patient information: Bedbugs (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/13/36049\">",
"           Patient information: Bedbugs (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/44/19138\">",
"           Patient information: Fire ants (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/44/16065\">",
"           Patient information: Head lice (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/5/43089\">",
"           Patient information: Lice (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/33/9746\">",
"           Patient information: Pinworms (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/12/27843\">",
"           Patient information: Pubic lice (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/18/18721\">",
"           Patient information: Scabies (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/19/1330\">",
"           Patient information: Scabies (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Lichen planus",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/28/6594\">",
"           Patient information: Lichen planus (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Melasma",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/41/37521\">",
"           Patient information: Melasma (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Mouth sores",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/34/16929\">",
"           Patient information: Leukoplakia (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/53/6994\">",
"           Patient information: Mouth sores (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Nail fungus",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/1/42001\">",
"           Patient information: Fungal nail infections (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Pityriasis rosea",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/60/17345\">",
"           Patient information: Pityriasis rosea (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Poison ivy",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/59/6068\">",
"           Patient information: Poison ivy (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/3/3122\">",
"           Patient information: Poison ivy (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Pressure sores",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/53/39761\">",
"           Patient information: Pressure sores (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Psoriasis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/11/3252\">",
"           Patient information: Psoriasis (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/9/3218\">",
"           Patient information: Psoriasis (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/52/835\">",
"           Patient information: Psoriatic arthritis in adults (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/6/7267\">",
"           Patient information: Psoriatic arthritis in children (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Pyoderma gangrenosum",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/28/29122\">",
"           Patient information: Pyoderma gangrenosum (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Ringworm",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/19/3377\">",
"           Patient information: Ringworm (including athlete's foot and jock itch) (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/0/33793\">",
"           Patient information: Ringworm, athletes foot, and jock itch (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Rosacea",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/14/40161\">",
"           Patient information: Rosacea (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Scars and healing",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/39/9842\">",
"           Patient information: Keloids (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Scleroderma",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/23/28017\">",
"           Patient information: Scleroderma (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Seborrhea",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/5/22610\">",
"           Patient information: Seborrheic dermatitis (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/1/6164\">",
"           Patient information: Seborrheic dermatitis (including dandruff and cradle cap) (Beyond the Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Seborrheic keratosis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/51/818\">",
"           Patient information: Seborrheic keratosis (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Skin burns",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/55/32625\">",
"           Patient information: Skin burns (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/43/25266\">",
"           Patient information: Skin burns (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Skin cancer",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/8/19586\">",
"           Patient information: Actinic keratosis (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/12/19650\">",
"           Patient information: Brain metastases (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/46/42722\">",
"           Patient information: Melanoma skin cancer (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/8/39042\">",
"           Patient information: Melanoma treatment; advanced or metastatic melanoma (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/6/28772\">",
"           Patient information: Melanoma treatment; localized melanoma (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/26/26018\">",
"           Patient information: Skin cancer (non-melanoma) (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Skin infections",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/63/20465\">",
"           Patient information: Boil (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/23/4466\">",
"           Patient information: Cellulitis and erysipelas (skin infections) (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/24/4482\">",
"           Patient information: Cold sores (oral herpes) (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/38/23137\">",
"           Patient information: Folliculitis (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/55/8048\">",
"           Patient information: Impetigo (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/18/26913\">",
"           Patient information: Impetigo (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/4/22595\">",
"           Patient information: Methicillin-resistant Staphylococcus aureus (MRSA) (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/47/31473\">",
"           Patient information: Methicillin-resistant Staphylococcus aureus (MRSA) (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/35/43583\">",
"           Patient information: Molluscum contagiosum (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/25/23953\">",
"           Patient information: Paronychia (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/62/16353\">",
"           Patient information: Pilonidal cyst (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/55/15217\">",
"           Patient information: Skin and soft tissue infection (cellulitis) (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/60/15297\">",
"           Patient information: Tinea nigra (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/47/24305\">",
"           Patient information: Tinea versicolor (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Skin tags",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/43/9905\">",
"           Patient information: Skin tags (acrochordon) (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Skin warts",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/16/25857\">",
"           Patient information: Skin warts (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/5/11346\">",
"           Patient information: Skin warts (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Sunburn",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/30/18913\">",
"           Patient information: Sunburn (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/20/23874\">",
"           Patient information: Sunburn (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/60/33729\">",
"           Patient information: Sunburn prevention (Beyond the Basics)",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-CDDA1069B6-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f22_10_22703=[""].join("\n");
var outline_f22_10_22703=null;
